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ABSTRACT
AN EXAMINATION OF MEDICAL TECHNOLOGY DISADOPTION AND ITS
RELATION TO TECHNOLOGY ADOPTION AND PHYSICIAN ORGANIZATION
Henry Bergquist
Guy David
Medical technology disadoption, a topic which has not previously been studied in great
detail by health economists, is of great importance in a health care system where
technology is understood to be a major driver of expenditure growth and the adoption of
new technologies is consistently promoted by cultural norms and financial incentives.
The disadoption of technologies with sub-optimal efficacy or safety is a key to improving
the quality and value of care, and thus there is obvious utility to learning more about
factors that influence technology disadoption. This dissertation establishes a novel
theoretical framework to characterize the disadoption process along multiple dimensions,
and then develops a simple mathematical model to describe physician disadoption
behavior. Disadoption is examined empirically by analyzing the use of coronary drugeluting stents (DES) in 2006-07(following their rapid adoption in 2003-04) using New
York and Florida hospital discharge data, national practice organization data, and
physician characteristic data. Preceding DES adoption behavior and physician group size
are the primary factors studied for association with DES disadoption behavior. Empirical
analyses indicate that faster DES adoption may be weakly associated with later DES
disadoption, which may be consistent with physician risk aversion or product loyalty
playing roles in disadoption decisions. Also, analyses suggest that there may be a week
negative relationship between group size and timing of DES disadoption, suggesting that
physicians in larger groups may begin the disadoption process later. These empirical
results, which are subjected to instrumental variable analysis and extensive robustness
checks, generally lack statistical significance, which highlights the current level of
uncertainty surrounding disadoption behavior, including the observation that it does not
appear to be empirically either similar or related to adoption behavior. Thus, this work
both promotes and guides future research on medical disadoption and its determinants.
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CHAPTER 1: Introduction
In the realm of United States health policy, few topics have received as much widespread
attention as the level and growth rate of the country’s overall health care expenditure.
Though the rate of growth of health care expenditures has dropped to historically low
rates in recent years (which has resulted in the level of expenditures as a percentage of
GDP remaining relatively constant), growth rates are still positive and the overall level of
spending is remarkably high, at more than 17% of GDP. (For data and discussions, see
for example: Chernew & Newhouse 2012 Handbook Health Econ; Emanuel et al 2012
NEJM; MedPAC 2014; CBO 2013.) Indeed, despite the more favorable recent trends in
growth rate, health care spending remains a major concern for the US federal budget in
the immediate and foreseeable future (CBO 2013).

While there is common understanding and agreement about the high level of health care
spending in the US, there is less agreement on whether or not the level of spending is too
high. On one side, there is the belief that spending rates are too high, a belief that has
spread as the level of spending has continued to climb. This view, which has long been
held by some within health policy research and academic medical circles, can now be
found frequently in newspaper and magazine articles, which has helped bolster
widespread concern about health care spending levels and make health care a hot-button
political topic over the past decade. Support for the view that the US is over-spending on
health care is frequently found in comparisons between the US and other countries, which
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show that the US, while spending much more than all other countries, lags behind all
other developed (and many developing) countries on various health-outcome metrics (see
for example, Davis et al 2014 Cmmnwlth Fund; OECD 2014). Though these findings
are compelling and prompt justifiable concern and inquiry, such data do not necessarily
indicate that the US is spending “too much” on health care. For example, differences
between the levels of spending in the US and other countries may relate to differences in
preferences for health care, particularly relative to other types of consumption. Such
cultural variations could explain how Americans and Europeans can both be utilitymaximizing, while exhibiting different health care spending habits and achieving
different health outcome measures. More generally, even though the US is spending a
large portion of its GDP on health care, it is not clear that the country’s utility or welfare
would be increased by diverting those funds to other sectors. As long as there are
positive marginal returns to each additional dollar spent on health care, the question of
whether or not that dollar should be spent elsewhere is a subjective one.

Though economists have cautioned policy-makers and health services researchers from
assuming that the US is over-spending on health care, recent studies have begun to
document serious inefficiencies in the health care industry. Researchers have observed
many examples where modest patient benefit does not seem to justify the cost of medical
tests or treatments, or where there is complete lack of benefit despite increased spending
(e.g. Lakdawalla et al 2015 Health Aff; Baicker & Chandra 2011 Fed econ symp; Garber,
Goldman, Jena 2007 Health Aff; Konski et al 2007 J Clin Onc; Lodge et al 2007 Radtx
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Onc). Other researchers have observed many examples of “inappropriate” use of
therapies, e.g. the continued use of treatments despite the lack of evidence-based criteria
(e.g. Al-Khatib et al 2011 JAMA; Kachalia et al 2015 Ann Int Med; Korenstein et al
2012 Arch Int Med); the continued use of therapies (e.g. preventative hormone
replacement therapy and prostate-specific antigen screening) that have been shown to
have health risks that exceed their benefits (e.g. WGWHII 2002 JAMA; Andriole et al
2009 NEJM); or the continued use of therapies that provide no benefit relative to placebo
(e.g Buchbinder et al 2009 NEJM). Furthermore, other studies have avoided the question
of clinical appropriateness and focused on system-level waste, i.e. aspects of the US
health care system that lead to spending without any identifiable patient benefit (e.g.
Bentley et al 2008 Millbank Q; Berwick & Hackbarth 2012 JAMA). Of course, one
could debate this evidence of over-spending, noting for example that individual examples
of inefficiency do not imply overall system- or country-level inefficiency. That said, as
the body of evidence grows alongside the common concern over excessive spending and
utilization, it is clear that this issue must be addressed; there is, if not a need, a strong
desire to identify ways to decrease spending or increase value in the US health care
system.

When considering ways to decrease US health care spending, one natural place to start is
by focusing on medical technologies. Researchers have shown that the development and
diffusion of new medical technologies are the primary drivers of US health care
expenditure growth—being responsible for up to nearly 50% of average annual growth in
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US healthcare spending—a fact which is facilitated by the structure of health care
delivery and financing in the US, which encourage such diffusion (e.g. Newhouse 1992 J
Econ Persp; Chernew & Newhouse 2012 Handbook Health Econ; Emanuel & Fuchs
2008 JAMA; Smith, Newhouse, Freeland 2009 Health Aff; MedPAC 2014; Thornton &
Beilfuss 2016 App Econ Let). Of course, given that new medical technologies are
typically designed to improve medical testing, treatment, or care delivery, it does not
seem optimal to generally discourage the development and diffusion of new technologies,
unless the population is willing to forego potential improvements in health care. One
approach that has become the topic of extensive research and debate is the development
and use of cost-effectiveness information to direct health care utilization, particularly in
the setting of medical technologies. (For general discussions of cost-effectiveness
analysis in the health care setting, see for example Meltzer & Smith 2012 Handbook
Health Econ; Garber & Sculpher 2012 Handbook Health Econ; or Chandra, Jena, Skinner
2011 JEP.) Though cost-effectiveness analysis (CEA) has become increasingly common
in the health services and clinical medicine literatures, unfortunately there is also growing
evidence that clinical practice recommendations and guidelines suggested by such studies
have only limited influence on clinical practice and health care utilization (Liang 2007
Health Aff; Howard & Shen 2012 AHEHSR; Deyell et al 2011 Arch Int Med; Grimshaw,
Eccles, Tetroe 2005 JCEHP; Grol & Grimshaw 2003 Lancet; Cochrane et al 2007
JCEHP; Timmermans & Mauck 2005 Health Aff). Furthermore, recent research has
shown that if CEA were used to guide technology adoption decisions, the results would
not be very different from the current use of clinically-based comparative effectiveness
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research (CER), which thus raises the question of how much value could be realized if
CEA data were widely disseminated and used to shape clinical practice (Glick et al 2015
Health Aff).

However, even if CEA data were used optimally to shape the diffusion of medical
technologies, thus inhibiting the adoption of technologies for which costs outweighed
benefits, there is no guarantee that the US health care system would achieve maximum
value, because the data used for CEA cannot be perfect. In the same way that
medications are considered to be safe at the time they receive FDA approval, but new
data from widespread use can reveal previously-unknown risks1, post-approval
technology use can provide more insight into a technology’s value. The data on new
medical technologies typically comes from carefully designed and controlled
experiments, which are very different from real-world clinical practice. Ignoring the
likely possibility that a new technology will be used in patients who do not perfectly
match the evidence-based clinical recommendations or guidelines (as mentioned above,
which would naturally lead to inappropriate or low-value care), non-experimental
patients generally do not receive the same intense scrutiny and detail-focused care, which
means that their outcomes may differ significantly from those observed in the
experiments that generated the original data. That is, the non-experimental patient
population can never be expected to have the same exact outcomes as the experimental
patient population. Still, even when real-world care and utilization of a new technology
1

The story of rofecoxib (Vioxx) is one such example, starting with approval and widespread adoption,
followed by the realization of major safety concerns, and ultimately concluding in market withdrawal (and
legal action against the drug manufacturer).
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perfectly mimics experimental conditions, the high cost of clinical trials generally means
that the number of patients studied in such experiments is relatively small. After a
technology receives FDA approval and diffuses widely, though, that technology can be
used in a much larger patient population, allowing the acquisition of new and broader
data on the technology, which may provide different insights into the efficacy, side
effects, and value of that technology. In sum, even if CEA is optimally used to drive the
adoption of high-value medical technologies, it is entirely possible (if not likely) that,
over time, new information and data will emerge that changes the general understanding
of the efficacy, safety, and value of a given medical technology. In that setting, once a
technology is in use and deemed to be low-value or have previously-unknown risks, a
researcher or policy-maker who seeks to find a way to reduce costs or improve quality of
care is left to ask, “how can we drive the disadoption of medical technologies?”

Thus, there is a unique value to studying and developing an understanding of the
disadoption of medical technologies. Indeed, this not a unique realization: one specific
goal of the widely-publicized Choosing Wisely campaign is to decrease the use of lowvalue services by educating physicians (and patients) (e.g. Morden et al 2014 NEJM;
Rabin 20120404 NYTimes). For this initiative, the American Board of Internal Medicine
(ABIM) Foundation collaborated with Consumer Reports and nine medical specialty
societies to produce, for each specialty involved, a list of the top 5 “tests, treatments, or
services that are commonly used in that specialty and for which the use should be
reevaluated” (Cassel & Guest 2012 JAMA). Thus, by encouraging the disadoption of
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specific low-value tests and procedures, the goal was to attempt to decrease some of the
over-utilization of services that has helped contribute to the massive cost of US health
care (Morden et al 2014 NEJM). This problem of technology disadoption—or, more
specifically, the lack of technology disadoption—within the healthcare industry is of
major importance.

In this dissertation, I will study physician technology disadoption, focusing specifically
on how it relates to technology adoption and physician organization. I focus specifically
on the behavior of physicians because they play an active role in almost all major medical
care decisions, including the use of most (if not all) high-cost medical technologies. In
fact, by some estimates, the decisions made by physicians are ultimately responsible for
over 80% of all dollars spent on health care (Crosson 2009 Commonwealth Fund). When
studying physicians’ technology disadoption behavior, I will first focus on its relationship
with physicians’ technology adoption behavior. As I will discuss more below
(particularly in Chapters 3 and 4), there are many similarities between technology
adoption and disadoption. Not only does an individual need to adopt a technology before
she can disadopt that technology, the processes represent a change in technology use.
While the topic of technology adoption has not yet been the topic of extensive research
(as will be discussed in Chapter 2), technology adoption and diffusion are the focus of a
very extensive literature. For these reasons, it is natural to try to determine if there are
any empirical relationships between technology adoption and disadoption behaviors.
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I next focus on the relationship between medical technology disadoption and physician
group size. While there are many factors that may influence technology disadoption, the
organization of physician groups is both conceptually significant and a topic of current
and future interest in health policy. Not only have doctors progressively moved into
larger groups over the past two decades (Burns, Goldsmith, Sen 2013 AHCM; Welch et
al 2013 Health Aff), the passage of the Patient Protection and Affordable Care Act
(ACA), with its emphasis on accountable care organizations (ACOs), will likely lead to
continued health care reorganization and grouping of physicians in the immediate future
(Greaney 2011 NEJM; Richman & Schulman 2011 JAMA; Vaughan & Coustasse 2011
Hosp Top; Blumenthal et al 2013 AJMC; Baicker & Levy 2013 NEJM). Understanding
how changes in physician organization may influence physician behavior and technology
disadoption will be valuable in considering the future course of medical technology use
and cost growth in the US health care system.

In this dissertation, I study physicians’ medical technology disadoption behavior, relating
that behavior to preceding technology adoption behavior and to physicians’ group size.
In Chapter 2, I discuss the relevant background for this work, including a review of the
literature and detailed description of coronary artery drug-eluting stents (DES), which
serve as the example medical technology that I study in the empirical portion of my
analysis. In Chapter 3, I delve into the details of adoption and disadoption behavior,
developing a conceptual framework to both consider and measure these behaviors, while
also evaluating the similarities and differences between them. Then in Chapter 3, I
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develop a basic decision-theoretic model to (a) provide structure for our understanding of
technology disadoption behavior and how it relates to group size, and (b) generate
empirically testable hypotheses about the disadoption behavior of physicians. I then turn
to empirical analyses, examining physicians’ adoption and disadoption of DES in the mid
to late 2000s, using data from New York and Florida. In Chapter 5, I look first at the
empirical relationship between physicians’ adoption behavior and subsequent disadoption
behavior. In Chapter 6, I turn to physician organization and study the empirical
relationship between physician group size and disadoption behavior. In Chapter 7, I
combine the perspectives of the previous two chapters and consider the differential
relationship between physician group size and both adoption behavior and disadoption
behavior. Finally, in Chapter 8, I provide a concluding summary evaluation and
discussion.

10

CHAPTER 2: Background
In Chapter 1, I provided the general motivation for the research questions I am asking in
this dissertation. In this chapter, I will further develop the setting for this research and
situate this work in the existing literature.

2.1 – Review of relevant literature
This dissertation relates to many different segments of the scientific literature. Here, I
will discuss the areas of the literature that are most relevant and closely related to the
current work.

Technology adoption
The topic of technology adoption has been extensively studied, both in health care and
the broader scientific literature. The academic economic study of technology adoption
dates back to the work of Joseph Schumpeter in the early 20th century, with the earliest
empirical studies typically focused on agriculture and the diffusion of hybrid corn, as
seen in the work of both sociologists (e.g. Ryan & Gross 1943 Rural Soc) and economists
(Griliches 1957 Econmetrica) (Fagerberg 2003 J Evol Econ; Diamond 2003 Res Pol).
Some of the most impactful early work was done by the economist Edwin Mansfield,
who produced significant advances in the theoretical and empirical study of technology
diffusion, noting the familiar s-shaped diffusion curve across several different industries
and technologies, and finding a positive relationship between rate of adoption and both
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technology profitability and firm size (Mansfield 1961 Econometrica; Mansfield 1963
QJE; Mansfield 1963 Rev Econ Stat). Much of the early work on technology adoption
focused on industry-wide phenomena, developing mathematical models that focused on
the technology itself and mapping the observed diffusion of that technology by using
probability distributions to describe the behavior of firms. Subsequent work, including
most notably the studies by Reinganum (1981 Rev Econ Stud) and Jensen (1982 J Econ
Theory), advanced the literature by developing decision-theoretic models of individual
firm behavior, providing additional insights into specific behaviors and factors that
influence the technology adoption process. Along with these peer-reviewed journal
articles in forming the foundation of the technology adoption literature is Everett
Rodgers’ classic work Diffusion of Innovations (published first in 1962 and most recently
updated in 2003). In his book, Rodgers provides as extensive discussion of the diffusion
and adoption of new technologies (along with a broad history of past diffusion research),
developing a language and methodology for studying technology adoption by describing:
the elements of diffusion (innovation, communication channels, time, and social
systems); phases of the diffusion process (e.g. innovation generation, communication,
evaluation, decision, implementation, etc.); relevant aspects of innovations (e.g.
complexity, compatibility, trialability, relative advantage, etc.); stakeholders in the
diffusion process (e.g. adopters, opinion-leaders, change agents, organizations); and
consequences of innovation (e.g. direct/indirect, desirable/undesirable). Since the
publication of Rodgers’ book and those early studies on technology diffusion, countless

12
other papers have been published, coming from various academic disciplines and
covering myriad technologies, including those used in the practice of clinical medicine.

Medical technology adoption
As was the case in the broader literature on technology diffusion, early work on medical
technology adoption was found in the sociology literature, including the study by
Coleman, Katz, and Menzel examining physicians’ use of a new medication (Coleman,
Katz, Menzel 1957 Sociometry). The topic has since been studied by researchers from
the disciplines of (among others) sociology, management, statistics, public health,
economics, and medicine itself. Reviews of this extensive literature can be found in Rye
& Kimberly (2007 MCRR), Fleuren, Wiefferink, Paulussen (2004 IJQHC), Phelps (2000
Handbook Health Econ), Chandra, Culter, Song (2012 Handbook Health Econ), and Scott
(1990 Med Care Rev). As the literature on medical technology adoption has grown, it
has expanded to address a growing number of questions, consider countless different
technologies, and provide progressively more nuanced detail about the various aspects
that influence and shape the diffusion process, including stakeholders and environmental
factors. Indeed, when approaching and evaluating this broad literature, studies can be
considered using different organizing principles. For example, one way to categorize the
literature is according to the adoption agent or stakeholder being studied. Patients’
technology adoption behavior has studied relatively infrequently, with some articles
examining the extent of patients’ adoption health-related technologies—including
smartphone-based mobile health apps (Murnane, Huffaker, Kossinets 2015 UBICOMP;
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Krebs & Duncan 2015 JMIR) or pedometers (Craig, Tudor-Locke, Bauman 2007 Health
Ed Res)—and other articles evaluating the patient characteristics, such as age and
education, that shape the rate of technology adoption (Olson et al 2011 Ageing Int;
Lleras-Muney & Lichtenberg 2002 NBER wp). Similarly, payers are another party in the
health care marketplace who’ve received little attention from technology adoption
researchers, with few studies considering the influence of payer structure (e.g. health
maintenance organization versus fee-for-service indemnity plans) or market share on
rates of technology diffusion (Ramsey & Pauly 1997 Inquiry; Baker 2001 JHE; Hirth,
Chernew, Orzol 2000 Inquiry). On the other hand, unlike with patients and payers, the
technology adoption behavior of health care providers has been exhaustively studied.
Indeed, this difference is entirely reasonable, given that providers are understood to play
a fundamental role in recommending, selecting, and/or providing medical technology for
use in the clinical care of patients. Given this influence and the importance of technology
in shaping both the cost and quality of medical care, it is unsurprising that there is a vast
literature evaluating the technology adoption behavior of hospitals (e.g. Skinner &
Staiger 2009 NBER wp; Teplensky et al 1995 HSR; Epstein et al 2004 JACC; Greenberg
et al 2005 IJTAHC; Kimberly & Evanisko 1981 Acad Mgmt J; Lee & Waldman 1985
JHE) and physicians (e.g. Coleman, Katz, Menzel 1957 Sociometry; Freiman 1985 Med
Care; Selder 2005 JHE; Hu et al 1999 JMIS; Navathe & David 2009 J Hum Cap; Escarce
et al 1995 Med Care). Of particular interest in the current dissertation—in which I study
the disadoption of coronary artery stents—is the adoption behavior of cardiologists (who
implant coronary artery stents), which has been the subject of several studies.
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Researchers have looked at the variation in cardiologists’ rates of adoption of surgical
techniques, technologies, and equipment, along with medications and imaging modalities
(e.g. Artis et al 2006 J Med Syst; Pisano et al 2001 Mgmt Sci; Webb & Barbanti 2013
JACC; Burke, Fournier, Prasad 2007 SEJ; Pozen et al 1984 Med Care; Steinberg et al
2013 JAHA).

To help digest the large literature on medical technology adoption by health care
providers, we can consider another means of categorizing this literature: according to the
technology that is being adopted. Unsurprisingly, given the role of technology in the
growth of health care spending (as discussed in Chapter 1), researchers have done
considerable work on the diffusion of expensive, new medical technologies2. For
example, there have been several studies examining the diffusion of magnetic resonance
imaging (MRI) (e.g. Weigel 2006 J Surg Onc; Teplensky et al 1995 HSR; Baker 2001
JHE; Palesh et al 2007 IJTAHC; Fujimura et al 2004 Acta Neurochir; Schmidt-Dengler
2006 wp) and computed tomography (CT) imaging (e.g. Ladapo et al 2009 Health Aff;
McHugh et al 2011 JACR; Hillman & Schwartz 1985 Med Care; Scheyerer et al 2014
EJNMMI; Hopkins et al 2013 Ped Rad; Nystrom, Ramamurthy, Wilson 2002 JETM).
Equipment aside, many researchers have examined the diffusion of medications, studying
how rapidly new medications enter into normal clinical practice and how that diffusion is
shaped by marketing, education, pricing, and/or policy changes (e.g. Crawford & Shum
2

Of course, “new” and “expensive” are both relative terms. Technologies that are considered “new” here
are ones that have been recently (at the time the research was conducted) introduced to a market.
“Expensive” refers generally to the cost faced by payers and patients, as opposed to the true cost of the
technology (e.g. development or production). As is the case in many other industries, how new or
expensive a medical technology is can change drastically (generally, both decrease) with time.
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2005 Econometrica; Coscelli & Shum 2004 J Econometrics; Berndt et al 1995 AER;
Skinner & Staiger 2005 NBER wp; Serra-Sastre & McGuire 2013 App Econ; Berndt,
Pindyck, Azoulay 2003 J Indust Econ; Azoulay 2002 JEMS; Bradford & Kleit 2013 wp;
Ching & Ishihara 2010 Quant Mrkt Econ; Nair, Manchanda, Bhatia 2010 J Mrkt Res).
In addition to work on diagnostic and therapeutic medical technologies, there has also
been extensive research on other diffusion of other innovations in the health care sector,
including a large and growing literature on electronic medical records and their impact on
health care quality, efficiency, and cost (e.g. Chaudhry et al 2006 Ann Int Med; Gans et
al 2005 Health Aff; Hillestad et al 2005 Health Aff; Menachemi et al 2008 HCMR;
Desai 2015 dissertation; Angst et al 2010 Mgmt Science; Bhattacherjee et al 2007 Info
Sys Mgmt; Miller & Sim 2004 Health Aff). Even further abstracted from physical
technology are clinical guidelines, policies, or diagnostic/therapeutic algorithms, each of
which has also been examined by medical and social science researchers (e.g. LaBresh et
al 2014 Pediatrics; Bernhardt et al 2015 Stroke; Faust et al 2015 AJTMH; Fiks et al 2015
HSR; Schauffler, Mordavsky, McMenamin 2001 Am J Prev Med; Bellows, McMenamin,
Halpin 2007 Med Care; Brehaut, Stiell, Graham 2006 Acad EM; LeFevre 2013 Prof Case
Mgmt; Gold et al 2012 Cancer Imag; Gupta et al 2014 JAMIA; Durston 2014 AJEM; Sen
2015 dissertation). Bridging the realm of treatment algorithms and physical technology
are various surgical techniques and methods, which have also been studied by diffusion
researchers (e.g. Sloan et al 1992 JHE; Hollingsworth et al 2008 Med Care; Escarce 1996
JHE; Escarce et al 1995 Med Care; Gross et al 2002 Am J Gastro; Giannopoulos et al
2013 SLEPT; Ho 2002 JHE). One specific surgical technology is coronary drug-eluting
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stents (DES), which is the technology that I study empirically in this dissertation. The
adoption of coronary stents in general (which include bare-metal stents, BMS) and DES
specifically have already been studied by many researchers, (e.g. Sfekas & Antwi 2014
wp; Chandra, Malenka, Skinner 2014 NBER chap; Karaca-Mandic & Town 2013 wp;
Epstein et al 2012 Med Care; Xu, Avorn, Kesselheim 2012 CCQO; Huesch 2011 Soc Sci
Med; Krone et al 2010 JACC Card Int; Shih & Berliner 2008 Health Aff; Burke,
Fournier, Prasad 2007 SEJ). This work, which has examined various factors that
influence stent adoption and the results of such adoption, provides relevant background
and groundwork upon which the current dissertation is built.

Yet another way to categorize the large literature on medical technology adoption is by
the various determinants that have been shown to influence adoption. To attempt to
detail each of the different factors that has been shown to influence technology diffusion,
or at least correlated with variations in adoption behavior, would be an exercise in futility
due to how many different factors have been studied. However, these determinants can
be divided into different groups. First, there are environmental factors, which exist
outside of the firm or adoption agent and do not relate specifically to the technology
itself. For example, studies have examined the relationships between medical technology
adoption and both geographical factors (e.g. Eisenberg et al 1989 JAMA; Poulsen et al
2001 Health Pol; Knudsen, Ducharme, Roman 2006 JSAT) and regulatory environment
(e.g. Bradford & Kleit 2013 wp; Chintagunta, Jiang, Jin 2009 Quant Mrkt Econ;
Teplensky et al 1995 HSR; Castle 2001 Gerontologist). Economists have also
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extensively studied the impact of market structure and competition—both between health
care providers and payers—on medical technology adoption (e.g. Barbash et al 2014 Ann
Surg; Karaca-Mandic & Town 2014 wp; Baker & Wheeler 1998 Health Aff; Baker &
Phibbs 2002 RAND; Roman & Johnson 2002 JSAT; Hirth, Chernew, Orzol 2000
Inquiry; Kimberly & Evanisko 1981 Acad Mgmt J; Lee & Waldman 1985 JHE; Wang et
al 2005 HCMR). A second set of factors related to the rate of medical technology
diffusion are the characteristics of the technology itself. As one would predict from
theory and intuition, empirical research has shown that both the profitability or financial
implications and the clinical quality or efficacy of a technology is strongly related to its
adoption rate (e.g. Selder 2005 JHE; Hillman & Schwartz 1986 Am J Roent; Cappallaro,
Ghislandi, Anessi-Pessina 2011 Health Pol; Schreyogg, Baumler, Busse 2009 Health Pol;
McHugh et al 2011 JACR; Abrishami, Boer, Horstman 2014 Soc Sci Med; Teplensky et
al 1995 HSR; Randeree et al 2003 JHIM; Lee & Waldman 1985 JHE). Third, the
characteristics of the adoption stakeholders are frequently related to the observed rate of
technology adoption. In the case of medical technology, this group of factors includes
characteristics of patients, physicians, hospitals, and other health care provider
organizations, all of which have been shown to be associated with technology diffusion
rates in empirical studies (e.g. Lleras-Muney & Lichtenberg 2002 NBER wp; Navathe &
David 2009 J Hum Cap; Sato & Zouain 2012 Einstein; Roman & Johnson 2002 JSAT;
Knudsen, Ducharme, Roman 2006 JSAT; Burke, Fournier, Prasad 2007 SEJ; Nair,
Manchanda, Bhatia 2010 J Mrkt Res). For the current dissertation, which will examine
the role of physician organization in relation to technology adoption and disadoption, this
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third category is most relevant. Most notably, because I will specifically focus on
physician group size, it is worth noting that a large number of studies have examined the
association of provider organization size and technology diffusion (e.g. Nystrom,
Ramamurthy, Wilson 2002 JETM; Poulsen et al 1998 Health Pol; Hirth, Chernew, Orzol
2000 Inquiry; Knudsen & Roman 2004 JSAT; Walston, Kimberly, Burns 2001 MCRR).

Technology disadoption
While technology adoption has been the subject of a vast and growing literature, the topic
of technology disadoption has been studied much less commonly. As with technology
diffusion, much of foundational work on technology disadoption if found in the literature
on farming and agriculture (e.g. An & Butler 2012 CJAE; An 2013 AEPP; FernandezCornejo et al 2002 ARER; Gedikoglu 2010 wp). While these papers offer general
guidance for ways to evaluate technology disadoption, the dissimilarities between the
agriculture and medical industries and their associated technologies are significant
enough to prohibit any deeper insight or revelations. Fortunately, there is a specific
literature dedicated to technology disadoption, though this literature is remarkably small.

Almost all of the current studies on medical technology disadoption have a similar design
and motivation in that they evaluate the decrease in use of a technology following the
publication of updated clinical guidelines or research that recommended abandonment of
the technology. For example, Shen et al (2013 Arch Gyn Ob), Howard et al (2011 HSR),
and Howard & Shen (2013 HSR) all assess the impact of a major trials (whether
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systematic reviews or large randomized controlled trials) recommending against the use
of a specific technique or technology (episiotomy, high-dose chemotherapy/
hematopoietic cell transplant, and percutaneous coronary intervention, respectively).
Howard et al (2012 Health Aff) similarly look at (and find as significant) the impact on
arthroscopic knee debridement and lavage of multiple research studies indicating no
benefit of that procedure for osteoarthritis, but the picture is compounded by multiple
payers contemporaneously dropping coverage for the procedure. Considering another
even that is arguably even more impactful than the publication negative research results,
Dorsey et al (2010 Arch Int Med) examine the impact of an FDA black box advisory
regarding the increased mortality risk linked to the use of atypical antipsychotics in
elderly patients with dementia, and they find a significant (negative) impact of the
advisory.

Another group of disadoption studies does not specifically examine the impact of a
specific publication or advisory, but instead focuses on the determinants that shape health
care providers’ disadoption behavior. For example, Duffy & Farley (1992 Med Care)
study the abandonment of intermittent positive pressure breathing (IPPB), an outdated
technology, and how that disadoption relates to various hospital, patient, and physician
traits. Similarly, Berez et al (2014 wp) study the role of physician peer influence on the
decrease in utilization of pulmonary artery (PA) catheters (following the publication of a
high-impact paper and multiple subsequent randomized controlled trials). Sen (2015
dissertation) also examines the influence of physician peer effects, looking at the change

20
in prostate and breast cancer screening rates (using prostate-specific antigen and
mammography, respectively) following updates to nationally-published screening
guidelines. In sum, these articles, building on the other disadoption studies that
demonstrate the impact of external information (publications or advisories), show that
physicians influence each others’ practice patterns, presumably via information transfer.

While these studies individually and collectively provide novel insights into medical
technology disadoption, they have significant limitations. First, most of these studies
lack a decision-theoretic economic model. Such studies, while providing empirical
evidence of technology disadoption, focus simply on whether or not a past intervention,
announcement, or policy change triggered disadoption. Generally speaking, such studies
do not attempt to provide insight into the fundamental mechanisms or incentives driving
technology adoption, or how that process relates to various structural characteristics that
define a physician’s practice environment. Similarly, while a few studies evaluate the
role of peer interactions in shaping disadoption behavior, they generally do not propose
theoretical foundations to explain such peer effects. Second, along these same lines,
rather than studying physician characteristics, several of the studies relate technology
disadoption behavior to hospital characteristics. Given the fundamental role of
physicians in the medical technology adoption and disadoption processes, there is value
to be gained from examining physician characteristics relative to those processes. Third,
these studies generally take a simplistic view of technology disadoption, either treating it
as a simple event or not measuring it specifically. As I will discuss in detail in Chapter 3,
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I propose that technology disadoption (like adoption) is not an event, but instead a
process that can be characterized along multiple dimensions. The studies that do not treat
disadoption as a single event instead examine it by simply studying technology use
during a period of general downward trends in population-level technology use, which
does not define or measure disadoption per se. In both cases, the studies generally lack a
detailed empirical measurement of the technology disadoption process. Fourth, while
some studies address the relationship of physician groups to medical technology
disadoption, they typically do so by empirically testing for the presence of looselydefined peer effects. Such studies provide value in showing that physicians’ disadoption
behavior relates to that of their peers, but they do not provide further insight into the
mechanisms for this relationship or the structural characteristics of a physician group that
might influence the relationship. Finally, and most importantly, none of the current
studies have related medical technology disadoption to a physician’s past adoption
behavior and very few of the studies consider the role of group size (and the ones that do,
measure disadoption very differently than I will, as mentioned above). It is this series of
limitations among the existing medical technology disadoption literature that the current
dissertation seeks to address, thus making it a novel and significant contribution to the
scientific literature.

Physician group size
The literature on physician group size is also directly related to this dissertation. Though
group size has been only occasionally related to technology disadoption behavior, the
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topic of group size has been the subject of frequent examination in the broader
technology adoption literature, as mentioned above. Dating back to one of the earliest
seminal works on technology adoption, Ryan and Gross identify connection and
communication between neighboring farmers as one of the key determinants in driving
differences in rates of diffusion of hybrid seed corn technology in Iowa in the 1930s
(Ryan & Gross 1943 Rural Soc). As Geroski (2000 Res Pol) notes, “firm size turns out
to be a very commonly explored variable [that characterizes the timing of technology
adoption] in the empirical literature on diffusion.” (However, he continues, this is “partly
because it is typically taken as a proxy for all kinds of things,” though there is no real
consensus on how exactly group size proxies for different characteristics3.) Despite these
findings and the similarities between technology adoption and disadoption, which will be
discussed at length below (in Chapter 3), there is very little work examining the
relationship between group size and technology disadoption.

Aside from its specific relationship to technology adoption, group size has also been the
topic of increasing interest in the health services and health economics literatures.
Multiple studies have examined the changing organization and group sizes of physicians,
showing a two-decade trend away from solo practices and toward larger groups (e.g.
Bauer et al 2012 Med Care; Burns & Muller 2008 Milbank Q; Welch et al 2013 Health
3

Indeed, some researchers present reasons to believe that larger firms will adopt new technology sooner,
while others argue that larger firms will adopt later. It is worth noting that some of the researchers who
consider group or firm size to be an important determinant of technology adoption study technologies that
are very different from drug-eluting stents, the technology that I study here. (For example, a technology
that requires a large capital investment but can reduce per-employee costs would be more beneficial to
firms with more employees.) Thus, it is not clear that the observations from these other studies can be
applied or translated directly to the current dissertation, but they still provide some motivation for studying
the important of group size in this setting.
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Aff; Burns, Goldsmith, Sen 2013 AHCM; Berenson, Ginsburg, Kemper 2010 Health Aff;
Liebhaber & Grossman 2007 CSHSC rep). Furthermore, there is a long literature
studying the role of physician organization in shaping physician behavior. Early studies
in the health economics literature have examined the general economic theory
surrounding physician group practice (e.g. Newhouse 1973 JHR; Pauly 1996 JACM), and
more recent studies have focused on the empirical association between group size and
physician behavior. Findings from some of the most recent examples from this literature
include that group-based physicians perform better on certification exams (e.g. Lipner et
al 2011 Acad Med); solo practitioners seem less likely to follow clinical guidelines
(Ketcham, Baker, MacIsaac 2007 Health Aff); larger group size is associated with great
engagement in quality improvement (Audet et al 2005 Health Aff); group-based
physicians offering more health promotion programs (McMenamin et al 2004 Am J Prev
Med); and large group size is associated with greater use of information technology tools
(Audet et al 2004 Medscape GM). Though this is an extensive literature, it has
limitations. First, many of the studies in this literature, which were published in clinical
or health services journals, are based on physician survey, and thus lack the ability to
draw causal inference between group size and physician behavior. Second, this literature
is generally lacking decision-theoretic models, which can provide insight into physician
behavior and the mechanisms through which group size influences actions. Third,
medical technology disadoption is a topic that appears only rarely in this literature, and
never with a detailed characterization of the disadoption process, as I will develop in this
dissertation.
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Despite these limitations, this sizeable (and growing) literature depicting the benefits to
increasing group size has understandably garnered a considerable amount of support.
Throughout the medicine and health policy literature, one can find many researchers,
thought-leaders, and policy-makers who promote continued growth of health provider
group size (e.g. Weeks et al 2010 Health Aff; Enthoven 2009 AJMC; Crosson 2005
Health Aff; Shih et al 2008 Cmnwlth Fund; Solberg et al 2009 AJMC; Casalino 2006
Ann Int Med). As this sentiment becomes increasingly common, the need to evaluate the
impact of group size on various behaviors and outcomes—for example, on the
disadoption of high-cost, low-efficacy, and/or low-value medical technologies—grows
commensurately.

2.2 – Empirical setting: drug-eluting coronary stents
Technology function and history
Through most of my discussion of technology adoption and disadoption thus far, I’ve
only referred to generically to “medical technology,” but to study these processes
empirically, it is necessary to choose a specific technology. In this dissertation, I focus
my empirical examination on coronary artery stents, the relevant details of which I will
describe here.

Coronary artery stents are tiny mesh tubes that are placed inside of coronary arteries to
hold open those arteries, as shown in Figure 2.1. Coronary arteries are the blood vessels
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which supply oxygenated blood to the heart, allowing it to pump and supply blood to the
entire body. Blockage of (or damage to) these vessels produces coronary artery disease,
the most common type of heart disease, which is the leading cause of death in the US. (A
complete blockage of a coronary artery can lead to myocardial infarction, or a heart
attack, an acutely severe and potentially lethal form of coronary artery disease.)
Coronary stents are implanted into the coronary arteries by interventional cardiologists
via percutaneous coronary intervention (PCI), a surgical procedure during which a thin
catheter is inserted into a large vessel (most typically in the femoral artery in the leg or
the radial artery in the arm) and threaded up through blood vessels to the heart, where the
coronary arteries are then accessed. The tip of the catheter generally contains a balloon,
which can be inflated in the lumen of a partially occluded vessel, thus pushing open that
vessel in a procedure known as percutaneous transluminal coronary angioplasty (PTCA),
or simply balloon angioplasty. PCI with angioplasty with was first used in the 1970s, but
had become widely used in medical center around the world by the mid-to-late 1980s
(Gresh 2003 BMJ). While angioplasty was capable of opening occluded vessels, there
was natural risk for those vessels to re-occlude (or restenose), which prompted the logical
development of coronary artery stents. The original coronary artery stents, which were
simple metal mesh, now referred to as bare-metal stents (BMS), were first implanted in
the late 1980s, but were in widespread use by the mid-to-late 1990s (Serruys, Kutryk,
Ong 2006 NEJM).
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Figure 2.1: Coronary artery stent diagram (Source: NHLBI, NIH)

Though the BMS provides the structural presence to hold open coronary vessels, clinical
experience over several years with coronary stents revealed that in-stent restenosis of the
vessel was a common problem. This persistent issue motivated the development of drugeluting stents (DES), which were similar structurally to BMS, but also coated with
pharmaceutical products that decreased the coronary vessels’ natural restenosis process.
The high prevalence of restenosis with BMS (with rates up to 50%) and the drastic
reduction in restenosis observed in early DES trials (rates between 0 and 9%) lead to
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tremendous excitement in the interventional cardiology community and rapid DES
adoption following FDA approval in April 2003 (Serruys, Kutryk, Ong 2006 NEJM). A
year after approval, more than 50% of coronary stents implanted were DES, with rates
continuing to climb and exceeding 90% by 2005 (Krone et al 2010 JACC Card Int). (See
literature review in Section 2.1 above for references to studies that examined the initial
diffusion of DES.)

However, this rapid diffusion was accompanied by continued research and real-world
experience with DES, which revealed potential concerns with the new technology. While
DES were designed to address the issue of in-stent coronary artery stenosis, another
critical issue was that of thrombosis, or the formation of new blood clots inside the stent,
which can then occlude the coronary vessel, leading to myocardial infarction or
dysfunction. In January 2004, Virmani and colleagues published the first case study
reporting late (i.e. several weeks or months after implantation) coronary stent thrombosis
and death in an individual who had received DES (Virmani et al 2004 Circ). Additional
similar cases were reported in The Lancet in October 2004 by McFadden and colleagues,
which was followed by the report of similar findings in a small study of “real-world”
patients in JAMA in May 2005, creating the first signs of momentum around concerns for
late stent thrombosis in DES (McFadden et al 2004 Lancet; Iakovou et al JAMA 2005).
In September 2006, these concerns reached their peak at the World Congress of
Cardiology in Barcelona, where Camenzind and colleagues presented meta-analysis of
the DES randomized clinical trials, which showed not only increased rates of late stent
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thrombosis DES relative to BMS, but also increased risk of myocardial infarction and
death (Camenzind 2006 World Cong Card). These findings—which represented a
coalescence and validation of the diffuse and generally muted concerns over DES
safety—received widespread publicity and marked the beginning of a period during
which DES rates began to sharply decline (Krone et al 2010 JACC Card Int). Eventually,
further research showed that the risk of late stent thrombosis in DES could be mitigated
with dual anti-platelet therapy (DAPT), which then lead to the eventual resurgence of
DES rates, beginning in 2008 (Lee et al 2007 Am J Card; Buonamici et al 2007 JACC;
Lee et al 2008 JACC; Gori et al 2008 JACC; Epstein et al 2011 JAMA). Figure 2.2
graphs the trend in physician-level DES implantation rates over this time period in
Florida and New York (using the data that will be later used for empirical analyses
throughout this dissertation).

Figure 2.2: DES usage rates in the 2000s in Florida and New York
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Important features of DES
Having established the general history of DES, there are several aspects of this
technology that make it an appropriate choice of setting for the empirical study of
medical technology disadoption. First, the technology was widely used (with usage rates
exceeding 90% from 2005 into 2006) and showed both significant increases and
decreases in use over time, which makes for easy observation of both adoption and
disadoption behavior in the data and improves both internal and external validity of any
study. Also, the relatively rapid changes in usage rates make it possible to observe both
the adoption and disadoption processes in a relatively small time window. Furthermore,
we are able to observe the diffusion of DES with high fidelity because, due to the early
excitement surrounding the technology, the Center for Medicare and Medicaid Services
established procedure codes allowing for DES implantation prior to FDA approval of the
technology. Hence, unlike many other medical technologies, which come to market and
in use before specific billing codes are established for the new technology, DES
implantation could be appropriately coded from its first approved implantation and thus
appears reliably in hospital discharge data files throughout its history, significantly
reducing the amount of error introduced by the data generation and collection processes.

Another advantage of using DES as the setting for empirical examination of medical
technology adoption and disadoption is the fact that there was significant variation
between cardiologists in DES usage rates. As seen in Figure 2.1, though the global trend
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of adoption, disadoption, and re-adoption is clear, there is significant deviation in DES
usage rates around that trend, which increases the statistical potential to empirically
identify factors that may partially be responsible for causing that variation. This varation
is the result of the fact that, unlike some other examples of medical technology, a
cardiologist’s choice of coronary stent (BMS vs DES) is largely subjective, based on
individual knowledge, experience, and preferences (as opposed to strict, well-established
guidelines). While some patients may have had clinical presentations that provided
obvious indications for one technology or the other, cardiologists were faced with many
patients whose coronary artery disease could be reasonably treated with implantation of
either BMS or DES, subject to the cardiologists’ judgement and inclinations. Indeed,
even though the FDA approval of DES brought with it specific indications for use, high
levels of enthusiasm for the new technology led to rapid, widespread adoption and
frequent off-label use. After the September 2006 publicization of data that indicated
increased risk of late stent thrombosis, the global decrease in DES implantation rates was
not due to general change in patient characteristics or concrete guidelines for DES use.
Rather, the appearance of evidence that was unfavorable towards DES simply led many
physicians to recalibrate their preferences and decision processes, leading them to favor
BMS over DES in patients who were on the technology choice margin. Thus, the fact
that a cardiologist’s specific choice of coronary stent was frequently a judgment call lead
to significant within-population variation in DES rates, which provide a favorable setting
for empirical analysis.
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Yet another strength of this empirical setting of medical technology use is that the
decision to use DES can be isolated with relative certainty to the physician and her
perception of the relative clinical value or appropriateness of DES. With many new
technologies, an individual’s ability to adopt or disadopt is directly influenced or
constrained by several external factors. For example, with medical technologies that
require pieces of expensive equipment (e.g. a surgical robot or a cyclotron for proton
beam therapy), an individual physician can only adopt the technology if a larger
organization (typically a hospital) makes the major capital investment in that equipment.
Similarly, if the organization decides to sell or eliminate the equipment, physicians who
were using that technology may be forced to disadopt it. In the case of DES, though
there were some supply constraints early on (as is the case with most new, popular
technologies), the technology was relatively small and cheap, in addition to being
extremely popular among physicians, so hospitals were able and motivated to make the
DES accessible to all physicians who wanted to implant it, even after September 2006.
Indeed, even though hospitals’ margins were lower for DES than BMS4, DES was wildly
popular among cardiologists and was generally considered to be the standard of care,
which resulted in persistently high physician (and patient) demand for DES. Thus,
because hospitals did not want to provide (or appear to provided) below-standard care or
run the risk of alienating their revenue-generating interventional cardiologists, hospitals
routinely provided physicians with unfettered access to DES (Shih & Berliner 2008
Health Aff).
4

Even though Medicare created a separate diagnosis-related group (DRG) for DES which provided more
payment than BMS, the acquisition cost of DES was more than commensurately higher, resulting in the
hospitals realizing lower per stent margin for DES than BMS (Epstein et al 2012 Med Care).
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In the same way that access to equipment can shape an individual’s ability to adopt
technology, acquisition of skills is often an important factor in shaping both adoption and
disadoption. Individuals may hesitate to adopt a technology due to the required fixed
cost of acquiring new skills necessary for its use, or they may be disinclined to disadopt a
technology if they believe their skills with it are so great that they can achieve greater
production with it than any other alternative. In the case of coronary stents, there is no
differential skill level required for DES relative to its substitute technology, BMS. Thus,
neither adoption nor disadoption of DES would be confounded by differences in provider
skill. Another external factor that can shape individuals’ technology adoption and
disadoption behavior is the difference in financial incentives between technology options.
If an individual gets paid more to use an old technology than a newer technology, that
may likely incentivize her to continue using the old technology. However, in the case of
coronary stents, physicians received the same financial reimbursement per stent
implanted, regardless of whether the stent was DES or BMS, so financial incentives
likely played no role in driving physicians’ adoption or disadoption behavior5.

Given all of these factors, DES provide a convenient setting to empirically study medical
technology disadoption, and I will use this empirical setting in the following chapters.
5

As mentioned above, the cost and reimbursement to the hospital that provided the stent and the setting for
its implantation differed significantly between BMS and DES, resulting in hospitals earning lower margins
for DES. Thus, there may have been an incentive for hospitals to try to influence physicians’ choice of
coronary stent away from DES, but appears to have been counterbalanced by incentives in favor of DES
(e.g. reputation for quality, relationship with physicians, which is critical for long-term revenue
generation). Furthermore, I am unaware of any evidence that hospitals attempted to persuade physician
stent choice in practice.
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However, before beginning this empirical investigation, I first must establish a
framework for characterizing the technology adoption and disadoption processes.
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CHAPTER 3: Characterizing technology adoption and disadoption
Having provided the motivation and background to substantiate this dissertation and the
specific topic of inquiry, I now begin the process of identifying and elucidating the
specific research questions to be addressed. My primary interest here is the examination
of medical technology disadoption, which will require thinking deeply about the meaning
and measurement of this phenomenon. In this chapter, I start by providing a conceptual
characterization of both technology adoption and disadoption. This characterization will
provide the framework for the creation of measurements that will be used in the
subsequent empirical analyses of the adoption and disadoption of drug-eluting stents.

3.1 – Conceptual framework
As described above in Chapter 2, technology adoption has been the subject of a large and
growing scientific literature. When studied empirically, the adoption of technology is
typically described by a simple definition: adoption occurs when an individual first uses
a technology. Disadoption, on the other hand, has been studied less frequently and, when
studied, has not been consistently defined. In fact (as described in Chapter 2), many of
the studies that claim to examine disadoption do not actually define disadoption at all, but
instead simply perform empirical analyses of technology use while restricting their focus
to a time period in which that technology’s usage rates are generally decreasing within a
population. While such analyses may broadly explore technology disadoption, it is
unclear that they provide insight specifically into disadoption itself, per se. However,
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some studies do provide a specific definition for disadoption and, among these studies,
the typically used definition is the inverse of that used most frequently for adoption:
disadoption occurs after an individual has used a technology for the final time. As shown
in Figure 3.1, which provides a graphical depiction of technology adoption and
disadoption, these common definitions focus on technology use as a binary, “yes-no”
state.

Figure 3.1: Technology adoption and disadoption with binary technology use

While this framework for understanding technology adoption and disadoption is both
well-defined and commonplace, there are at least two issues with it. First, though the
definitions are (in a way) symmetric, they actually create disparate measures of two
processes that we may wish to view through a similar lens. When studying adoption, it is
both natural and informative to examine the time when a technology is first used—hence
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the traditional definition of adoption that is used in the literature. However, if we are
similarly interested in examining the initial change that represents technology
disadoption, we see that this information is absent from the traditional definition of
disadoption, i.e. as occurring after a technology is used for the final time. Thus, if we
want to examine the similarities or relationships between technology adoption and
disadoption (which may be motivated by our understanding of the two phenomena as
being relatively similar, as will be discussed below), it seems that we may want to
consider a different definition of disadoption, if not also adoption.

Second, deeper examination of the technology use reveals that the traditional views of
adoption and disadoption may be overly simplistic and ignore some important aspects of
the adoption and disadoption processes. To consider these processes in more detail, we
start by examining Figure 3.2, which depicts technology use in greater detail than was
shown in Figure 3.1. Rather than reducing technology use to a binary, on-off state, this
figure plots technology usage rate, which can vary between 0 and 100%. As an example,
technology usage rate may be measured as the percentage of a physician’s patients who
receive the specified technology. Even if a physician adopts a new technology (e.g.
purchases a surgical robot or starts prescribing a given medication), she may not use that
technology to treat all of her patients. Thus, even for individuals who adopt (and
disadopt) a technology at the same time, there may be significant differences between
those individuals in terms of how much that technology is used. This type of variation is
depicted in Figure 3.2, which shows four individuals with visibly different technology
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usage rates, even though each of the four individuals adopts and disadopts the technology
in the same time periods and would thus appear identical if depicted in the framework
used in Figure 3.1, which ignores the intensive margins of technology use.

Figure 3.2: Technology adoption and disadoption with continuous technology usage rate

The distinction noted here raises a question: when studying technology adoption and
disadoption, do we think there are significant differences between the four individuals
depicted if Figure 3.2, or do we believe that all four individuals can be treated as
identical? In this dissertation, I take the stance that these individuals should be treated as
different. Rather than using the simple traditional definitions to characterize technology
adoption and disadoption, I choose to take a more detailed perspective. While we can all
agree that each of the four individuals in Figure 3.2 first uses and last uses the specified
technology at the same times, it is not entirely clear when each of the individuals starts
the process of disadopting that technology. Indeed, instead of treating adoption and
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disadoption as events, I view these as processes which can be characterized along
multiple dimensions, which I will explain below.

It is important to note here that this concept of technology “usage rate,” like any other
rate, is composed of two parts mathematically: a numerator and denominator. In the
example described here, the denominator could be a physician’s total number of patients
(at least those who would be eligible for use of the given technology) and the numerator
would be the number of patients for whom the given technology is actually used. In this
framework, then, it is important to keep in mind that changes in technology usage rate,
which will be used to define adoption and disadoption (as explained below), may be the
result of changes in either the numerator or denominator, or both. Generally, if we
assume a physician’s patient volume and mix are relatively consistent—i.e. changes in
patient volume are due to addition or removal of patients who are similar in number and
characteristics—we would not expect the numerator or denominator to change out of
proportion to each other, and technology usage rate should theoretically be a reliable and
consistent measure of physician behavior. However, an influx of a unique type of patient
(e.g. of a risk profile that made technology use very unlikely, or more importantly,
significantly less likely than the physician’s existing patient population) could lead to a
disproportionate change in the denominator, causing a drastic change in technology usage
rate, without an underlying change in physician preferences or behavior. Similarly,
changes in total patient volume to the extreme (e.g. reduction to 1 or 0 patients) would
also likely result in extreme fluctuations of a technology usage rate measure. Of course,
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such changes in patient population could also introduce problems for any other
quantitative measure of physician technology use, including adoption or disadoption
measures, but the unique potential for variation in a ratio-dependent metric must always
be kept in mind.

Also, as with any analysis that is fundamentally temporal in nature (including adoption
analyses under the traditional framework), measurement of time is a critical component
of these calculations. If we again assume a relatively stable patient volume and
characteristic mix, the parsing of time periods into larger or smaller pieces should only
change temporal resolution of the analysis. However, in reality, use of progressively
smaller time periods, which might seem preferable in the interest of improving temporal
resolution, can reduce a physician’s per-period patient volume (i.e. technology usage rate
denominator) to the point where stochastic variations are on the same order as true
variations, and the technology usage rate would become too noisy to use reliably. (For
example, even if a physician generally sees the same number of patients every month or
week, there will very likely be some days—due to illness, vacation, or other
obligations—when the physician will treat few or no patients. As such, a blind
comparison of that physician’s day-to-day technology usage rate could produce bizarre
results due to relatively significant changes in the patient volume, i.e. the use rate
denominator.) Thus, there is a natural trade-off between limiting noise from expected
time-based variations (by choosing larger time periods) and improving resolution of a
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fundamentally temporal analysis (by choosing smaller time periods), and the balance of
these countervailing forces can only be determined empirically.

3.2 – Dimensions of technology adoption and disadoption
Figure 3.3 provides a simple, stylized graphical depiction of an individual’s technology
usage rate over time. Given that the empirical setting of interest in this dissertation is the
use of coronary artery stents, we can imagine that the curve drawn here represents a
physician’s quarterly DES rate, i.e. the fraction of coronary stents placed by the physician
that are drug-eluting (as opposed to bare-metal) in each quarter. There are several
important aspects to note in this figure. First, rather than adoption and disadoption being
illustrated as discrete events, they are depicted as processes that take place over multiple
time periods. These processes, however, are still characterized by multiple different
discrete events. For example, there is a time period labeled with “technology approved,”
which marks when the medical technology received FDA approval and reached the
market, and is thus the first time period in which the technology adoption process could
begin. Similarly, we may also be interested in identifying the first time period in which
the technology disadoption process could begin. In this respect, though, disadoption is
not perfectly analogous to adoption because the disadoption process can begin any time
after the technology is in use. However, there generally is (and should be) a reason for
individuals to disadopt a technology, whether it’s the availability of a new, superior
technology or the development of disfavor with the existing technology. In the specific
case of DES (as was discussed in Chapter 2), the announcement of safety concerns (at the
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World Congress of Cardiology in September 2006) regarding increased risk of
thrombosis with DES lead to the widespread decline in DES placement rates. Thus, we
can use this point to delineate the first time period in which individuals could begin the
DES disadoption process6.

Figure 3.3: Graphical characterization of technology adoption and disadoption processes

To further characterize the adoption and disadoption processes, there are other events or
points along the technology use curve to consider. In an attempt to simplify analyses of
these processes while still gathering useful information, I focus specifically on the two
points that can be used to mark the beginning and end of the processes, as shown in
Figure 3.3 and further highlighted in Figure 3.4. For the adoption process, the starting

6

In reality, it was indeed possible for cardiologists to disadopt DES before September 2006. However, in
practice, this was very rarely observed, as population-wide DES placement rates remained stable above
90%, up until September 2006. As such, and also for empirical reasons to be described later, many of the
analyses in this dissertation restrict definitions of DES disadoption to start no earlier than September 2006.
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point is the “initial adoption” and the ending point is the “maximum technology use7.”
On the disadoption side, the starting point is the “initial disadoption” and the ending point
is the “minimum technology use.8” Providing more detailed description and definitions
of these points, we start with the first point, “initial adoption.” This point marks the time
period when an individual first uses a technology and the level of technology use in that
time period. Of course, this is just one criteria (albeit a logical one) that can be used to
define “initial adoption.” Alternatively, one could choose to define “initial adoption”
based on some threshold level of technology use. That is, rather than setting that
threshold at zero and saying an individual begins adoption when she starts using any
technology, one could set the threshold at, for example, 50% and label individuals as
having initiated the adoption process when their technology usage rate first exceeds 50%.
In the empirical analyses of this dissertation, I will focus primarily on the first and more
intuitive definition, whereby initial adoption is recognized as occurring upon the first use
of the technology. The second point, “maximum technology use,” leaves relatively little
room for interpretation: this point occurs when an individual reaches her maximum level
of technology use (before beginning the disadoption process).

7

Given the development of this framework and the creation of these distinct terms to describe the adoption
and disadoption processes, it is clear that the term “initial adoption” is a big incongruous with the current
framework; rather, the term for this first point would more precisely be “initiation of adoption process.”
However, in the interest of being succinct, I will continue to use the somewhat imprecise and potentially
confusing term “initial adoption” to label this first point (and analogously, “initial disadoption” on the
disadoption side).
8
The terms “maximum” and “minimum” here are meant to be local, not global, extrema.
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Figure 3.4: Quantification of the adoption and disadoption processes using two points

The third point in the sequence, which labels “initial disadoption,” is the point whose
exact definition and location is least obvious. Logically, this point should occur when an
individual’s technology usage rate begins to decline, which is easily observed in the
illustrations used here (Figures 3.3 and 3.4). However, in reality, an individual’s
observed usage rate will not follow a path as smooth as that depicted here; for many
technologies, usage rate may vary slightly from period to period. With such variation, a
definition that identified “initial disadoption” as occurring “when an individual’s
technology usage first declines” would likely result in a noisy measure that may occur
long before the development of a persistent downward trend in technology use, which we
would believe to be consistent with the “true” disadoption process. As a result of natural
variation or noise in the data, I impose additional conditions on the definition of “initial
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disadoption” to make the point a more reliable marker for the beginning of the
disadoption process. For example, in the empirical analyses of this dissertation, the
primary definition used for “initial disadoption” labels it as occurring in the first time
period when an individual’s technology rate decreases from the previous time period and
does not increase in the subsequent time period9. At the other end of the disadoption
process is the fourth point, which has a definition as simple and obvious as the second
point: this point occurs when an individual reaches her minimum level of technology use
(after beginning the disadoption process).

These four, now-defined points depicted in Figure 3.4 provide the foundation for my
quantification of the adoption and disadoption processes in this dissertation. By
measuring the distance between the points, each of which can move along two different
dimensions (as depicted in Figure 3.4), I can provide a measurable characterization of the
adoption and disadoption processes. To describe the quantification of the processes, I
will consider the two different dimensions of the process separately. The first dimension
is timing, which is measured along the horizontal axis in Figures 3.2 – 3.6. For both the
adoption and disadoption processes, two measurements can be made along this
dimension, as shown in Figure 3.5. The first measurement gives the time to the initial
change (adoption or disadoption), measured from when that change was first possible
(e.g. from technology approval or safety concern announcement, respectively). The
9

To test the sensitivity of the results to this definition, I also perform robustness checks where I use other
definitions for this “initial disadoption” period, varying (a) the threshold for decrease in technology usage
rate, (b) the logical conditions of sequential changes in rate, and (c) the possible implementation of global
time criteria, e.g. only allowing the initiation of the disadoption after a specified time period. These will be
described in more detail in the subsequent chapters, starting with Chapter 4.
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second measurement gives the length of the process (adoption or disadoption), or the time
between the points that define the beginning and end of the process. This second
measurement, by providing an indicator of how long an individual takes to progress from
initial change to maximum change, gives a sense of the speed with which that individual
goes through the given process. The introduction of this metric is novel, providing a
quantitative characterization of both the adoption and disadoption processes that has
been, to the best of my knowledge, absent from all past empirical work.

Figure 3.5: Measurement of adoption/disadoption processes along the time dimension

Along this dimension of technology use, our discussion of adoption and disadoption can
be facilitated with terminology. When discussing movement of the first point (i.e. time to
initial adoption or time to initial disadoption) forward or backward in time, I refer to
individuals as “early” or “late” adopters/disadopters. This terminology is consistent with
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that generally used by the greater literature on technology adoption and disadoption,
though it is admittedly simplified; though I may say “early disadopter,” I truly mean
“early initial disadopter,” because I consider disadoption as a process instead of an event.
For the second measurement of process timing, which gives the amount of time between
the first and second points of the adoption or disadoption process, as I mentioned above,
this measurement gives a sense of the speed of the process. For that reason, I refer to
individuals who have smaller observed values of this measure as “faster”
adopters/disadopters (because they reach their maximum change of technology usage rate
in less time), whereas individuals who have larger values are “slower”
adopters/disadopters. Thus, there is an important distinction between an individual being,
for example, an “early adopter” and a “fast adopter,” as I use these two terms to refer to
two distinct measures of the adoption process. So, for example, a “late” adopter would
be someone who lets a lot of time pass before first using a technology (e.g. due to risk
aversion, or lack of knowledge about the technology), whereas a “slow” adopter would
be someone who, even if she first uses a technology very early, takes a lot of time to
transition from initial adoption to maximum use of that technology.

The second dimension along which to quantify the processes of technology adoption and
disadoption is extent or level of use, which is measured along the vertical axes in Figures
3.2 – 3.6. As with the dimension of timing, the quantification of the extent of adoption
and disadoption involves the measurement of two distances between the same points
discussed above and shown in Figure 3.6. The first measurement gives the initial extent
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of change at the beginning of the process, which in the case of adoption is the
individual’s level of technology use in the first period of the adoption process, and in the
case of disadoption is the difference in level of use from pre-disadoption to the first
period of the disadoption process. The second measurement gives the full extent of
change over the course of the process, which for adoption is the maximum level of
technology use (following adoption), and for disadoption is the overall decrease in
technology use from pre-disadoption level to the minimum use rate (following
disadoption). Along this dimension of extent of adoption/disadoption, the terminology I
will use in discussions will be relatively straightforward, referring to individuals with
large values for either of these two measures as “large” or “big” adopters/disadopters
(making sure to indicate, of course, whether that is initial or full adoption/disadoption).
Conceptually, we can think of “big” adopters as individuals who show a big
“commitment” to the technology in use it in a (relatively) large fraction of cases (e.g.
eligible patients), whereas a “small” adopter uses the new technology a (relatively) small
fraction of cases (e.g. eligible patients), which could be the result of such factors as risk
aversion, distaste for the technology, or simple difference in technology preferences.
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Figure 3.6: Measurement of adoption/disadoption processes along extent dimension

Using these two dimensions and points to characterize the adoption and disadoption
processes, there are four separate measurements, which are generally independent10, to
quantify each process. This compares to the literature’s traditional use of a single
empirical quantification of adoption, which matches the “time to initial adoption”
measure described here. By characterizing adoption and disadoption as processes instead
of events, adding an additional dimension to characterize these processes, and
establishing three more measures of these processes, I am able to develop greater insight

10

These measures are not all truly independent of each other due to some natural constraints that exist on
the location of the points described above. For example, an individual’s full extent of adoption can never
be smaller than her initial extent of adoption (and similarly for disadoption), and her full extent of
disadoption can never be larger than her full extent of adoption. However, aside from basic requirements
such as these, the fact that the four different points that characterize adoption and disadoption can exhibit
great freedom in their location in the time-use space leads to the understanding that the four different
measures of adoption and disadoption can be treated as generally independent. Examples of the loose
relationship between these measures are exhibited in Appendix 3, which provides illustrative examples of
different individuals’ adoption and disadoption processes.
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into both technology adoption and disadoption behaviors. While I am still interested in
the question of what drives earlier or later technology adoption or disadoption, I am also
able to investigate other aspects of these processes, including the difference between
individuals who are aggressive versus tentative adopters or disadopters, and the
connection (if any) between the timing and the extent of adoption or disadoption.

However, while this novel framework for measuring the adoption and disadoption
processes offers new benefit, it is not without cost. This multidimensional
characterization of these processes obviously introduces added complexity, which
complicates both analysis and interpretation. In the interest of simplification, we can
combine the two dimensions of adoption/disadoption to make a single measure of
technology change, as depicted in Figure 3.7. Rather than separately measuring the
vertical (extent of technology use/change) and horizontal (timing/speed) distances
covered by the technology use curve, we can instead measure the area above or below the
curve. Specifically, we measure area below the curve for the adoption phase (because
this process represents deviation from low/no technology usage rate) and we measure
area above the curve for the disadoption phase (because this process represents deviation
from high technology usage rate). While these area measures simplify the evaluation of
the technology change processes by reducing their quantification to a single value for
each process, it also captures information ignored by the previous two-point system.
Though that framework measured two dimensions, it reduced the relevant segments of
the technology use curve to two points, thus forming simple linear measurements and
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ignoring the contour of the technology use curve. By measuring area below or above the
curve, we are now able to capture the information contained within the specific shape of
the technology use curve. (Appendix 3 depicts a series of different technology use
curves, helping to illustrate how different curve shapes could yield similar vertical and
horizontal dimensions, but describe different paths of technology use change.)

Figure 3.7: Composite measures of adoption/disadoption processes using area
under/above the technology use curve

3.3 – Comparing adoption and disadoption
Above, I characterized the adoption and disadoption processes in parallel. The
dimensions of timing and extent are relevant for both processes, and the defined
measurements are almost identical for the two processes. Indeed, aside from the fact that
adoption represents an increase in use of a given technology whereas disadoption
represents the decrease in use, these two processes share many similarities. For example,
both processes represent changes in an individual’s choice of technology, which requires
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a change in knowledge or beliefs about the technology and/or a change in access to the
technology. In fact, when taking a very simplistic view of these processes, they become
virtually identical (which will become more apparent below, in Chapter 4, when I
develop a theoretical model of disadoption).

However, in reality, there are several differences between adoption and disadoption,
beyond the simple positive versus negative change in technology use. The first and
biggest difference between the two processes is the difference in knowledge of and
experience with the product. By definition, an individual adopting a technology has no
previous experience with that technology, whereas an individual disadopting the
technology has obviously used it. Because disadoption occurs among individuals who
have experience with a technology, whereas adoption occurs among individuals who are
not using the technology, there is potential for behavioral or psychological factors—
including to status quo bias, inertia, optimism, and confirmation bias—to play a bigger
role in disadoption (Roman & Asch 2014 Ann Int Med). As such, we may expect a
traditional rational economic model to have greater success describing the technology
adoption process, whereas a more complex behavioral model may be necessary to
provide the same level of fidelity for the disadoption process. Also, more simply, an
individual who is disadopting a technology inevitably knows more about the technology
than she did when adopting that same technology11. Furthermore, the additional
information that an individual has about a technology when she is in a position to

11

This assumes that knowledge about a technology cannot be lost or destroyed, and that experience
generates knowledge.
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disadopt that technology necessarily includes personal knowledge of the technology
gained through experience, which has the potential to be more detailed and nuanced than
information that can be practically learned from other people (Burns & Wholey 1993
Acad Mgmt J, Berez et al 2014 wp). Not only does real-world experience offer the
ability to learn technology complexities that cannot be conveyed secondhand, but
personal characteristics and work environment can shape both the individual’s
technology-use experience and her interpretation and understanding of information from
that experience. For example, a particularly skilled (and arrogant) surgeon may disregard
information about technology failure if she hasn’t used the technology herself because
she believes that other the other surgeons for whom the technology has failed are less
skilled than herself. Even if self-learned information about a technology could be
identical to that gained from external sources, an individual may place greater value in or
certainty on information gained through personal experience. Risk aversion is another
critical factor in shaping technology adoption or disadoption decisions, and the fact that
uncertainty about the technology is greater during the adoption phase may mean that an
individual’s level of risk aversion, while likely an important factor for both processes,
may play a larger role during the adoption process than the disadoption process. Of
course, the shape of an individual’s utility curve and the choices that that individual faces
(i.e. the alternative choices faced, and their outcome likelihoods and relative utilities) are
the most important factors that determine how risk aversion will manifest its influence on
either adoption or disadoption.
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Second, the adoption and disadoption processes differ in the role and influence of other
potential stakeholders. These roles are illustrated well if we focus on a specific example:
prescription pharmaceuticals. When a new pharmaceutical is coming to market (and still
under patent protection), the drug’s manufacturer will often invest heavily in marketing
for that new product. This marketing can, for example, take the form of both physician
detailing (by pharmaceutical company representatives) and direct-to-consumer (DTC)
advertising (in general media, e.g. magazines and television). Ultimately, the physician
controls access to the new drug (because she must write a prescription for a patient to be
able to acquire the drug), but both of these marketing streams seek to influence the
physician’s prescribing patterns, whether directly (via detailing by representatives) or
indirectly (through patients’ inquiries about or requests for the drug). On the other hand,
after a physician has already “adopted the technology,” i.e. started prescribing the given
drug, and is considering disadoption, the roles of these stakeholders has changed. Rarely
(if ever) do pharmaceutical companies attempt to dissuade a physician from prescribing
their products12. Patients are also in a different position, having taken the medication that
is “at risk” for disadoption, so the physician is able to gain valuable information from the
patients’ opinions and experiences with the technology.

The third difference between the adoption and disadoption processes is individuals’
access to the technology. In the case of disadoption, if an individual is facing the choice

12

As I describe below, my focus here on disadoption does not view this process in terms of adoption of an
outside good, i.e. the active move towards another technology. Were that the case, the role of the
pharmaceutical manufacturers’ marketing efforts could obviously play a role in the adoption of that new
technology and thus disadoption of the current technology.
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of abandoning a technology13, she has access to it and the ability to continue using it.
However, on the adoption side, it is not uncommon for the diffusion of technology to be
limited by producers’ supply of the technology; even if individuals are aware of a
technology and interested in adopting it, they simply may be unable to do so because they
cannot acquire that technology. Even when the market for a technology is not facing
supply-side constraints, some new technologies represent large capital investments and
challenging financial situations. On the other hand, if a technology has already been
purchased, that cost is sunk, so the disadoption decision is not usually complicated by the
same financial issues14. Related to these issues of technology access, researchers who
attempt to study these two processes also face distinct challenges. In the case of
adoption, some technologies may be so new that they are not yet well-recognized, so data
characterizing their use may not be developed. With disadoption, however, if the
technology is long-established, these data issues are less likely to be present, making
technology use easier to study by researchers.

Despite all of these differences, there is still a fundamental similarity between the
technology adoption and disadoption processes because they both represent decisions
regarding changes in technology use. It is this similarity that motivates the desire to
study the relationship between disadoption behavior and the preceding adoption behavior

13

Of course, there are cases where disadoption can be “forced” upon an individual when she loses access to
a technology, e.g. a surgeon working at a hospital where a given piece of technology is discarded or
replaced. This, however does not represent a willing choice or behavior on the part of the disadopting
individual, so such situations are outside of my realm of interest for this dissertation.
14
There are some examples of technologies were there may be a secondary market for used capital. In such
cases, the full cost of capital is not truly sunk, as some may be recouped.
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with the same technology. Given the vast literature focused on technology adoption (as
discussed above in Chapter 2), we are left to wonder if our knowledge of adoption
behavior is (at least partially) transferrable to disadoption behavior. Even if these
processes are sufficiently distinct that conclusions about determinants do not translate
between the two behaviors, both behaviors may be equally influenced by the same
unspecified characteristics. This will become relevant when we later study how some
factors (e.g. physician group size) impact medical technology disadoption, but we want to
control for various physician- or technology-specific characteristics that shape behavior
but are unknown or unobservable to us. The inherent similarity between adoption and
disadoption behaviors may allow us to control for such unobservable characteristics by
controlling instead for the observed adoption behavior with the same technology. Also
relating to the similarity between adoption and disadoption decisions, we’ll see that a
basic decision-theoretic model must represent these two processes similarly, if not
identically, thus generating symmetric predictions for the two different behaviors. (As
will be discussed below in Chapter 4, the incorporation of the factors discussed above
that distinguish adoption and disadoption behaviors from a theoretical perspective
requires fairly complex model construction.)

Again putting differences aside, if we consider the adoption and disadoption processes
together in practical settings, we realize another way that the two are linked: disadoption
of one technology occurs when it is being replaced by another technology, i.e. when
adoption of that other substitute technology is occurring. From this perspective, when the
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adoption of a new technology is the active process that results in abandonment of an
older technology, the description and evaluation of disadoption per se seems irrelevant,
because disadoption is passive and the disasdopted technology is an innocent bystander in
the process. Indeed, depending on the specific setting, it may well be that the majority of
cases of medical technology disadoption are more appropriately characterized and studied
through the lens of the adoption of another substitute technology15. However, as
described in Chapter 1, there are cases in which newly discovered information indicates
that an old technology is actually providing lower than desired clinical benefit, safety, or
value. In these cases, disadoption is a process to be undertaken independent of the
development of a new substitute technology and, as such, the disadoption process itself is
worth characterizing and examining16. It is these types of “disadoption-driven” cases for
which my work in this dissertation has the most direct and pertinent application. (Of
note, the disadoption of DES following the publicization of safety concerns regarding late
in-stent thrombosis is one such case, making it an ideal empirical setting to be used in
this dissertation. )

Though the above conceptual framework of the adoption and disadoption processes
provides methods for quantifying these processes along multiple dimensions, this
15

In both clinical practice and clinical research, providers generally have a professional and ethical
obligation to provide patients with treatment that meets the “standard of care.” In the setting of new
technology development, this obligation precludes the adoption of technologies that do not improve (or at
least maintain) this standard of care. Thus, the motivation to maximize patient health and benefit prompts
technology change when it improves care, which usually means adopting newer, superior substitute
technology.
16
Indeed, the adoption of a substitute technology does likely often occur in these “disadoption-driven”
cases. However, because disadoption is the driving motivation, I will generally disregard the replacement
technology, understanding that the decision is not made in a vacuum and the benefit, safety, and value of
the two technologies are only meaningful relative to each other.
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framework is focused specifically on the empirical measurement of technology use.
Before we can use the above framework to empirically evaluate technology disadoption,
we first want to provide some basic theoretical structure to guide our conception of the
physician incentives and behaviors that shape the disadoption process. Thus, to further
frame our understanding and guide our examination of disadoption, I will next develop a
basic decision-theoretic model of medical technology disadoption by physicians.
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CHAPTER 4: Theoretical model of medical technology disadoption
In the previous chapter, I developed a framework to help understand and empirically
measure the technology adoption and disadoption processes. However, to develop
further insight into the technology disadoption process and how physicians behave during
that process, I next seek to develop a basic decision-theoretic model of that process. My
goal here is not to develop a structural model that perfectly captures that disadoption
process or can be used to estimate fundamental parameters that dictate that process.
Instead, my aim is simply to use a theoretical model to provide basic structure and
guidance for our evaluation and empirical analysis of the disadoption process, offering
insight into how underlying factors may influence that process. One factor that I will
focus on specifically in the development of this model is group size, motivated by an
inherent interest in this organizational feature (as discussed in Chapters 1 and 2), and
detailed further below.

4.1 –Background and approach
Adoption vs. disadoption
As described at length above (in Chapter 3), though there are differences between the
technology adoption and disadoption decisions, there are also many similarities between
the two processes; fundamentally, both are processes of change in choice of technology
utilization. Though the aspects of disadoption that make it distinct from adoption (e.g.
the roles of inertia and “learning-by-doing”) are important, the incorporation of such
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aspects into a decision-theoretic model is non-trivial. Given that my goal here in
developing a model is simply to provide basic structure and guidance for our evaluation
of the disadoption process—something that is generally lacking in the current literature
on disadoption—the attempt to specifically distinguish between adoption and disadoption
behaviors in the decision-theoretic model would require an increase in complexity of the
model that extends beyond my basic goals here. So, while it is important to keep in mind
the distinct features and implications of the two processes, we will see that there is very
little about the model developed here that is truly specific to disadoption per se. One
product of this approach is that the model, as developed, should make symmetric
predictions about the adoption and disadoption processes. For example, if the model
predicts that larger groups will begin to disadopt a technology earlier than small groups,
then the same model would also predict that larger groups would similarly begin to adopt
(or would have begun to adopt, given that adoption necessarily precedes disadoption) that
technology earlier. Even without having yet created a specific model, we now know one
theoretically generated empirical prediction, i.e. that there is symmetry between the
adoption and disadoption processes. As already mentioned, one could choose to make a
sufficiently sophisticated model (e.g. by incorporating behavioral factors, or measures of
technologic experience) that (may) generate desperate predictions for adoption and
disadoption behaviors, but such complications are beyond the purview of the current
model-building exercise. However, it should be noted that, just as the theoretical
disadoption process can be complicated by various other factors, so too is the adoption
process confounded by various issues (e.g. technology supply issues, greater uncertainty,
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requirements for capital investment), so in that way, one could argue that the relatively
simple model developed below provides a more accurate depiction of disadoption than
adoption.

As mentioned in Chapter 2, not only is the medical technology disadoption literature
relatively sparse, it also appears to be largely devoid of theoretical economic models.
However—having just revisited the issue of similarities and differences between the
adoption and disadoption processes—the vast literature on technology adoption does
include many theoretical models, to which we can look for guidance in developing the
current model. Much of the early work on technology diffusion and adoption focused on
the population-level phenomena. In these papers, researchers developed mathematical
models that produced the widely-observed S-shaped curve of new technology diffusion,
typically modeling “infection rate,” i.e. the spread of a technology to non-users, as
proportional to the number of current users. (For a general discussion and examples, see
for example Geroski 2000 Res Pol.) Though these models provide insight into the
diffusion process and are historically valuable, their application here is limited because,
whereas they focus on the population-level process, my interest is in the individual-level
technology use decision and the determinants that shape that. Of course, after these
works were published, other economists who studied diffusion made the same
observation, which lead to the publication of several studies with decision-theoretic
models of individuals’ technology adoption behavior. (Again, see Geroski 2000 Res Pol
for a general discussion and examples.) Generally, these papers’ models focus on
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individuals’ beliefs about the expected productivity or value (e.g. expected profits) of the
new technology and the process of updating those beliefs (typically, a Bayesian
perspective), with the endpoint for that updating processing being a sufficiency threshold
for adoption of the new technology.

While each of these general categories of theoretical models represents a valuable
contribution to the economic literature on technology adoption and diffusion, in my
survey of the literature, I have been unable to identify any models that can be
appropriately applied to capture one of the key relationships of interest in this
dissertation, i.e. the impact of physician group size on technology disadoption.17 While I
can take some guidance from past models in establishing my own theoretical model, my
approach here is primarily to start from scratch. That is, rather than attempting to take
the given characteristic of interest, i.e. group size, and build it into one of the existing
models, thus creating an even more complicated model, my approach is instead to start
with an even simpler model. Though this approach requires additional work to establish
the basic foundations of the theoretical model, it allows the creation of a simpler model,
which enhances the goals of providing basic structure and guidance for my evaluation
and analysis of the disadoption process, specifically in terms of how an individual’s
group size may influence that individual’s disadoption behavior.

17

Of course, I cannot and do not claim definitively that no economists have previously created a model that
describes the topic of interest in this dissertation; the literature is too vast (especially on the topic of
technology diffusion) to examine every published work.
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Group size
As discussed above, there are many motivations for examining the relationship between
group size and technology disadoption, especially when evaluating physician behavior.
However, groups or networks of physicians are becoming increasingly complicated. Not
only are physicians increasingly organized into groups and those groups are growing in
size (as discussed in Chapter 2), different types of physician groups and organizations
continue to appear in practice. In addition to multi-office practices and multi-practice
groups, physicians can also belong (simultaneously) to independent physician
associations (IPAs), accountable care organizations (ACOs), or other types of clinical or
administrative organizations. To keep the theoretical model here relatively simple,
intuitive, and mathematically tractable, I will focus on a very basic characteristic of
physician groups: group size, i.e. the number of physicians in a group. Of course,
though this is a conceptually simple measurement, given the complexities of current
physician organization that I’ve just alluded to, the practical measurement of physician
group size may be a non-trivial issue. When calculating the number of physicians in a
given physician group, which group to we consider and which physicians do we count?
When measuring group size, which physician groups should we consider: offices,
practices, networks (e.g. IPAs, ACOs), or hospitals? Also, given that we’re interested in
technology choice, do we only count the physicians using a given type of technology, or
do we count all physicians regardless of technology usage? Though there may be
theoretical grounds to identify preferred answers to some of these questions, the model I
develop here will remain generalizable and not take a stance on such specific group-
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based characteristics. Instead, I will defer attempts to answer these questions to the
empirical section of this dissertation (namely, Chapters 6 and 7), looking to the data to
reveal which specific physician groupings have significant relationships with physicians’
choices of medical technology.

Information and knowledge
In addition to the inclusion of group size, there are two other primary features of my
model that distinguish it from the bulk of other decision-theoretic adoption models. First,
while previous models have focused on a set of knowledge and beliefs (about
technology) that evolve over time, I choose to deconstruct those beliefs by focusing on a
single piece of knowledge or information. Indeed, any set of beliefs can ultimately be
decomposed into a series of binary (“yes” or “no”) pieces. By using this deconstruction,
the view of disadoption drastically simplifies. Rather than treating it as a change that is
triggered when a composite set of beliefs crosses some threshold, we can instead see
disadoption as a change that occurs when a single specific belief is acquired. This “single
specific belief” in the simplified view is merely the final incremental belief that pushes an
individual over the threshold to change behavior in the “composite beliefs” model.

Second, whereas the bulk of decision-theoretic models focus on each individual’s
decision to adopt technology, that decision is based on beliefs that evolve over time by
basic Bayesian updating (e.g. a periodic draw from a probabilistic distribution of beliefs,
which depends on the observed behaviors in the population, and is incorporated with past
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beliefs to created updated beliefs). That is, these models focus specifically on the
behavior of adoption, rather than on the behavior that leads to the evolution of beliefs,
which thus leads to adoption. In contrast, the model I develop here considers the
determinants that drive changes in beliefs (e.g. acquisition of knowledge, which requires
effort and can be shared within a group) and examines how those determinants can thus
shape the disadoption process.

Dimensions of technology use
As described at length in Chapter 3, the disadoption (and adoption) process can be
characterized along the two different dimensions of time and level of technology use.
Here, as I begin to construct a theoretical model of this process, I again consider these
two dimensions. As described above, my attention here is focused on the acquisition of
critical information that persuades an individual to change their behavior, i.e. disadopt
technology. It is easy to see that in studying when an individual acquires critical
knowledge I am examining the timing dimension of disadoption, i.e. when the initial
disadoption process begins. However, the translation of the empirical measurement of
the other dimension of the disadoption process, i.e. the extent of disadoption, into a
theoretical framework is less obvious. Evaluating this dimension, we want to ask: why
would different individuals have smaller or larger extents of disadoption? One possible
explanation for observed differences between individuals in the level of technology use
following disadoption is characteristics of each individual’s environment, as opposed to
inherent characteristics of the individuals themselves. For example, in the case of

65
physicians, one may observe differences in the level of technology use simply because
different physicians care for different patient populations, and patient characteristics may
drive technology use decisions. Though such factors may shape an individual’s
technology use, they are not directly related to the individual’s behavior or choices, so
they are orthogonal to my focus and interest in developing the current decision-theoretic
model18.

Another possible explanation for differences in the extent of disadoption (i.e. the level of
technology use during the disadoption process) is the presence of differences in intrinsic
individual characteristics like risk aversion. Though two individuals may learn the same
critical information at the same time, differences in preferences for risk and uncertainty
may influence how drastically those individuals change their levels of technology use.
Indeed, in his classical work on diffusion of innovations, Rogers notes that it is “useful to
conceptualize the diffusion and adoption of innovations in terms of a framework based on
information and uncertainty” (2003). Here, in the interest of keeping the theoretical
model simple and tractable, my focus will be on the information aspect and the timing of
that information acquisition. Though there is little doubt that individual’s risk
preferences play a critical role in determining their levels of technology, specifically how
those preferences would relate to extent of disadoption is ambiguous. For example, upon
learning critical information that initiates the disadoption process, would risk-loving
individuals have a larger or smaller initial extent of disadoption? It is unclear whether
18

Obviously, this ignores the endogeneity of environment; it is not only possible but likely that individuals
have an active role in determining the environment that they work in. In the interest of keeping the current
theoretical model simple, I will ignore such complexities here.
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uncertainty surrounding the technology itself or uncertainty of the newly acquired
information is more important, which is particularly confounding during a “negative”
process like disadoption, when such uncertainties can have effects that act in opposite
directions. Thus, for these reasons, the model I develop here will focus on the timing
dimension of the disadoption process, leaving the consideration of the other dimension
(extent of disadoption) to the empirical analysis.

4.2 – Model setup and assumptions
Consider a utility-maximizing physician who faces a multi-period choice over how much
effort, 𝑒, to expend on the process of acquiring of knowledge (i.e. learning), 𝑘. As
described above, the acquisition of knowledge is treated as a binary event, so I consider a
single discrete piece of information, which the physician either acquires or does not
acquire in the given period. In the context of disadoption, this piece of knowledge is the
critical information that sways a physician to disadopt a technology; without this
knowledge, the physician continues to use the current technology. The physician can
acquire this critical knowledge (i.e. learn), 𝑘 ∗ , by either of two different mechanisms, one
of which involves effort and one that is effort-independent, but both of which are treated
as probabilistic processes. For the former, the physician can expend effort to increase her
likelihood of acquiring knowledge. Obvious examples of this type of learning are the
reading of medical journals or attending educational meetings, but neither of these
behaviors (or any other effort-based learning) guarantees the acquisition of critical
knowledge. Rather, the expenditure of effort merely increases the likelihood of gaining
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knowledge. Thus, I use a function 𝑔(𝑒), which has a non-negative domain and a range
[0,1), to represent the probability that a physician gains critical knowledge in a given
period by expending effort 𝑒. However, it is also possible that a physician gains
knowledge without spending any effort, for example when informed by a colleague or
contacted by a pharmaceutical/biotech sales representative. So, for effort-independent
learning, I simply use 𝜃 to represent the likelihood that a physician gains critical
knowledge in a given period, regardless of the level of effort expended by that physician.
Now, given these two knowledge-acquisition processes, we can determine a physician’s
likelihood of gaining critical knowledge in a given period as a function of effort, 𝑒:
Pr(𝑘 = 𝑘 ∗ ) = 1 − (1 − 𝜃)(1 − 𝑔(𝑒))

(1)

Though equation (1) gives the likelihood that an individual physician acquires critical,
disadoption-triggering knowledge in a single period, I want to introduce two additional
layers of complexity. First, consider that the physician belongs to a group, which has a
total count of 𝑛 physicians, and assume that if any physician in the group acquires
information in a given period, that information is shared among all members of the group.
I again want to determine the probability that a given physician acquires critical
knowledge in a given period. If I further assume that each physician in a group has both
the same effort-independent learning likelihood and the same effort-based knowledge
production likelihood function19, the updated probability expression (which can

19

In fact, the actual assumption here is merely that a given physician believes that all other members of her
group have the same effort-based and effort-independent knowledge acquisition likelihood expressions,
which is more benign than assuming that each physician in a group actually has the same knowledge
acquisition likelihood expressions.
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alternatively be described as “the probability that, in a given period, nobody in the given
physician group does not acquire the critical knowledge”) is as follows:
Pr(𝑘 = 𝑘 ∗ ) = 1 − [(1 − 𝜃)(1 − 𝑔(𝑒))]

𝑛

(2)

Second, because I am interested in studying the timing of the disadoption process, I am
also naturally interested in incorporating multiple periods into the model. With multiple
time periods, my shift focuses from a single period to a string of periods, so we now ask:
what’s the probability that a physician has acquired critical knowledge by time period 𝑡?
If I assume that a physician’s behavior and decision-making is the same in all periods and
that 𝑡 is an integer that counts up from 1 in the initial period, then equation (2) simply
becomes:
Pr(𝑘 = 𝑘 ∗ ) = 𝜅(𝑒, 𝑡) = 1 − [(1 − 𝜃)(1 − 𝑔(𝑒))]

𝑛𝑡

(3)

where I now use 𝜅 to represent a physician’s likelihood of acquiring critical knowledge.

Having established how a physician’s effort translates into the acquisition of knowledge,
and how that acquisition of knowledge relates to both time and group size, I can now turn
to the physician’s utility maximization problem. Obviously, a physician’s utility will
depend on many different factors, including income, leisure, and consumption, but if I
assume that the physician’s utility function is additively separable (at least in the
variables of interest), then I can restrict my attention to the factors of interest here
because, when maximizing the physician’s utility function, all terms relating to other
factors will fall out of the equation. For the current theoretical model, then, the factors of
interest are physician knowledge and effort. With respect to these two factors, I make the
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relatively mild assumptions that a physician’s utility increases with increasing knowledge
but decreases with increasing effort. However, the model constructed above focuses on a
physician’s likelihood of acquiring knowledge, 𝜅, not on the level of that knowledge
itself, 𝑘, so we’re left to ask how a physician’s utility is related to 𝜅. Though it may be
difficult to understand a conceptual link between 𝜅 and physician utility at the level of an
individual technology, if we consider a very large set of medical technologies, it becomes
clear that increasing the likelihood of critical knowledge for multiple technologies will
increase a physician’s overall level of knowledge (with increasing certainty as the
number of technologies increases). Using this logic, I assume that a physician’s utility is
increasing with increasing 𝜅. Given these assumptions, the first order condition of the
physician’s utility-maximizing choice of effort can be expressed as follows:
𝑑𝑈 𝜕𝑈 𝜕𝜅 𝜕𝑈
=
+
=0
𝑑𝑒 𝜕𝜅 𝜕𝑒 𝜕𝑒

(4)

While this theoretical model is very simple and it focuses on an individual physician, it is
important to note that this formulation of the model still allows for variation within a
population of physicians. That is, this model does not predict that all physicians will
exhibit the same technology disadoption behavior. Variation in the timing of a
physician’s disadoption can be driven by between-physician differences in any of the
following: utility from effort and knowledge; effort-independent and effort-dependent
probabilities of knowledge acquisition; or group size.
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Before further analyzing the theoretical model, I want to briefly summarize and provide
more details on the assumptions used in formulating the model:


The physician’s utility is additively separable in knowledge and effort, and it
increases with increasing knowledge, but decreases with increasing effort.



The physician’s utility from effort, 𝑒, (i.e. effort expended on knowledge
acquisition) is represented by a negative concave downward function, as
exemplified in Figure 4.1, which has negative first and second derivatives with
respect to effort. The shape of this function can be justified and understood if we
believe that effort is directly proportional to time and that a physician faces a
binding time constraint. The disutility from effort increases as a physician spends
more effort (time) on knowledge acquisition. There is an upper limit to how
much effort a physician can spend (e.g. in a day or week), and her disutility from
effort increases as she asymptotically approaches that limit.

Figure 4.1: Physician utility as a function of effort expended on knowledge acquisition
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The physician gains positive utility from knowledge, 𝑘, and, because knowledge
is directly proportional to the likelihood of acquiring critical information, 𝜅, the
physician’s utility is increasing with increasing probability of learning critical
knowledge. We believe that a physician’s utility will increase with knowledge if
knowledge helps provide superior medical care to patients and a physician gains
positive utility from providing superior care for patients.



The physician’s effort-dependent probability of knowledge acquisition, 𝑔(𝑒),
which is effectively a probabilistic effort-based knowledge production function, is
a positive concave downward function, as exemplified in Figure 4.2, which has a
negative first derivative and a positive second derivative with respect to effort.
This production function represents the probability of acquiring knowledge with
effort, so it increases as effort increases and its range is bounded between 0 and 1.

Figure 4.2: Physician likelihood of acquiring critical knowledge as a function of effort
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If any physician in a group acquires knowledge, that information is instantly and
costlessly shared among all members of that group.



The physician believes that (and acts as if) all other physicians in her group have
both the same effort-independent (𝜃) and effort-dependent (𝑔(𝑒)) probabilities of
knowledge acquisition.



The physician treats all time periods the same, i.e. spends the same amount of
effort on knowledge acquisition in each period.

These assumptions were made only to simplify the math in this model; most of them can
be relaxed without changing the intuition of or predictions generated by the model. Of
course, this model can be extended by relaxing some of the above assumptions or
introducing additional complexities. For example, instead of assuming that information
is immediately and costlessly shared between group members, one could choose to model
how knowledge is transferred between members of a group. Similarly, one could impose
more structure on the acquisition of knowledge by, for example, modelling the presence
of experts or thought-leaders in a group or community. Also, as discussed above, the
model could be complicated by introducing physician risk preferences, which would
require the imposition of additional structure on the functional form of physician utility
from knowledge and effort. However, as stated above, the purpose of the model in this
dissertation is simply to provide guidance for my analysis of physician technology
disadoption, and some of this guidance is gained by examining the comparative statics
produced by the model.
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4.3 – Comparative statics
By using equation (3) and the above assumptions to solve the model’s first-order
condition (equation (4)), I can generate comparative statics that provide basic predictions
about relationships between various model parameters. One of the relationships of
interest here is that between group size and time to disadoption. Specifically, I want to
ask: does time to acquisition of critical information, i.e. time to initiation of the
disadoption process, increase or decrease as group size increases? I can use the
theoretical model to generate an answer to this question by using it to solve for 𝑑𝑡/𝑑𝑛.
Using equations (3) and (4), and applying the implicit function theorem (see Appendix 4
for details of these calculations), the expression for this derivative is as follows:
𝑑𝑡
=
𝑑𝑛

−

𝜕𝑔
𝜕𝑈
(1 − 𝜃) 𝑡[𝑛𝑡 ln(𝑓(𝑒)) + 1](𝑓(𝑒))𝑛𝑡−1
𝜕𝜅
𝜕𝑒

𝑛𝑡−1 𝜕 2 𝑔
𝑛𝑡−2 𝜕𝑔
𝜕𝑈
𝜕 2 𝑈 ln(𝑓(𝑒)) 𝑓(𝑒)𝑛
+ (𝑛𝑡 − 1)(1 − 𝑔(𝑒))
) + 2][
]
[ (1 − 𝜃)𝑛𝑡 𝑛𝑡 ((1 − 𝑔(𝑒))
2
𝜕𝜅
𝜕𝑒
𝜕𝑔
𝜕𝑒
𝜕𝑒
(1 − 𝜃)
𝜕𝑒

While this expression is very complicated, my purpose in developing this model was not
to calculate specific quantitative relationships, but merely to provide general qualitative
insight. So here, I only want determine the sign (positive or negative) of the above
expression. To do this, we consider the signs of the individual components, an exercise
that is shown in detail in Appendix 4. Ultimately, this exercise shows that the sign of
𝑑𝑡/𝑑𝑛 is ambiguous, i.e. we cannot know if it is positive or negative without more
information. That is to say, this model predicts that time to the initiation of the
disadoption process may either increase or decrease with increasing group size.
Examination reveals that the sign of the above expression depends on the relative
magnitudes of the different factors that appear in the first large term of the denominator,
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including: physician utility from knowledge and disutility from effort; time (i.e. number
of periods) and group size; and both the effort-based and effort-independent likelihoods
of acquiring critical knowledge.

Though lack of a definitive prediction by the model here may seem disappointing, further
reflection shows that this prediction (or lack thereof) by the model agrees with intuition.
On one hand, a physician may begin the disadoption process sooner if in a larger group
because she (and the other members of her group) receive high utility from knowledge
and have high probability of acquiring knowledge when applying effort, so a larger group
leads to more effort and faster knowledge acquisition. On the other hand, a different
physician may begin the disadoption process later if in a larger group because she has
high disutility from effort and, as group size increases, is inclined to attempt to “freeride” off the effort of her group members with whom she shares knowledge, so a larger
group leads to less effort and slower knowledge acquisition. This acquisition of
knowledge is what ultimately triggers the technology disadoption decision and initiation,
though it is worth remembering at this point that the model was of sufficiently generic
construction that it may similarly be used to depict the technology adoption decision.
Indeed, as was mentioned before, for this reason, the model makes symmetric predictions
technology adoption and disadoption decisions. So, if balance of relevant factors (e.g.
disutility from effort and group size) is such that the sign of 𝑑𝑡/𝑑𝑛 is negative, the model
predicts that increasing group size will result in decreased time to acquire critical
information, and earlier initiation of both the adoption and disadoption processes.
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In summary, while the theoretical model has provided a framework to guide our
understanding of a physician’s technology disadoption process (via acquisition of critical
information) and how the timing of that process relates to group size, it has also shown
that the relationship between group size and the timing of disadoption is theoretically
ambiguous. Thus, the question is an empirical one, for which I must turn to data to
search for an answer, which I will do in the following chapters. However, before
focusing on the empirical relationship between group size and technology disadoption, it
is worth noting that, as with any theoretical model, the model developed here is a gross
simplification of a real-world process that neglects many potentially important factors.
Though I focus specifically on the role of physician knowledge-acquisition effort and
how that effort can be shaped by group size, there are many other physician
characteristics and practice environment qualities that may shape her technology use
decisions. For example, as discussed briefly above (in Chapter 3), a physician’s risk
preferences may shape that physician’s willingness to disadopt a technology in light of
new, uncertain information. Similarly, other behavioral factors—including status quo
bias, confirmation bias, and loss aversion—may influence a physician’s disadoption
behavior20. Indeed, there is a potentially endless list of factors that may shape the
disadoption process, which complicates our ability to empirically investigate that process
with great clarity. However, as discussed at length above (in Chapter 3), there are many
20

Recalling the similarities between adoption and disadoption behaviors, these factors may also be relevant
for the technology adoption process. However, as mentioned in Chapter 1, the delivery structure and
financing of the US health care system, combined with the predominant culture of American clinical
medicine, provide significant pressures promoting technology adoption, whereas such pressures are not
present for the technology disadoption process.
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parallels between the technology adoption and disadoption processes. Insofar as we think
these processes are similar, we might be able to use measures of the technology adoption
process to proxy for unidentified or unobservable factors that influence the technology
disadoption process. Of course, theory aside, the question of “how similar are these
distinct processes?” can also be treated as an empirical one. It is this empirical question
that I will examine in the following chapter.
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CHAPTER 5: Relating medical technology disadoption to adoption
In the preceding chapters, I provided the motivation and background for the study of
technology disadoption, established a framework to empirically characterize the
processes of adoption and disadoption, and developed a theoretical model of a
physician’s technology disadoption behavior. Though the theoretical model focuses
specifically on the relationship between group size and the timing of disadoption, we also
understand now that the disadoption is considerably more complex (being characterized
along multiple dimensions and potentially influenced by a wide range of factors) and that,
as discussed above, there is reason to believe that it shares many similarities with the
technology adoption process, while also being noticeably different. This understanding
sets the stage for the first empirical analysis of this dissertation: an examination of the
empirical relationship between the various measure of disadoption and adoption.

As described above, while the topic of technology disadoption has been the subject of
relatively few research studies, technology adoption has been studied exhaustively.
Given the vast existing knowledge surrounding technology adoption and the
understanding that this process parallels technology disadoption in many ways, it
becomes natural to ask: what is the empirical relationship between these two different
processes? To answer this question, I will focus on the setting of coronary stents, where
cardiologists could choose between bare-metal stents (BMS) and drug-eluting stents
(DES), with DES serving as the technology that was originally adopted and subsequently
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disadopted. In these analyses, the primary outcome of interest will be an individual’s
“time to initial disadoption” (the variable which was also examined in the theoretical
model developed in Chapter 4), which I will relate to an individual’s “time to initial
adoption” and the other measures of adoption. I focus specifically on this outcome
variable because, as discussed above (in Chapters 2 and 3), the question of the timing of
adoption and disadoption—whether that timing refers to the occurrence of an event or the
beginning of a process—has been the one most frequently studied in the literature and is
of obvious interest and practical application. The other measures of disadoption, which
were described in Chapter 3, provide important characterizations of the disadoption
process, but represent a relatively unusual and less intuitive framework for studying
disadoption, so they will serve as secondary outcomes.

5.1 – Research questions
1) What is the observed empirical relationship between a cardiologist’s time to initial
disadoption of DES and the various measures of that physician’s adoption of DES?
2) What are the observed empirical relationships between the other measures of
cardiologist’s disadoption of DES (namely, time to minimum use, initial extent of
disadoption, full extent of disadoption, and area below the DES adoption curve) and
the various measures of that physician’s adoption of DES?
3) How do various covariates and controls, including cardiologist characteristics (e.g.
age and training) and experience (e.g. DES volume), shape the observed empirical
relationships between DES disadoption measures and adoption measures?
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5.2 – Data and methods
Original data
In the empirical analyses performed throughout this dataset, I use three primary datasets.
First, in order to study physicians’ use—or, more accurately, placement or
implantation—of coronary stents, I use hospital discharge data from the states of Florida
and New York. These datasets are available as annual releases, and I focus specifically
on the years 2002 through 2011. Providing a record for each hospital discharge within
the states, these datasets include hospital identifiers and basic patient data, such as sex,
ZIP Code of residence, age, insurance type, and multiple diagnosis and procedure codes.
Most importantly, both datasets also include physician identifiers (either state license
number or National Provider Identifier, NPI, or both), which allows me to track
physicians both over time and across datasets, as will be discussed below. Though the
New York dataset details the specific month of admission associated with each hospital
stay, the date information in the Florida discharge dataset is specified down to the quarter
level. To allow combination of the two datasets and provide consistent time
measurements, I reduce the date granularity of the New York discharge dataset to the
quarter level.

The second dataset I use is the AMA Physician Masterfile, which is produced by the
American Medical Association. This dataset provides various details about physicians
and their training, including sex, year of birth, specialties of practices (self-identified),
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medical school, residency, fellowship, and the years of completion for each phase of
training. Using state license numbers, I am able to link this dataset to the discharge
dataset at the physician level, thus being able to identify doctors’ basic demographics,
training, and experience. This dataset, like the Florida and New York datasets, is used
frequently in published research studies.

The third dataset that I use in the dataset is less well-known than either of the first two
datasets. It is a dataset, which is produced by SK&A, a healthcare marketing company
that provides an annual list of office-based physicians throughout the country. The
dataset, which is compiled and updated annually by repeated phone surveys, is created
with the purpose of providing companies (e.g. pharmaceutical or medical device
companies) with detailed information on the practice location, organization, and hours of
physicians (so that those physicians may be targeted by marketing efforts). Organized at
the physician-office level, the dataset includes basic physician information (e.g. specialty,
title, state license number, and NPI) and detailed practice information (including name,
location, hours, size, and estimated patient volume). For this dissertation, I use the
portion of this dataset that covers Florida and New York from 2005 to 2011, and I focus
specifically on cardiologists (which I detail more, below). This dataset is relatively new
to the health care economics and policy researchers, so only a few recent studies can be
found in the current literature (e.g. Dunn & Shapiro 2014 J Law Econ; Dunn & Shapiro
2015 JHE; Frech et al 2015 Rev Ind Org; Capps, Dranove, Oddy 2015 wp).
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Data processing
While the original datasets described above contain all of the necessary information,
some processing of the data is necessary to generate the desired variables for analysis.
All data processing performed in this dissertation (unless otherwise noted) is performed
using the statistical software package Stata (StataCorp), with most work completed using
the Stata 13 release. To start, by using patient procedure codes in the hospital discharge
data along with physician identifiers, I am able to track each physician’s history of
coronary stent placement, separately identifying BMS and DES, and restricting the
hospital discharge files to only include hospitalizations in which a stent was placed. As
already mentioned in Chapter 2, one reason that I chose to study the technology of DES
is the fact that, thanks to the publicity and excitement leading up to the FDA approval of
DES (in April 2004), the Centers for Medicare and Medicaid Services (CMS) established
novel procedure codes to identify (and bill for) DES placement and made these codes
available by the time DES was introduced into the market. Thus, I am able to observe,
with high fidelity, physicians’ initial adoption of DES, along with their continued use and
later disadoption (if and when it occurs). Throughout this empirical work, I make
frequent reference to and use of each physician’s “DES use rate” or “DES rate,” which is
defined as the fraction of coronary stents placed by a physician that are DES in a given
time period (e.g. quarter). This is the measure of physician DES use rate that is used for
various purposes and calculations, including the determination of each physician’s DES
adoption and disadoption measures, which will be defined below.
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Considerable processing of the SK&A dataset was required before it could be used for
analyses. To start, because the dataset covers the entirety of US office-based physicians,
its scope exceeds the interest of this dissertation and its size made it difficult to work with
(particularly for the processing of practice identifiers, which will be discussed below).
To restrict the dataset to a more manageable and useful sample, I exclude any physicianpractice pairs that have addresses that are not in Florida or New York. Next, to focus on
the specific physicians of interest (i.e. cardiologists who implant coronary stents), I also
exclude any physician who is not identified as specializing in cardiology by any of the
three specialty variables that are associated with each physician observation in the
dataset. Because these specialty variables are self-identified (or identified by the practice
members or administrators who provided the information to SK&A) and not necessarily
based on formal training (e.g. cardiology fellowship), this sample inclusion criterion is
generous and is very unlikely to exclude many (if any) physicians who regularly implant
coronary stents.

Next, in the original SK&A dataset, many observations (physician-office pairs) are
missing values for physician identifiers such as state license number or NPI. However,
this can be addressed by taking advantage of the facts that individual physicians appear
multiple times (in different years and sometimes multiple times per year, if they practice
in multiple offices) and the dataset includes multiple identifiers, including state license
number, NPI, DEA number, Unique Physician Identification Number (UPIN), SK&Aspecific identifiers, and name (first, middle initial, and last). By connecting shared values
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of identifiers across observations (while making sure to exclude identifier values that are
ambiguous or not shared uniquely), I am able to impute missing values of NPI and state
license number, which ultimately allows both the consistent tracking of physicians’
practice membership and the combination of this data with the discharge data at the
physician-year level.

Similar to the physician identifiers, the practice identifiers in the SK&A dataset also
require processing, though of a different nature. Whereas the physician identifiers are
plagued by missing values in the original dataset, the original practice identifiers, which
include the listed name and location of practices, are almost always non-missing but
compromised by frequent errors (e.g. incorrect or inconsistent spellings), which are likely
due to data collection and/or entry21. To deal with these errors, I use Google Refine22, a
tool designed to clean and transform “messy data,” to help identify and group together
similar practice identifier values. By organizing the data by practice name, address, and
phone number and by physician identifier, and then checking each unique value, I
exhaustively comb through the dataset to identify practices, manually changing the
practice names where appropriate (e.g. when two practices have the same physicians,
address, and phone number, but differently spelled names)23. With these changes (which

21

In fact, the SK&A dataset provides an SK&A-specific identifier variable for practices, but cursory
examination reveals that this variable has both frequent missing and inconsistent values (e.g. a single
practice—as identified by name, address, and phone number—will have different values for the variable in
different years). Due to these frequent problems, I ignore this practice identifier and instead use the
variable that provides practice name to identify practices, combining this name with other information (e.g.
state, street address, and/or phone number) to uniquely identify practices within the dataset.
22
This software package has since become known as OpenRefine.
23
Admittedly, this process of manually identifying practices, with the help of Google Refine, is not only
labor intensive, but also occasionally subjective; it is not always immediately obvious whether or not two
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occasionally include adding the name of a city to a practice name if that name is very
generic, e.g. “Cardiology Associates”), the practice name variable becomes a consistent
identifier for practices and is used as such in analyses throughout this dissertation. This
use includes the creation of practice dummy variables, which are used to include practicelevel fixed effects in regression analyses, and the calculation of group size, which will be
discussed in more detail in Chapter 6.

With the individual files processed, they can be combined to form a single composite
dataset. The AMA Physician Masterfile data, which contains one observation per unique
physician, can be simply merged (by physician identifier) with either the SK&A or
discharge data, but the combination of those two larger datasets is less trivial. The
discharge data contains an observation for each unique discharge, with time granularity at
the quarter level. On the other hand, the finest level of time gradation in the SK&A
dataset is at the year level, not the quarter level. Furthermore, not only does the SK&A
dataset combine multiple separate years of data, physicians can also appear multiple
times per year if they belong to multiple different groups, practices, or practice locations
in a given year. Thus, the combination of these datasets requires a “many-to-many”
merge24 to allow each discharge to be matched with the appropriate physician-practiceyear in the SK&A dataset, creating a file at the discharge level, with discharges repeated

practice names represent the same practice. The application of logic, careful consideration, and basic
investigation (e.g. Google searches of practices and physicians) are used to sort through potentially
ambiguous cases, and the default decision is to not change the names of practices unless there is a very high
level of confidence in the change.
24
In fact, though the Stata “merge” function allows for “many-to-many” merges, these are very messy and
unreliable in practice. Thus, the files are combined instead using the “joinby” function.
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(within a given quarter-year) for each practice attributed to a physician (within a year) by
the SK&A data.

Defining and measuring adoption
The adoption and disadoption of DES are the primary processes of interest in this
chapter, but to be studied empirically, they must be precisely defined and measured. As
described in Chapter 3, there are four different measures of interest for both the adoption
and disadoption processes: time to initial DES adoption/disadoption, initial extent of
adoption/disadoption, time to maximum/minimum DES use, and full extent of
adoption/disadoption. To calculate each of these eight measures, the first step is to
identify the two key points in each of the two processes (recall Figures 3.3 – 3.6 for an
illustration of these points and the measures that they delineate). Starting with the
adoption process, the point of initial adoption is identified as the first period in which the
physician placed any DES. With this first point, the first two DES adoption measures can
be calculated: time to initial adoption is calculated as the number of time periods
(quarters) from FDA approval of DES (in April 2003, or 2003Q2) to the physician’s
period of initial adoption; and initial extent of adoption is calculated as the physician’s
DES use rate in the period of initial adoption. (More precisely, this initial extent of
adoption is meant to be the change from pre-adoption use to initial adoption, but because
pre-adoption use is 0, we can simply take the level of use in the initial adoption period.)
The second key point in the adoption process is the point of maximum DES use, which is
calculated as the point in which the physician’s DES use rate reaches a maximum. The
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determination of this point’s location allows for the calculation of the next two DES
adoption measures: time to maximum use is calculated as the number of time periods
from the physician’s initial DES adoption (not from DES approval) to her period of
maximum DES use; and full extent of adoption is calculated as the physician’s DES use
rate at its maximum. (Again, this is more precisely calculated as the difference between
the maximum use rate and pre-adoption use rate, which is 0.)

Having established the two key points that characterize the beginning and end of the DES
adoption process, we can then use these points, along with the technology use curve, to
calculate the area below the DES adoption curve, as was described in Chapter 3 and
depicted in Figure 3.7. Because the empirical reality of this technology use curve is a
connection of discrete data points, the area above (or below) the curve can be calculated
with a simple Riemann sum. Thus, to determine the area below the observed DES
adoption curve for a physician, I simply sum together that physician’s DES use rate in all
periods between (and including) each physician’s period of initial adoption period and
period of maximum DES use.

Defining and measuring disadoption
The process to establish the DES disadoption measures is very similar to that used for the
DES adoption measures, but some more intricacies are required when establishing the
location of the relevant points. First, we consider the point that identifies initial DES
disadoption. As discussed briefly in Chapter 3, this point should logically represent the
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point when an individual’s technology use rate begins to decline, though issues with
noise in the data (i.e. natural fluctuations in DES use rate over time) make the precise
identification of this point somewhat challenging. In an attempt to deal with this noise
and appropriately identify the time period when a physician begins the DES disadoption
process, I impose the following conditions when defining the initial DES disadoption
point:
(i) It must occur after DES adoption has occurred (and, by obvious logical extension,
can only occur if DES adoption has occurred).
(ii-a) It must occur after the widespread publicization of DES safety concerns in
September 2006 (2006Q3) (coinciding with the presentation of results from a
comprehensive study at the World Congress of Cardiology, and subsequent
popular press coverage).
(iii-a) It occurs in the first time period when a physician’s DES use rate decreases
from the previous period and does not increase in the following period.
Because these conditions—or more specifically, conditions (ii) and (iii)—may be viewed
as somewhat restrictive, I also relax them in various analyses to test how sensitive
findings are to these definitions. Specifically, I also allow for the following replacements
for condition (ii):
(ii-b) It must occur after the earliest publicization of DES safety concerns in January
2004 (2004Q1) (when concerns over increased risk of thrombosis with DES
were first published by Virmani et al in Circulation).
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(ii-c) It must occur after the earliest conference presentation of suggestions for
modified implantation guidelines and post-implementation medication regimen
in March 2005 (at the American College of Cardiology annual meeting)
(Huesch 2011 Soc Sci Med).
(ii-d) It must occur after the first conference presentation of detailed evidence for
increased DES safety concerns, due to increased risk of late stent thrombosis, in
March 2006 (at the American College of Cardiology annual meeting) (Huesch
2011 Soc Sci Med).
and the following replacements for condition (iii):
(iii-b) It occurs in the first time period when a physician’s DES use rate decreases
from the previous period (with no condition for DES use in the following
period).
(iii-c) It occurs in the first time period when a physician’s DES use rate drops below
80% (a condition which obviously also requires that a physician’s use reach or
exceed 80% before she can meet this definition for initial disadoption).
While the use of these different conditions provide robustness checks for the analysis
results, it must be noted that, given the concerns (about natural noise in the data) that
motivated the creation of these conditions, variation of the conditions represents a
tradeoff between sensitivity and specificity of the DES initial disadoption definition;
relaxing a condition may allow for more physicians to fulfill the definition, but it will
also increase the number of inappropriately or erroneously labeled DES initial
disadoption points (because those points actually just represent noise), with the converse
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also being true (i.e. tightening a condition will decrease the number of physicians who
meet criteria to be measurable DES disadopters, but that tightening of the condition also
decreases the noise). For this reason, my analyses will focus on the definition of DES
initial disadoption that uses the primary set of conditions (i, ii-a, and iii-a), which seem to
balance the sensitivity-specificity tradeoff, with results based on other DES disadoption
definitions relegated to the appendices. With these conditions set, the point of initial
disadoption is identified and the first two DES disadoption measures can be calculated:
time to initial disadoption is calculated as the number of time periods (quarters) from the
publicization of DES safety concerns to the physician’s period of initial disadoption; and
initial extent of disadoption is calculated as the change in physician’s DES use rate from
the immediate pre-disadoption period to the period of initial disadoption.

Next, we turn to the second key point of the disadoption process: the point of minimum
DES use. Though this point is somewhat simpler to define than the point of initial DES
disadoption, we still need to impose some basic logical conditions when defining this
point. Specifically, the point occurs in the period in which the physician’s DES use rate
reaches a minimum after initial DES disadoption, which thus makes this point conditional
on the DES initial disadoption definition. With this second point determined, the
calculation of the last two DES disadoption measures is possible: time to minimum use is
calculated as the number of time periods form the physician’s initial DES disadoption
(not from the DES safety concern publicization) to her period of minimum DES use; and
full extent of disadoption is calculated as the change in the physician’s DES use rate from
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the immediate pre-disadoption period to the minimum DES use rate level. Figure 5.1
provides histograms of the four DES disadoption measures used as outcome variables in
this chapter’s analyses.

Figure 5.1: Distributions of DES disadoption measures observed in discharge data

Having now established the two points that characterize the beginning and end of the
DES disadoption process, we can use these points, along with the technology use curve
itself, to calculate the area above the DES disadoption curve, as was described in Chapter
3 and depicted in Figure 3.7. As was the case with adoption, we can determine the
desired area by using a simple Riemann sum because the empirical technology use curve
is a connection of discrete data points. However, the area above the DES disadoption
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curve requires a slightly more involved calculation than the area below the DES adoption
curve. First, having identified the time period of initial DES disadoption, along with the
level of DES use in that time period, and the time period of minimum DES use (postdisadoption), I calculate the area of an imaginary rectangle of “DES disadoption
potential,” which is bounded above by the level of DES use prior to disadoption, bounded
below by 0 DES use, bounded on the left by the initial DES disadoption period, and
bounded on the right by the end of the DES disadoption period (i.e. minimum DES use).
I then use the observed DES use curve to calculate the area below the curve, as was done
with the adoption curve. By subtracting this area below the disadoption curve from the
area of the full “DES disadoption potential” rectangle, I then calculate the area above the
observed DES disadoption curve.

Covariates
Though these measures of DES adoption and disadoption are the primary outcome and
explanatory variables of interest in the following analyses, there are other variables of
interest that I wish to use as covariates that need to be calculated. First, there are
variables generally grouped together as “physician characteristics.” These include
physician age, years of experience, and training. Age and years of experience are
calculated by finding the difference between the current year and the physician’s year of
birth and final year of training (whether residency or fellowship), respectively. Physician
training is described using dummy variables that label physicians who have, according to
the AMA Physician Masterfile, completed cardiology fellowship or interventional
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cardiology fellowship, with a separate variable for the different types of fellowship.
These variables are included in the analyses to address concerns that physicians of
different age, experience, or training may exhibit different DES disadoption behaviors. A
second set of variables are grouped together as “physician DES use measures,” which are
included because, as discussed in Chapter 3, it is reasonable to expect an individual’s
disadoption behavior to be influenced by that individual’s experience with the given
technology. For this reason, I calculate two different measures of a physician’s DES use:
the total cumulative number of DES implanted by a physician before she was at-risk for
disadoption (i.e. across all time periods before DES safety concerns were publicized), and
the total number of DES implanted by the physician during a fixed time period after
becoming “at-risk for disadoption” phase (i.e. from the publicization of DES safety
concerns through 2007). (The second measure was specifically chosen be defined over a
fixed period, not one based on the physician’s time period if initial disadoption, due to
concern over a potential mechanical relationship between an outcome variable based on
time period length and an explanatory variable whose definition is also based on that time
period length.) Together, these variables provide a general measure of each physician’s
total experience with the technology in question.

In addition to physician-specific variables, I also wish to control for other factors that
may impact a physician’s DES disadoption behavior. Specifically, there may be concern
that some unobserved group-level characteristics are systematically related to DES
disadoption behavior, and an inability to control for such characteristics would
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systematically bias the results. In these analyses, a specific concern is that some
unobservable characteristics of groups (e.g. the use of electronic health records, or
regular access to medical device specialists/representatives) might influence DES
disadoption behavior, thus biasing the results. If these unobservable characteristics are
time-invariant, the inclusion of group-level dummy variables (or fixed effects)—which
are thus perfectly collinear with all time-invariant group-level variation in the model—in
the regression analyses will control for all such unobserved characteristics, thus
eliminating those potential sources of bias. Specifically, I want to include both hospitaland practice-level fixed effects in the regression analyses. Hospital fixed effects are
determined easily, as the discharge data, which provides information on physicians’ stent
use, includes hospital identifiers for both Florida and New York. Practice-level fixed
effects, however, required additional data processing and the incorporation of the SK&A
dataset, which was described above.

Sample selection
Though the datasets are processed and combined, the original datasets include physicians
and patients outside of the purview of this dissertation, so the dataset should be reduced
in size. The first steps in sample selection, which were already described above, include
restricting the file to only include physicians located in Florida or New York (according
to the SK&A data) and physicians who implant coronary stents (according to the hospital
discharge data from Florida and New York).
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The next steps of sample selection, which are delineated in Table 5.1 (for the primary
outcome variable), can be broken into two general categories: (1) selection of appropriate
physicians for the given research questions and (2) exclusion of physicians who are
missing data necessary for the desired analyses. The first type of selection was already
begun when the sample was restricted to Florida and New York physicians who implant
coronary stents, but we can restrict this even more. First, I can narrow the date range of
the sample to a window that focuses on DES adoption and disadoption. For the
beginning of the time window I use 2003, as this was the year in which the FDA
approved DES, and for the end of the time window I use 2009, as our observation of
global trends in DES use indicate that the population-wide disadoption phase was
finished by this year (as shown in Chapter 2). Next, given that I am specifically
interested in studying the disadoption of DES, I can exclude any physicians who never
implanted any DES. I also want to exclude physicians who adopt DES after September
2006 (when DES safety concerns were widely publicized), as this date was set as the
initial period in which physicians were able to disadopt DES (or at risk for DES
disadoption) and I want to focus my attention on a sample in which all physicians are
capable of having the same values of the DES disadoption measures. (If I did not
exclude physicians who adopted DES after September 2006, those physicians’ measures
for time to initial disadoption would be inappropriately measured.) Next, given that the
measures of disadoption are based on DES usage rates and there are concerns about
natural noise in these measures (as discussed at length above), I want to exclude
physicians who implant very few stents per time period. For example, if a physician
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implants only 1 or 2 stents per time period and we expect there to be natural variation
(e.g. patient differences) that can drive changes in stent choice, such low stent use
volume would make it difficult to make an accurate empirical determination of the time
period in which that physician’s DES disadoption process begins. Thus, I choose to only
include physicians who implant at least 4 coronary stents per quarter on average, where
the choice of this number is somewhat arbitrary, but is driven by a desire to have
physicians who implant at least 1 stent per month and also weigh the trade-offs of
decrease sample size against increased noise in the DES disadoption measures. The final
step in the selection of desired physicians for the analysis is the exclusion of physicians
who disadopt DES after 2009. Though the sample was restricted to the years 2003-2009
above, that selection was made at the observation level, so physicians may have been
remained in the dataset if they appeared between 2003 and 2009, but we only want to
keep them in the dataset if they started the DES disadoption process before 200925.

The second general step in sample selection is the exclusion of physicians who are
missing information that I wish to use for the desired analyses. This sample selection
step is motivated by the fact that, when performing statistical analyses with the dataset,
the given software package (Stata) will exclude from an analysis any observation that is
missing a variable used in that analysis. Table 5.1 shows how the sample size changes as
25

An examination of Table 5.1 indicates that different sample restriction steps reduce the number of
physicians included in the sample by different numbers. For example, it appears that, in terms of
percentage change in sample size, the exclusion physicians who implant less than 4 stents/qtr (on average)
has the largest sample reduction impact. However, it is worth noting that these sample selection steps are
not order-dependent (i.e. combining the sample selection steps in any order will produce the same final
sample), so determining the marginal impact of each selection step is difficult. For example, if the first step
is the exclusion of physicians who disadopt DES after 2009, the number of physicians in the sample
immediately drops from 10,669 to 992.
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physicians are excluded for having missing values of any variable in the different groups
of variables used in the planned analyses. We observe here that, while the data does not
have issues with missing values of the DES disadoption, adoption, or use variables (at
least after having gone through the first set of sample restriction steps, discussed above),
there are issues with physicians missing values of the “physician characteristic” variables.
Given that the information in those variables comes from the AMA Physician Masterfile,
this problem is indicative of issues with the match between the AMA Masterfile and the
combined SK&A/discharge dataset.

Methods
With the final sample selected, analyses of the data can now be performed. After initial
data processing, the combined dataset is at the discharge level, I then reduce it to the
physician-time-period (i.e. physician-quarter) level to simplify calculation of the DES
adoption and disadoption measures. However, the primary variables of interest here—
namely the measures of DES adoption and disadoption—are all determined at the
physician level, i.e. each physician will only have one value for each of these measures,
regardless of time period. Thus, after these measures are calculated (by using data cross
multiple time periods), the dataset can be further reduced to the physician level (i.e. one
observation per physician) for the bulk of the analyses to be performed here.

As described above (first generally in Chapter 3 and then specifically in this chapter), the
different measures of DES adoption and disadoption are all continuous variables. The
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measures along the time dimension (i.e. time to initial adoption/disadoption and time to
maximum/minimum use) have integer values (numbers of quarters), and the measures
along the level dimension (i.e. initial extent of adoption/disadoption and full extent of
adoption/disadoption) can have any values along the range of DES use, which varies
continuously between 0 and 1. Given variables in this format, I use ordinary least
squares (OLS) linear regression to examine the relationship between the disadoption
measures and the adoption measures. As mentioned above, the primary outcome of
interest is a physician’s initial time to DES disadoption, and secondary outcomes are
initial extent of DES disadoption, time to minimum DES use, and full extent of DES
disadoption. For each outcome, each of the four measures of adoption (initial time to
DES adoption, initial extent of DES adoption, time to maximum DES use, and full extent
of DES adoption) will be the primary explanatory variables of interest. In addition to
these explanatory variables, I also include as covariates various measures of “physician
characteristic” (i.e. age, years of experience, and relevant fellowship training status) and
“physician DES use” (i.e. the total number of DES implanted by a physician before
becoming “at risk” for DES disadoption and the total number of DES implanted during a
fixed window after becoming “at risk”). Furthermore, due to potential concerns for
unobservable physician characteristics that may relate to both DES adoption and
disadoption behavior, I also include practice- and hospital-level fixed effects. Though
physician-level fixed effects would more directly control for unobserved physician
characteristics, the outcome variables used in these analyses are determined at the
physician-level, which prevents the use of physician-level fixed effects.
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While the measures of both DES adoption and disadoption are continuous variables, as
described above, I also convert these continuous measures into binary variables by using
the sample mean of each variable and identifying individuals who have values above the
mean (or below the mean, depending on the specific measure). Though the continuous
forms of these variables provides information on the levels of the different measures (and
effect sizes relative to those levels), the conversion of the variables to binary form allows
me to perform a more general investigation for relationships between the variables.
Though the use of binary explanatory variables does not require any change in analysis
approach, the use of binary outcome variables suggests the use of a probit or logit model.
However, the inclusion of practice- and hospital-level fixed effects in these models
makes the use of these binary outcome models very computationally intensive. Thus,
motivated by resource constraints and comforted by the qualitative similarity of results
from selective applications of logit models, I use OLS regression with the binary
measures of DES disadoption behavior, thus assuming a linear probability model. Also, I
use these binary variables to generate descriptive statistics and compare physicians with
high versus low values of the different DES disadoption measures. Tables 5.2 – 5.5
provide these basic descriptive statistics. For example, Table 5.2 compares early versus
late DES disadopters in terms of their means (and standard deviations) of the various
independent variables (i.e. DES adoption measures) and covariates (i.e. physician
characteristics). These statistics reveal that, across each of the different DES disadoption
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measures, there are not obvious differences between physicians who fall on either side of
these binary variables.

5.3 – Results
The results for regression analyses in this chapter are displayed in the Tables 5.6a – 5.9d.
The analyses that produced these results, and all other results in this chapter, should be
generally viewed as exploratory analyses that seek to determine associations between the
variables of interest; it is understood that these analyses to not specifically identify causal
relationships between these variables. With that said, there is still value to be gained
from these exploratory analyses. Though there is no exogenous source of identification
in these regression analyses, the concerns about endogeneity are relatively limited. For
example, there are no specific reasons to believe that there is systematic measurement
error in the measures of DES disadoption, nor should we believe that there is simultaneity
or reverse causality, given that DES disadoption is a distinct process that occurs after
adoption. Of course, it is impossible to rule out the existence of a relevant omitted
variable, but the inclusion of “physician characteristics” and “physician DES use”
variables should address concerns about physician-level factors that are likely related to
the adoption and disadoption processes, while the use of hospital- and practice-level fixed
effects can control for some unobservable time-invariant characteristics that may be
important. Thus, the associations identified here between DES disadoption measures and
adoption measures, while not causal, are still informative and valuable.

100
Tables 5.6a – 5.6d show the results from the analyses with the primary outcome variable,
initial time to DES disadoption. As described above, both the outcome variable and
explanatory variables of interest can be presented in continuous or binary form, and each
of these four tables represents a different combination of the continuous vs. binary
variables, with each table using the same series of model specifications, each of which is
presented in a separate column, where Model 1 is the most basic model and Model 9 has
the complete set of covariates included. Looking across these models and different
choices of variable formulations, we can observe that, except for time to maximum DES
use, the various measures of DES adoption—which importantly includes initial time to
DES adoption—are not associated with initial time to DES disadoption. Across all
models and variable formulations, there is a negative relationship between initial time to
DES disadoption and time to maximum DES use, though this relationship is only
statistically significant in some models and choices of variable formulation. (It must be
noted here that in binary formulation of all of the time-based adoption and disadoption
variables, including initial time to DES disadoption and time to maximum DES use, the
binary variables were given a value of 1 for smaller times, representing earlier or faster
adoption/disadoption behavior, and a value of 0 for larger values. As a result, a negative
relationship between these two measures will present with a positive coefficient estimate
when one of the variables is represented with a binary formulation and the other is in
continuous form, as is seen in Tables 5.6b and 5.6c.) In other words, we observe that
physicians who were slower to adopt DES (i.e. took longer to reach their maximum DES
use rate) are generally earlier to start disadopting (i.e. take less time to begin the DES
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disadoption process), or conversely, physicians who were faster to adopt DES generally
start disadopting later.

In addition to this association, we can also observe relationships between the outcome
variable and the different covariates in Tables 5.6a – 5.6d. For example, we see that
neither the hospital- nor practice-level fixed effects offer significant predictive power in
modelling time to initial DES disadoption, as indicated by the p-values (> 0.05) for the
incremental F-statistics in the models where those fixed effects were added. On the other
hand, the sets of “physician characteristic” variables and “physician DES use” variables
both (separately) significantly increase the statistical power of the models. Examining
individual variables, both physicians with interventional cardiology fellowship training
and those who implant a greater number of DES before the publication of safety concerns
start disadopting DES earlier, while those who implant a greater number of DES after the
publication of safety concerns start disadopting DES later.

As described above, the definition of DES disadoption is based on various criteria, for
which multiple options exist. Thus, in sensitivity analyses, I repeat the analyses
performed above with the primary outcome variable but use different DES disadoption
definitions (twelve different definitions in total), varying the conditions (both for the
change in DES use rate and for the earliest allowable time period) that identify the initial
period of DES disadoption. Figures 5.2 and 5.3 provide summaries of the estimated
coefficients—plotted with bars depicting their 95% confidence intervals—on the four
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measures of DES adoption from the analyses using each of the different DES disadoption
criteria to define time to initial DES disadoption, selecting the coefficient estimates from
the models run with the most complete set of covariates (i.e. Model 9, as displayed in
Table 5.6). Figure 5.2 provides coefficient estimates from models that use continuous
measures of both time to initial DES disadoption and the DES adoption explanatory
variables, whereas Figure 5.3 provides coefficients estimates from models where both
DES disadoption and adoption measures are represented in binary formulations. As these
figures show, by examination of both the different point estimates and the calculated
averages of the coefficients (with corresponding 90% confidence intervals), the point
estimate results are indeed sensitive to the choice of DES disadoption definition criteria,
but the estimates are mostly not different from zero with statistical significance and it is
generally difficult to identify relationships that are consistently different from zero across
the different DES disadoption definitions. One may note, though, that the relationship
that is closest to achieving statistical significance in its difference from 0 is the negative
relationship between initial time to DES disadoption and time to maximum DES use.

103

Figure 5.2: Coefficient estimates from models relating continuous DES adoption
measures to continuous DES disadoption outcome measures (basic OLS regression),
using different DES disadoption definitions; coefficient means with 90% CI are shown
in text.
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Figure 5.3: Coefficient estimates from models relating binary DES adoption measures to
binary DES disadoption outcome measures (basic OLS regression), using different DES
disadoption definitions; coefficient means with 90% CI are shown in text.

Results from the analyses of the secondary outcomes of interest are shown in Tables 5.7 –
5.10. For the sake of space, I have only included the results of analyses where either both
DES disadoption and adoption measures were in continuous form (tables with “a”) or
both were in binary form (tables with “d”). Across these analyses, we observe very few
statistically significant relationships, both for the measures of individual DES disadoption
measures and for the measure of area above the DES disadoption curve. There is a
positive and significant relationship between time to minimum DES use (i.e. a disadoption
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measure) and extent of full DES adoption, indicating that physicians who had higher
maximum DES use rates take more time to reach their minimum DES use level, i.e. move
more slowly through the disadoption process. However, neither of the measures of extent
of DES disadoption (initial extent of disadoption or full extent of disadoption) have
statistically significant associations with any of the DES adoption measures in any of the
specified models. Also, the individual covariates very rarely have statistically significant
relationships with any of the secondary disadoption outcome measures. Of note, there is
a positive and statistically significant relationship between a physician’s area above the
DES disadoption curve and that physician’s level of DES use in the period prior to
initiating disadoption.

5.4 – Discussion
The analyses performed in this chapter are meant to be exploratory. Because I do not
identify a source of exogenous variation (of DES adoption behavior, or any other
physician-level characteristic), I cannot and do not claim to observe any causal
relationships in these analyses. However, there is still interesting information to be
gleaned from the observed correlations. By including several different physician-level
covariates, along with practice- and hospital-level fixed effects, I am able to control for
many factors that potentially cofound any observed association between the various
adoption and disadoption process measures. Furthermore, we need not worry about
reverse causality in these analyses, because the DES adoption process is completed
before disadoption begins. Thus, though I do not suggest that the differences in DES
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adoption behavior cause the observed differences in DES disadoption behavior, concerns
that the observed relationships are spurious should be reduced.

One of the most interesting findings in the above analyses is the relationship between
time to initial DES disadoption and time to maximum DES use: faster DES adopters (i.e.
physicians who take less time to move from initial DES adoption to maximum use) tend
to start disadoption later (i.e. take more time from DES safety concern publicization to
initial disadoption) or conversely, slower DES adopters tend to start disadoption earlier.
The reason for this association is unclear and could be explained by multiple possible
factors. For example, this observation may be partially explained by a manifestation of
risk aversion towards new technologies. Those cardiologists who are concerned about
uncertainty associated with a new technology like DES when it first reaches the market
may be slower to fully adopt the technology (i.e. longer time to maximum DES use) and
then also more eager to begin disadoption (i.e. short time to initial DES disadoption)
when they learn about safety risks associated with thrombosis. Another possible
explanation for the observed behavior is that physicians who adopt DES faster have a
superior knowledge of the technology, which then prevents them from hastily disadopting
after the publicization of safety concerns (which were ultimately addressed, resulting in
the observed global trend of DES “re-adoption”, as discussed in Chapter 2). However,
contrary to this story of experience-based knowledge of the technology, we observe that
those who implanted more DES per quarter after the publicization of safety concerns
actually started the disadoption process sooner. Another different factor that may
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partially explain the observed results is product loyalty: cardiologists who develop a
strong preference for DES may quickly increase their use of the technology (i.e. short
time to maximum DES use), and then be hesitant to stop using the technology (i.e. long
time to initial DES disadoption). This notion that technology loyalty is important is
further supported by the observed relationship between time to minimum DES use and full
extent of DES adoption: cardiologists who had higher levels of DES use (post-adoption)
tended to be slower to disadoption (i.e. take more time to move from initial DES
disadoption to minimum use).

Aside from these results, the above analyses are also noteworthy for all of the
relationships that were not statistically significant. Importantly, there were no positive
relationships between any of the analogous measurements of DES adoption and
disadoption (e.g. time to initial adoption and time to initial disadoption), i.e. the
theoretical prediction of symmetry between the adoption and disadoption processes
presented in Chapter 4 was not supported empirically. This result may indicate that the
two processes are more different than can be explained by a simple theoretic model, or
that the factors shaping the behaviors are beyond any of the basic measurable covariates
included in the above analyses. As is frequently the case in economics, we see here that
there could be increased empirical accuracy gained from either a more detailed model or
comprehensive dataset.
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Also, we note that neither initial extent of DES disadoption nor full extent of DES
disadoption were found to be correlated with any DES adoption measures or many (if
any) physician-level characteristics. As discussed in Chapter 3, one possible explanation
for variation in an individual’s extent of technology adoption or disadoption is risk
aversion. Using this explanation, it would appear that it is difficult to predict
cardiologists’ risk aversion, or at least that risk aversion associated with DES adoption
seems unrelated to the risk aversion associated with DES disadoption. Another possible
explanation for variation in extent of technology adoption/disadoption is difference in
physicians’ patient populations. At first glance, this explanation seems problematic
because we would generally expect a physician to be treating the same patient population
during her DES adoption and disadoption processes. However, the paths of the
technology use curve that describes adoption and disadoption are different. If differences
in extent of technology use are driven by differences in patient characteristics, then we
expect there to a spectrum of patient characteristics, where some would be very
appropriate recipients of DES and these individuals would receive DES first (i.e. at low
levels of use), whereas other patients would be less appropriate and would only receive
DES later (i.e. at high levels of use). With this perspective and with an understanding
that the paths of adoption and disadoption are different—because adoption represents
movement up the technology use curve, from highly appropriate to less appropriate
patients, whereas disadoption represents movement down the curve, from less appropriate
to more appropriate patients—we can see that even if a physician’s general patient
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population is the same during the adoption and disadoption phases, the marginal
“adoption patient” is still different from the marginal “disadoption patient.”

In addition to observed relationships between the DES disadoption outcomes and the
DES adoption measures, we can also notice interesting relationships between some of the
covariates and DES disadoption behavior. For example, interventional cardiology
fellowship training is associated with earlier initial DES disadoption, which could be
consistent with the belief that physicians with the most technically advanced coronarystent-related training might be most likely to learn first about safety concerns, and thus
disadopt earlier. Of course, learning earlier about safety concerns (and resultant earlier
disadoption) could just as well be driven by greater experience with the technology,
which we also observe empirically by noting the negative relationship between time to
initial DES disadoption and physicians’ average quarterly DES volume (after DES safety
concern publicization). Indeed, we might just as likely expect the individuals who have
interventional cardiology training to implant more DES (or coronary stents in general),
which is observed in the data. It is interesting to note that, among the set of covariates
are other physician-level factors that one might have expected to be related to an
individual’s adaptability with respect to technology, such as physician age and years of
experience, but none of these is associated with time to initial DES disadoption. We also
observe a positive and significant relationship between area above the DES disadoption
curve and level of DES use prior to initiating disadoption, but there is reason to think this

110
might be a mechanical relationship: lower levels of DES use prior to disadoption simply
allow for lower area above the potential DES disadoption curve.

In addition to the main results presented above, there are also the sensitivity analyses,
which test the use of different DES disadoption definitions. As noted above, the negative
relationship between time to initial DES disadoption and time to maximum DES use does
change with the use of different DES disadoption definitions, but the qualitative results
remain when taking a global view across the different definitions. As discussed above
when characterizing and precisely defining the DES disadoption process, it is not
surprising that variation in the conditions used to characterize this process would
influence the observed empirical results, given natural noise in the DES use data, the
tradeoff between sensitivity and specificity of disadoption measures, and the relatively
small sample size used here. This uncomfortable fact—that a precise definition of
technology disadoption is required to develop a detailed characterization of the process,
but that such precision is somewhat arbitrary—may partially explain why past
researchers have either avoided studying disadoption altogether or have studied it by
instead simply examining technology use during a period of general downward trends in
use. However, as discussed above, I assert that there is distinct importance in studying
the process of technology disadoption, particularly in the setting of medical technology,
so as long as the definition and conditions used to characterize the disadoption process
are transparent and justifiable, there is value in taking that stand and examining the
process.
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Of course, it is also important to note that the observed results must be discussed within
the limitations of this examination. Though this dissertation has focused generally on
technology disadoption, this empirical analysis has only examined one specific
technology (coronary drug-eluting stents) in a relatively restricted population
(cardiologists in New York and Florida). Thus, our ability to extrapolate from this setting
to broader understandings about medical technology disadoption behavior depends on
how representative we believe this group and setting is of the larger population. Also, the
sample size used in these analyses is relatively small (640 physicians), which, when
combined with the covariates and group-level fixed effects, provides low statistical power
to detect modest effect sizes. Thus, an increase in sample size may allow us to uncover
true relationships that the current analyses are unpowered to identify. Similarly, access to
more data—bother observations and variables—would be useful. Despite the inclusion
of various physician-level covariates and group-level fixed effects, we cannot rule out the
possibility of omitted variable bias. As discussed above, patient characteristics likely
play a large role in a physician’s decision of which stent type to select, but these
characteristics are unobserved here. Though there is no reason to suspect that there were
any systematic changes in patient characteristics, the realization of increased thrombosis
risk with DES lead to an indication for dual-anti platelet therapy for DES patients, and
this change in medication regimen likely influenced physicians’ selections of DESappropriate patients, and also increased the role for patient preferences in the selection of
stent type.
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Despite these limitations, the above analyses provide some insight into the technology
disadoption process. However, these analyses represent a very small step in this
investigation of technology disadoption, and much more work is required. This work
continues in the next chapter, where I begin to examine the relationship between
disadoption and physician group size.
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Table 5.1: Sample selection for analyses relating time to initial DES disadoption to
adoption measures
Sample restriction step
Initial sample
Selection of appropriate/desired physicians
After selecting years 2003 – 2009
After excluding docs who never implant DES
After selecting docs who adopt DES before safety concern publicization
After selecting docs who implant, on average, at least 4 stents/quarter
After excluding docs who disadopt DES after 2009
Exclusion of physicians who are missing necessary data
After excluding docs missing DES disadoption outcome (time to initial
dis.)
After excluding docs missing any DES adoption measure
After excluding docs missing any “physician characteristic” variable
After excluding docs missing any “physician DES use” variable
Final sample size

Unique docs
10,669
8,694
7,200
4,822
967
760
760
760
640
640
640

Table 5.2: Descriptive statistics for early vs. late initial DES disadopters (initial time to DES disadoption)
Early DES disadopters (time to initial dis < pop. Mean)
Early
Late
Sample size (physician count; total = 640)
465
175
Mean
SD
Mean
SD
Physician time (quarters) to initial DES adoption
.4210905
.2805479
.4200931
.2696884
Physician initial level DES use (increase) upon adoption
.988361
.0338622
.9925691
.0278064
Physician time (quarters) from adoption to max DES use
5.07957
2.668485
4.96
2.564927
Physician full level DES use (increase) after adoption
9.055914
6.420359
7.668571
6.337617
Physician age (at time of DES safety concern publicization)
369.6473
293.9991
302.0743
279.8314
Physician years of experience (at time of DES safety concern pub)
139.6495
123.7706
125.08
122.1802
Physician has cardiology fellowship training
.9311828
.2534157
.9028571
.297002
Physician has interventional cardiology fellowship training
.1354839
.3426083
.0514286
.221504
Physician total num. DES placed before safety concerns
47.66452
7.355748
49.33714
6.76838
Physician total num. DES placed from safety concern pub. thru 2007
14.83011
7.867378
16.6
7.702067
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Table 5.3: Descriptive statistics for big vs. small initial DES disadopters (initial extent of DES disadoption)
Big initial DES disadopters (extent initial dis > pop. Mean)
Big
Small
Sample size (physician count; total = 640)
191
449
Mean
SD
Mean
SD
Physician time (quarters) to initial DES adoption
.4179991
.2769371
.4220168
.2779128
Physician initial level DES use (increase) upon adoption
.9870316
.0449179
.9905666
.0251696
Physician time (quarters) from adoption to max DES use
5.052356
2.686689
5.044543
2.621643
Physician full level DES use (increase) after adoption
8.659686
6.890451
8.683742
6.2212
Physician age (at time of DES safety concern publicization)
223.8743
154.132
405.3207
318.2908
Physician years of experience (at time of DES safety concern pub)
71.95812
49.1106
162.7661
135.0374
Physician has cardiology fellowship training
.9267016
.2613107
.922049
.2683935
Physician has interventional cardiology fellowship training
.1413613
.3493094
.1002227
.3006317
Physician total num. DES placed before safety concerns
48.37173
7.531201
48.01559
7.108673
Physician total num. DES placed from safety concern pub. thru 2007
15.29319
7.943743
15.32294
7.827689

Table 5.4: Descriptive statistics for fast vs. slow DES disadopters (time to minimum DES use)
Fast DES disadopters (time to min use < pop. Mean)
Fast
Sample size (physician count; total = 640)
307
Mean
SD
Physician time (quarters) to initial DES adoption
.4338178
.2856613
Physician initial level DES use (increase) upon adoption
.9876163
.0384398
Physician time (quarters) from adoption to max DES use
5.260586
2.858969
Physician full level DES use (increase) after adoption
8.452769
6.433182
Physician age (at time of DES safety concern publicization)
324.6417
302.0928
Physician years of experience (at time of DES safety concern pub)
124.6873
130.4181
Physician has cardiology fellowship training
.9120521
.2836815
Physician has interventional cardiology fellowship training
.1270358
.3335568
Physician total num. DES placed before safety concerns
47.76547
7.261933
Physician total num. DES placed from safety concern pub. thru 2007
14.94463
8.0501

Slow
333
Mean
.4088327
.991259
4.84985
8.882883
375.6276
145.7868
.9339339
.0990991
48.45045
15.65465

SD
.2694569
.0254218
2.406375
6.415914
279.6889
115.8613
.2487714
.2992447
7.201998
7.669625
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Table 5.5: Descriptive statistics for big vs. small complete DES disadopters (full extent of DES disadoption)
Big total DES disadopters (extent total dis > pop. Mean)
Big
Small
Sample size (physician count; total = 640)
327
313
Mean
SD
Mean
SD
Physician time (quarters) to initial DES adoption
.4308144
.2859492
.4103739
.2682608
Physician initial level DES use (increase) upon adoption
.9896447
.0269476
.9893726
.0372142
Physician time (quarters) from adoption to max DES use
5.281346
2.918166
4.801917
2.291091
Physician full level DES use (increase) after adoption
8.281346
5.770168
9.089457
7.025935
Physician age (at time of DES safety concern publicization)
264.5719
199.9704
441.6422
340.9144
Physician years of experience (at time of DES safety concern pub)
92.55963
74.30534
180.6997
146.4343
Physician has cardiology fellowship training
.9388379
.2399946
.9073482
.2904081
Physician has interventional cardiology fellowship training
.1406728
.3482165
.0830671
.2764255
Physician total num. DES placed before safety concerns
47.52599
7.28296
48.74441
7.139533
Physician total num. DES placed from safety concern pub. thru 2007
14.65443
7.768497
16.00319
7.900624

Table 5.6a: Relating continuous DES adoption measures to continuous initial time to DES disadoption (basic OLS regression
results)
Physician time (quarters) to initial
DES adoption
Physician initial level DES use
(increase) upon adoption
Physician time (quarters) from
adoption to max DES use
Physician full level DES use
(increase) after adoption
Physician age (at time of DES safety
concern publicization)
Physician years of experience (at time
of DES safety concern pub)
Physician has cardiology fellowship
training
Physician has interventional
cardiology fellowship training
Physician total num. DES placed
before safety concerns
Physician total num. DES placed from
safety concern pub. thru 2007
r2
F
p
N
Unique docs
Practice FEs
Hospital FEs
Incremental F stat
Prob > incrm F

Model 1
(β/[95%CI])
-0.028
[-0.14,0.08]
-0.252
[-1.34,0.83]
-0.054**
[-0.09,-0.02]
2.956
[-3.56,9.47]

Model 2
(β/[95%CI])
0.002
[-0.15,0.15]
-0.559
[-2.05,0.93]
-0.051*
[-0.10,-0.00]
2.735
[-5.07,10.54]

Model 3
(β/[95%CI])
-0.014
[-0.14,0.12]
-0.569
[-1.91,0.77]
-0.045*
[-0.09,-0.01]
3.884
[-3.96,11.73]

Model 4
(β/[95%CI])
-0.007
[-0.19,0.18]
-0.494
[-2.41,1.42]
-0.032
[-0.09,0.02]
4.688
[-5.49,14.87]

Model 5
(β/[95%CI])
0.030
[-0.08,0.15]
-0.100
[-1.18,0.98]
-0.056**
[-0.09,-0.02]
3.319
[-3.16,9.80]
0.070
[-0.01,0.15]
-0.049
[-0.12,0.02]
-0.011
[-0.85,0.83]
-1.098**
[-1.92,-0.28]

0.018
2.849
0.023
640.000
640

0.378
0.979
0.571
640.000
640
X

0.214
1.117
0.206
640.000
640

0.520
0.948
0.684
640.000
640
X
X
0.86091859
0.882449912

0.948529188
0.672297465

X
1.058777225
0.333185646

0.040
3.277
0.001
640.000
640

Model 6
(β/[95%CI])
-0.070
[-0.19,0.05]
0.137
[-0.94,1.21]
-0.043*
[-0.08,-0.01]
2.559
[-3.84,8.95]
0.061
[-0.01,0.14]
-0.042
[-0.11,0.03]
-0.096
[-0.92,0.73]
-1.078**
[-1.89,-0.27]
-0.003***
[-0.00,-0.00]
0.005**
[0.00,0.01]
0.070
4.729
0.000
640.000
640

Model 7
(β/[95%CI])
-0.042
[-0.21,0.12]
-0.079
[-1.53,1.38]
-0.044
[-0.09,0.00]
3.734
[-3.88,11.35]
0.088
[-0.00,0.18]
-0.062
[-0.15,0.03]
0.580
[-0.42,1.58]
-1.346**
[-2.36,-0.33]
-0.004***
[-0.01,-0.00]
0.005*
[0.00,0.01]
0.427
1.151
0.108
640.000
640
X

3.656549095
0.00590517

10.15760808
4.55353E-05

1.002044551
0.489374894

Model 8
(β/[95%CI])
-0.040
[-0.18,0.10]
-0.362
[-1.68,0.96]
-0.030
[-0.07,0.01]
2.423
[-5.29,10.14]
0.091*
[0.01,0.17]
-0.072
[-0.15,0.01]
0.180
[-0.73,1.09]
-1.110*
[-2.02,-0.20]
-0.004***
[-0.01,-0.00]
0.005*
[0.00,0.01]
0.259
1.355
0.011
640.000
640
X
1.070603998
0.305344644

Model 9
(β/[95%CI])
-0.014
[-0.22,0.19]
-0.208
[-2.10,1.68]
-0.029
[-0.08,0.03]
3.239
[-6.80,13.28]
0.100
[-0.02,0.21]
-0.043
[-0.15,0.07]
0.816
[-0.36,1.99]
-0.929
[-2.20,0.34]
-0.003*
[-0.01,-0.00]
0.004
[-0.00,0.01]
0.550
1.027
0.407
640.000
640
X
X
0.85957032
0.884633047
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Table 5.6b: Relating binary DES adoption measures to continuous initial time to DES disadoption (basic OLS regression results)
Physician early DES initial adopter
(before sample mean)
Physician big DES initial adopter
(more than sample mean)
Physician fast DES full adopter (less
time than sample mean)
Physician big DES full adopter (more
than sample mean)
Physician age (at time of DES safety
concern publicization)
Physician years of experience (at time
of DES safety concern pub)
Physician has cardiology fellowship
training
Physician has interventional
cardiology fellowship training
Physician total num. DES placed
before safety concerns
Physician total num. DES placed from
safety concern pub. thru 2007
r2
F
p
N
Unique docs
Practice FEs
Hospital FEs
Incremental F stat
Prob > incrm F

Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 4
(β/[95%CI])

Model 5
(β/[95%CI])

Model 6
(β/[95%CI])

Model 7
(β/[95%CI])

Model 8
(β/[95%CI])

Model 9
(β/[95%CI])

0.371
[-0.26,1.00]

0.140
[-0.68,0.96]

0.272
[-0.45,0.99]

0.357
[-0.67,1.39]

-0.007
[-0.69,0.68]

0.487
[-0.23,1.21]

0.314
[-0.62,1.25]

0.276
[-0.55,1.10]

0.199
[-0.98,1.38]

-0.091
[-0.57,0.38]

-0.451
[-1.09,0.19]

-0.388
[-0.94,0.16]

-0.387
[-1.18,0.40]

-0.059
[-0.53,0.42]

0.006
[-0.46,0.48]

-0.299
[-0.92,0.33]

-0.387
[-0.93,0.16]

-0.365
[-1.15,0.41]

0.808***
[0.36,1.26]

0.902**
[0.26,1.55]

0.787**
[0.24,1.33]

0.840*
[0.06,1.62]

0.801***
[0.35,1.25]

0.660**
[0.21,1.11]

0.751*
[0.11,1.39]

0.601*
[0.05,1.15]

0.721
[-0.07,1.51]

0.585*
[0.03,1.14]

0.601
[-0.14,1.34]

0.663*
[0.00,1.32]

0.724
[-0.13,1.58]

0.571*
[0.02,1.13]

0.372
[-0.19,0.93]

0.465
[-0.27,1.21]

0.372
[-0.29,1.04]

0.491
[-0.38,1.36]

0.065
[-0.01,0.14]

0.059
[-0.02,0.13]

0.083
[-0.01,0.17]

0.092*
[0.01,0.17]

0.090
[-0.02,0.20]

-0.047
[-0.12,0.03]

-0.041
[-0.11,0.03]

-0.060
[-0.15,0.03]

-0.072
[-0.15,0.01]

-0.036
[-0.14,0.07]

-0.090
[-0.92,0.74]

-0.121
[-0.94,0.70]

0.535
[-0.45,1.52]

0.169
[-0.74,1.07]

0.831
[-0.34,2.00]

-0.940*
[-1.74,-0.14]

-0.984*
[-1.78,-0.19]

-1.282*
[-2.27,-0.29]

-1.075*
[-1.97,-0.18]

-0.856
[-2.11,0.40]

-0.003***
[-0.00,-0.00]

-0.004***
[-0.01,-0.00]

-0.003***
[-0.01,-0.00]

-0.003*
[-0.01,-0.00]

0.005**
[0.00,0.01]

0.005*
[0.00,0.01]

0.005*
[0.00,0.01]

0.004
[-0.00,0.01]

0.052
4.317
0.000
640.000
640

0.077
5.272
0.000
640.000
640

0.433
1.180
0.072
640.000
640
X

0.267
1.413
0.005
640.000
640

2.906421921
0.021137844

8.672534568
0.000192558

1.009565407
0.463714518

0.557
1.057
0.313
640.000
640
X
X
0.871443394
0.862087994

0.034
5.659
0.000
640.000
640

0.391
1.033
0.386
640.000
640
X
0.957495591
0.642557136

0.228
1.217
0.074
640.000
640
X
1.068126243
0.310875371

0.532
0.995
0.520
640.000
640
X
X
0.885191382
0.833804968

X
1.086979631
0.268705009
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Table 5.6c: Relating continuous DES adoption measures to binary (early) initial time to DES disadoption (linear probability model)
Physician time (quarters) to initial
DES adoption
Physician initial level DES use
(increase) upon adoption
Physician time (quarters) from
adoption to max DES use
Physician full level DES use
(increase) after adoption
Physician age (at time of DES safety
concern publicization)
Physician years of experience (at time
of DES safety concern pub)
Physician has cardiology fellowship
training
Physician has interventional
cardiology fellowship training
Physician total num. DES placed
before safety concerns
Physician total num. DES placed from
safety concern pub. thru 2007
r2
F
p
N
Unique docs
Practice FEs
Hospital FEs
Incremental F stat
Prob > incrm F

Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 4
(β/[95%CI])

Model 5
(β/[95%CI])

Model 6
(β/[95%CI])

Model 7
(β/[95%CI])

Model 8
(β/[95%CI])

Model 9
(β/[95%CI])

0.005
[-0.01,0.02]

0.001
[-0.02,0.03]

0.002
[-0.02,0.02]

0.005
[-0.03,0.03]

-0.005
[-0.02,0.01]

0.009
[-0.01,0.03]

0.006
[-0.02,0.03]

0.005
[-0.02,0.03]

0.006
[-0.03,0.04]

0.035
[-0.15,0.22]

0.101
[-0.14,0.34]

0.095
[-0.13,0.32]

0.010
[-0.30,0.32]

0.007
[-0.17,0.19]

-0.024
[-0.20,0.16]

0.033
[-0.21,0.27]

0.055
[-0.17,0.28]

-0.031
[-0.34,0.27]

0.007*
[0.00,0.01]

0.008*
[0.00,0.02]

0.006
[-0.00,0.01]

0.003
[-0.01,0.01]

0.008*
[0.00,0.01]

0.006*
[0.00,0.01]

0.007
[-0.00,0.01]

0.004
[-0.00,0.01]

0.003
[-0.01,0.01]

-0.625
[-1.71,0.46]

-0.718
[-1.99,0.56]

-0.904
[-2.22,0.41]

-0.755
[-2.39,0.88]

-0.646
[-1.72,0.43]

-0.547
[-1.62,0.52]

-0.795
[-2.05,0.46]

-0.692
[-2.00,0.62]

-0.560
[-2.18,1.06]

-0.004
[-0.02,0.01]

-0.003
[-0.02,0.01]

-0.001
[-0.02,0.01]

-0.003
[-0.02,0.01]

-0.003
[-0.02,0.02]

0.001
[-0.01,0.01]

-0.000
[-0.01,0.01]

-0.002
[-0.02,0.01]

0.000
[-0.01,0.01]

-0.006
[-0.02,0.01]

0.038
[-0.10,0.18]

0.048
[-0.09,0.19]

-0.063
[-0.23,0.10]

-0.014
[-0.17,0.14]

-0.143
[-0.33,0.05]

0.178*
[0.04,0.31]

0.176*
[0.04,0.31]

0.197*
[0.03,0.36]

0.155
[-0.00,0.31]

0.105
[-0.10,0.31]

0.000***
[0.00,0.00]

0.001**
[0.00,0.00]

0.001**
[0.00,0.00]

0.000*
[0.00,0.00]

-0.001**
[-0.00,-0.00]

-0.001
[-0.00,0.00]

-0.001*
[-0.00,-0.00]

-0.001
[-0.00,0.00]

0.034
2.739
0.006
640.000
640

0.053
3.514
0.000
640.000
640

0.428
1.158
0.097
640.000
640
X

0.219
1.089
0.259
640.000
640

3.300173
0.010867

6.426047
0.001727

1.057413
0.311724

0.572
1.127
0.146
640.000
640
X
X
1.076876
0.275135

0.013
2.147
0.074
640.000
640

0.397
1.060
0.302
640.000
640
X
1.041883
0.357797

0.194
0.992
0.511
640.000
640
X
0.954604
0.615519

0.549
1.063
0.295
640.000
640
X
X
1.059163
0.320554

X
0.894595
0.770211
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Table 5.6d: Relating binary DES adoption measures to binary (early) initial time to DES disadoption (linear probability model)
Physician early DES initial adopter
(before sample mean)
Physician big DES initial adopter
(more than sample mean)
Physician fast DES full adopter (less
time than sample mean)
Physician big DES full adopter (more
than sample mean)
Physician age (at time of DES safety
concern publicization)
Physician years of experience (at time
of DES safety concern pub)
Physician has cardiology fellowship
training
Physician has interventional
cardiology fellowship training
Physician total num. DES placed
before safety concerns
Physician total num. DES placed from
safety concern pub. thru 2007
r2
F
p
N
Unique docs
Practice FEs
Hospital FEs
Incremental F stat
Prob > incrm F

Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 4
(β/[95%CI])

Model 5
(β/[95%CI])

Model 6
(β/[95%CI])

Model 7
(β/[95%CI])

Model 8
(β/[95%CI])

Model 9
(β/[95%CI])

-0.091
[-0.20,0.01]

-0.113
[-0.25,0.02]

-0.085
[-0.21,0.04]

-0.123
[-0.29,0.04]

-0.027
[-0.14,0.09]

-0.094
[-0.21,0.03]

-0.133
[-0.29,0.02]

-0.076
[-0.22,0.06]

-0.095
[-0.29,0.10]

0.010
[-0.07,0.09]

0.021
[-0.08,0.13]

0.054
[-0.04,0.15]

-0.009
[-0.14,0.12]

0.005
[-0.07,0.08]

-0.003
[-0.08,0.08]

0.004
[-0.10,0.11]

0.051
[-0.04,0.14]

-0.009
[-0.13,0.12]

-0.165***
[-0.24,-0.09]

-0.209***
[-0.31,-0.11]

-0.175***
[-0.27,-0.08]

-0.174**
[-0.30,-0.05]

-0.166***
[-0.24,-0.09]

-0.151***
[-0.23,-0.08]

-0.189***
[-0.29,-0.08]

-0.159***
[-0.25,-0.07]

-0.162*
[-0.29,-0.03]

-0.056
[-0.15,0.04]

-0.053
[-0.17,0.07]

-0.074
[-0.18,0.04]

-0.053
[-0.19,0.08]

-0.054
[-0.15,0.04]

-0.031
[-0.12,0.06]

-0.032
[-0.15,0.09]

-0.045
[-0.16,0.07]

-0.026
[-0.17,0.11]

-0.003
[-0.02,0.01]

-0.002
[-0.01,0.01]

-0.000
[-0.02,0.01]

-0.003
[-0.02,0.01]

-0.002
[-0.02,0.02]

0.000
[-0.01,0.01]

-0.001
[-0.01,0.01]

-0.002
[-0.02,0.01]

0.000
[-0.01,0.01]

-0.007
[-0.02,0.01]

0.051
[-0.09,0.19]

0.053
[-0.08,0.19]

-0.059
[-0.22,0.10]

-0.012
[-0.16,0.14]

-0.154
[-0.34,0.03]

0.148*
[0.02,0.28]

0.155*
[0.02,0.29]

0.174*
[0.01,0.34]

0.142
[-0.01,0.29]

0.087
[-0.11,0.29]

0.000***
[0.00,0.00]

0.001**
[0.00,0.00]

0.000**
[0.00,0.00]

0.000*
[0.00,0.00]

-0.001**
[-0.00,-0.00]

-0.001
[-0.00,0.00]

-0.001*
[-0.00,-0.00]

-0.001
[-0.00,0.00]

0.055
4.614
0.000
640.000
640

0.072
4.911
0.000
640.000
640

0.444
1.234
0.032
640.000
640
X

0.238
1.208
0.079
640.000
640

2.539282541
0.038903177

5.816588237
0.003140246

1.075347583
0.262212019

0.582
1.170
0.082
640.000
640
X
X
1.075595914
0.278321913

0.040
6.624
0.000
640.000
640

0.418
1.154
0.103
640.000
640
X
1.06109794
0.300537264

0.218
1.147
0.156
640.000
640
X
0.967185506
0.580413207

0.561
1.119
0.159
640.000
640
X
X
1.054158896
0.333948613

X
0.909163062
0.735371184
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Table 5.7a: Relating continuous DES adoption measures to continuous initial extent of DES disadoption (basic OLS regression
results)
Physician time (quarters) to initial
DES adoption
Physician initial level DES use
(increase) upon adoption
Physician time (quarters) from
adoption to max DES use
Physician full level DES use
(increase) after adoption
Physician age (at time of DES safety
concern publicization)
Physician years of experience (at time
of DES safety concern pub)
Physician has cardiology fellowship
training
Physician has interventional
cardiology fellowship training
Physician total num. DES placed
before safety concerns
Physician total num. DES placed from
safety concern pub. thru 2007
r2
F
p
N
Unique docs
Practice FEs
Hospital FEs
Incremental F stat
Prob > incrm F

Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 4
(β/[95%CI])

Model 5
(β/[95%CI])

Model 6
(β/[95%CI])

Model 7
(β/[95%CI])

Model 8
(β/[95%CI])

Model 9
(β/[95%CI])

0.001
[-0.00,0.01]

0.004
[-0.00,0.01]

0.001
[-0.00,0.01]

0.003
[-0.00,0.01]

0.001
[-0.00,0.01]

-0.001
[-0.01,0.00]

0.002
[-0.00,0.01]

0.001
[-0.00,0.01]

0.004
[-0.00,0.01]

-0.012
[-0.06,0.03]

-0.034
[-0.09,0.02]

-0.020
[-0.07,0.03]

-0.037
[-0.11,0.04]

-0.012
[-0.06,0.03]

-0.005
[-0.05,0.04]

-0.029
[-0.08,0.03]

-0.032
[-0.08,0.02]

-0.050
[-0.12,0.02]

-0.001
[-0.00,0.00]

-0.001
[-0.00,0.00]

-0.001
[-0.00,0.00]

-0.001
[-0.00,0.00]

-0.001
[-0.00,0.00]

0.000
[-0.00,0.00]

-0.000
[-0.00,0.00]

-0.000
[-0.00,0.00]

-0.001
[-0.00,0.00]

-0.121
[-0.39,0.14]

-0.095
[-0.40,0.21]

0.090
[-0.22,0.40]

-0.016
[-0.40,0.37]

-0.122
[-0.39,0.14]

-0.149
[-0.40,0.10]

-0.105
[-0.39,0.18]

0.047
[-0.25,0.35]

-0.026
[-0.40,0.34]

0.001
[-0.00,0.00]

0.000
[-0.00,0.00]

0.001
[-0.00,0.00]

0.000
[-0.00,0.00]

0.001
[-0.00,0.01]

-0.000
[-0.00,0.00]

-0.000
[-0.00,0.00]

-0.000
[-0.00,0.00]

0.001
[-0.00,0.00]

-0.001
[-0.00,0.00]

0.015
[-0.02,0.05]

0.007
[-0.03,0.04]

0.013
[-0.02,0.05]

0.015
[-0.02,0.05]

0.006
[-0.04,0.05]

0.011
[-0.02,0.04]

0.014
[-0.02,0.05]

0.018
[-0.02,0.06]

0.026
[-0.01,0.06]

0.026
[-0.02,0.07]

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

-0.000***
[-0.00,-0.00]

-0.000***
[-0.00,-0.00]

-0.000***
[-0.00,-0.00]

-0.000***
[-0.00,-0.00]

0.004
0.355
0.944
640.000
640

0.147
10.806
0.000
640.000
640

0.491
1.490
0.000
640.000
640
X

0.313
1.767
0.000
640.000
640

0.32388508
0.862009548

52.37759025
9.11553E-22

1.088642462
0.22873943

0.623
1.389
0.002
640.000
640
X
X
1.115299375
0.189926979

0.002
0.388
0.817
640.000
640

0.416
1.145
0.118
640.000
640
X
1.156733459
0.101312295

0.232
1.243
0.055
640.000
640
X
1.270416397
0.040602875

0.574
1.179
0.072
640.000
640
X
X
1.147875796
0.133059557

X
1.016648033
0.442414197
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Table 5.7d: Relating binary DES adoption measures to binary (big) initial extent of DES disadoption (linear probability model)
Physician early DES initial adopter
(before sample mean)
Physician big DES initial adopter
(more than sample mean)
Physician fast DES full adopter (less
time than sample mean)
Physician big DES full adopter (more
than sample mean)
Physician age (at time of DES safety
concern publicization)
Physician years of experience (at time
of DES safety concern pub)
Physician has cardiology fellowship
training
Physician has interventional
cardiology fellowship training
Physician total num. DES placed
before safety concerns
Physician total num. DES placed from
safety concern pub. thru 2007
r2
F
p
N
Unique docs
Practice FEs
Hospital FEs
Incremental F stat
Prob > incrm F

Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 4
(β/[95%CI])

Model 5
(β/[95%CI])

Model 6
(β/[95%CI])

Model 7
(β/[95%CI])

Model 8
(β/[95%CI])

Model 9
(β/[95%CI])

-0.013
[-0.13,0.10]

-0.090
[-0.24,0.05]

-0.012
[-0.14,0.12]

-0.120
[-0.30,0.06]

0.016
[-0.11,0.14]

0.066
[-0.06,0.19]

-0.008
[-0.17,0.15]

0.021
[-0.12,0.17]

-0.076
[-0.27,0.12]

-0.049
[-0.14,0.04]

-0.118*
[-0.23,-0.01]

-0.046
[-0.15,0.05]

-0.100
[-0.24,0.04]

-0.052
[-0.14,0.03]

-0.040
[-0.12,0.04]

-0.092
[-0.20,0.01]

-0.067
[-0.16,0.03]

-0.096
[-0.23,0.04]

0.058
[-0.02,0.14]

0.027
[-0.09,0.14]

0.089
[-0.01,0.19]

0.056
[-0.08,0.19]

0.055
[-0.03,0.14]

-0.005
[-0.08,0.07]

-0.030
[-0.14,0.08]

0.033
[-0.06,0.13]

-0.008
[-0.14,0.12]

0.025
[-0.08,0.13]

0.089
[-0.04,0.22]

0.064
[-0.06,0.18]

0.078
[-0.07,0.23]

0.021
[-0.08,0.12]

-0.036
[-0.13,0.06]

0.020
[-0.11,0.15]

0.020
[-0.10,0.14]

0.036
[-0.11,0.18]

0.009
[-0.00,0.02]

0.007
[-0.01,0.02]

0.013
[-0.00,0.03]

0.003
[-0.01,0.02]

0.009
[-0.01,0.03]

-0.006
[-0.02,0.01]

-0.005
[-0.02,0.01]

-0.006
[-0.02,0.01]

0.000
[-0.01,0.01]

-0.000
[-0.02,0.02]

-0.004
[-0.16,0.15]

-0.032
[-0.17,0.11]

0.036
[-0.13,0.20]

0.000
[-0.16,0.16]

0.003
[-0.19,0.20]

0.121
[-0.03,0.27]

0.131
[-0.01,0.27]

0.159
[-0.01,0.33]

0.164*
[0.01,0.32]

0.212*
[0.00,0.42]

-0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

-0.001***
[-0.00,-0.00]

-0.001***
[-0.00,-0.00]

-0.001***
[-0.00,-0.00]

-0.002***
[-0.00,-0.00]

0.012
0.942
0.481
640.000
640

0.130
9.408
0.000
640.000
640

0.487
1.465
0.000
640.000
640
X

0.293
1.605
0.000
640.000
640

1.038137181
0.386673175

42.77030415
3.83851E-18

1.118031336
0.16500122

0.606
1.295
0.011
640.000
640
X
X
1.069939514
0.29266046

0.005
0.846
0.496
640.000
640

0.407
1.105
0.191
640.000
640
X
1.10827248
0.183799686

0.226
1.197
0.092
640.000
640
X
1.207865737
0.084512413

0.553
1.081
0.246
640.000
640
X
X
1.026426148
0.414924959

X
0.965354199
0.585496174
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Table 5.8a: Relating continuous DES adoption measures to continuous time to minimum DES use (basic OLS regression results)
Physician time (quarters) to initial
DES adoption
Physician initial level DES use
(increase) upon adoption
Physician time (quarters) from
adoption to max DES use
Physician full level DES use
(increase) after adoption
Physician age (at time of DES safety
concern publicization)
Physician years of experience (at time
of DES safety concern pub)
Physician has cardiology fellowship
training
Physician has interventional
cardiology fellowship training
Physician total num. DES placed
before safety concerns
Physician total num. DES placed from
safety concern pub. thru 2007
r2
F
p
N
Unique docs
Practice FEs
Hospital FEs
Incremental F stat
Prob > incrm F

Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 4
(β/[95%CI])

Model 5
(β/[95%CI])

Model 6
(β/[95%CI])

Model 7
(β/[95%CI])

Model 8
(β/[95%CI])

Model 9
(β/[95%CI])

-0.060
[-0.29,0.17]

-0.131
[-0.42,0.16]

-0.219
[-0.47,0.03]

-0.066
[-0.40,0.27]

-0.044
[-0.28,0.19]

0.008
[-0.25,0.26]

-0.101
[-0.43,0.22]

-0.221
[-0.50,0.06]

-0.087
[-0.46,0.29]

-0.525
[-2.75,1.70]

-1.199
[-4.10,1.71]

0.923
[-1.68,3.52]

-0.810
[-4.26,2.64]

-0.465
[-2.70,1.77]

-0.639
[-2.87,1.59]

-1.396
[-4.30,1.51]

1.132
[-1.49,3.75]

-0.744
[-4.20,2.71]

0.048
[-0.02,0.12]

0.017
[-0.07,0.11]

0.036
[-0.04,0.11]

0.031
[-0.07,0.13]

0.047
[-0.02,0.12]

0.027
[-0.05,0.10]

0.003
[-0.09,0.09]

0.023
[-0.06,0.10]

0.025
[-0.08,0.13]

16.082*
[2.77,29.39]

18.478*
[3.27,33.68]

12.770
[-2.50,28.04]

24.607**
[6.28,42.93]

16.055*
[2.68,29.43]

16.686*
[3.39,29.98]

18.183*
[3.00,33.36]

13.590
[-1.77,28.95]

25.531**
[7.16,43.90]

-0.002
[-0.16,0.15]

0.009
[-0.15,0.16]

-0.077
[-0.26,0.11]

-0.028
[-0.19,0.14]

-0.116
[-0.33,0.09]

0.013
[-0.14,0.16]

0.006
[-0.14,0.16]

0.070
[-0.11,0.25]

0.034
[-0.13,0.19]

0.048
[-0.15,0.25]

0.843
[-0.89,2.57]

0.991
[-0.73,2.71]

0.524
[-1.47,2.51]

0.425
[-1.39,2.24]

-0.253
[-2.40,1.89]

-0.059
[-1.75,1.63]

-0.125
[-1.81,1.55]

0.392
[-1.63,2.41]

0.106
[-1.71,1.92]

-0.359
[-2.68,1.96]

0.001
[-0.00,0.00]

0.000
[-0.00,0.00]

-0.000
[-0.00,0.00]

-0.000
[-0.01,0.00]

0.005
[-0.00,0.01]

0.008
[-0.00,0.02]

0.005
[-0.00,0.01]

0.006
[-0.00,0.02]

0.017
1.325
0.228
640.000
640

0.034
2.223
0.015
640.000
640

0.452
1.275
0.016
640.000
640
X

0.294
1.614
0.000
640.000
640

0.234141036
0.919142032

5.73897918
0.003388916

1.227937112
0.036674704

0.637
1.480
0.000
640.000
640
X
X
1.30326249
0.016650375

0.015
2.427
0.047
640.000
640

0.433
1.228
0.035
640.000
640
X
1.205090315
0.051327298

0.285
1.636
0.000
640.000
640
X
1.601046526
0.000254092

0.627
1.466
0.000
640.000
640
X
X
1.311972235
0.01432907

X
1.544549215
0.000692133
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Table 5.8d: Relating binary DES adoption measures to binary (fast) time to minimum DES use (linear probability model)
Physician early DES initial adopter
(before sample mean)
Physician big DES initial adopter
(more than sample mean)
Physician fast DES full adopter (less
time than sample mean)
Physician big DES full adopter (more
than sample mean)
Physician age (at time of DES safety
concern publicization)
Physician years of experience (at time
of DES safety concern pub)
Physician has cardiology fellowship
training
Physician has interventional
cardiology fellowship training
Physician total num. DES placed
before safety concerns
Physician total num. DES placed from
safety concern pub. thru 2007
r2
F
p
N
Unique docs
Practice FEs
Hospital FEs
Incremental F stat
Prob > incrm F

Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 4
(β/[95%CI])

Model 5
(β/[95%CI])

Model 6
(β/[95%CI])

Model 7
(β/[95%CI])

Model 8
(β/[95%CI])

Model 9
(β/[95%CI])

-0.145*
[-0.26,-0.03]

-0.142
[-0.28,0.00]

-0.185**
[-0.31,-0.06]

-0.097
[-0.27,0.08]

-0.132*
[-0.26,-0.01]

-0.140*
[-0.27,-0.01]

-0.143
[-0.31,0.02]

-0.194**
[-0.34,-0.05]

-0.108
[-0.31,0.09]

0.005
[-0.08,0.09]

0.055
[-0.06,0.17]

-0.029
[-0.13,0.07]

0.019
[-0.11,0.15]

0.002
[-0.08,0.09]

0.003
[-0.08,0.09]

0.059
[-0.05,0.17]

-0.036
[-0.13,0.06]

0.019
[-0.11,0.15]

0.039
[-0.04,0.12]

-0.007
[-0.12,0.11]

0.011
[-0.08,0.11]

-0.031
[-0.16,0.10]

0.039
[-0.04,0.12]

0.029
[-0.05,0.11]

-0.027
[-0.14,0.09]

-0.001
[-0.10,0.10]

-0.048
[-0.18,0.09]

-0.107*
[-0.21,-0.01]

-0.143*
[-0.27,-0.01]

-0.154**
[-0.27,-0.04]

-0.155*
[-0.30,-0.01]

-0.107*
[-0.21,-0.01]

-0.113*
[-0.22,-0.01]

-0.160*
[-0.29,-0.03]

-0.161**
[-0.28,-0.04]

-0.169*
[-0.32,-0.02]

0.000
[-0.01,0.01]

-0.000
[-0.01,0.01]

0.002
[-0.01,0.02]

0.002
[-0.01,0.02]

0.005
[-0.01,0.02]

-0.000
[-0.01,0.01]

-0.000
[-0.01,0.01]

-0.002
[-0.02,0.01]

-0.000
[-0.01,0.01]

0.000
[-0.02,0.02]

-0.079
[-0.23,0.07]

-0.085
[-0.24,0.07]

-0.081
[-0.26,0.10]

-0.028
[-0.19,0.13]

-0.015
[-0.21,0.18]

0.032
[-0.11,0.18]

0.037
[-0.11,0.18]

-0.008
[-0.18,0.17]

0.040
[-0.12,0.20]

0.058
[-0.16,0.27]

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

-0.001
[-0.00,0.00]

-0.001*
[-0.00,-0.00]

-0.001
[-0.00,0.00]

-0.000
[-0.00,0.00]

0.024
1.943
0.051
640.000
640

0.031
2.044
0.027
640.000
640

0.440
1.213
0.044
640.000
640
X

0.280
1.510
0.001
640.000
640

0.344023268
0.8482221

2.415069409
0.090189357

1.172885754
0.082165781

0.597
1.247
0.025
640.000
640
X
X
1.051470098
0.342259512

0.022
3.557
0.007
640.000
640

0.428
1.203
0.052
640.000
640
X
1.160458
0.096427643

0.274
1.555
0.000
640.000
640
X
1.477689531
0.002067931

0.591
1.263
0.019
640.000
640
X
X
1.06153333
0.313814256

X
1.450919287
0.003203999
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Table 5.9a: Relating continuous DES adoption measures to continuous full extent of DES disadoption (basic OLS regression
results)
Physician time (quarters) to initial
DES adoption
Physician initial level DES use
(increase) upon adoption
Physician time (quarters) from
adoption to max DES use
Physician full level DES use
(increase) after adoption
Physician age (at time of DES safety
concern publicization)
Physician years of experience (at time
of DES safety concern pub)
Physician has cardiology fellowship
training
Physician has interventional
cardiology fellowship training
Physician total num. DES placed
before safety concerns
Physician total num. DES placed from
safety concern pub. thru 2007
r2
F
p
N
Unique docs
Practice FEs
Hospital FEs
Incremental F stat
Prob > incrm F

Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 4
(β/[95%CI])

Model 5
(β/[95%CI])

Model 6
(β/[95%CI])

Model 7
(β/[95%CI])

Model 8
(β/[95%CI])

Model 9
(β/[95%CI])

0.008
[-0.00,0.02]

0.008
[-0.00,0.02]

0.006
[-0.00,0.02]

0.006
[-0.01,0.02]

0.007
[-0.00,0.02]

0.005
[-0.00,0.01]

0.006
[-0.01,0.02]

0.007
[-0.00,0.02]

0.007
[-0.01,0.02]

-0.054
[-0.14,0.03]

-0.041
[-0.15,0.07]

-0.022
[-0.12,0.07]

-0.005
[-0.14,0.13]

-0.057
[-0.14,0.03]

-0.046
[-0.12,0.03]

-0.044
[-0.15,0.06]

-0.055
[-0.15,0.04]

-0.035
[-0.16,0.09]

-0.002
[-0.00,0.00]

0.001
[-0.00,0.00]

-0.002
[-0.00,0.00]

-0.001
[-0.00,0.00]

-0.002
[-0.00,0.00]

0.000
[-0.00,0.00]

0.001
[-0.00,0.00]

-0.001
[-0.00,0.00]

-0.001
[-0.00,0.00]

0.078
[-0.44,0.60]

0.248
[-0.33,0.82]

0.456
[-0.11,1.03]

0.470
[-0.23,1.17]

0.077
[-0.45,0.60]

0.030
[-0.44,0.50]

0.265
[-0.28,0.81]

0.408
[-0.13,0.95]

0.507
[-0.16,1.17]

0.000
[-0.01,0.01]

-0.001
[-0.01,0.00]

0.003
[-0.00,0.01]

-0.003
[-0.01,0.00]

0.004
[-0.00,0.01]

0.000
[-0.01,0.01]

0.001
[-0.00,0.01]

-0.004
[-0.01,0.00]

0.003
[-0.00,0.01]

-0.005
[-0.01,0.00]

0.070*
[0.00,0.14]

0.053
[-0.01,0.11]

0.049
[-0.02,0.12]

0.047
[-0.02,0.11]

0.050
[-0.03,0.13]

0.039
[-0.03,0.11]

0.048
[-0.01,0.11]

0.045
[-0.03,0.12]

0.074*
[0.01,0.14]

0.044
[-0.04,0.13]

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

-0.001***
[-0.00,-0.00]

-0.001***
[-0.00,-0.00]

-0.001***
[-0.00,-0.00]

-0.001***
[-0.00,-0.00]

0.019
1.547
0.138
640.000
640

0.213
17.060
0.000
640.000
640

0.540
1.816
0.000
640.000
640
X

0.430
2.928
0.000
640.000
640

1.730812709
0.141463186

77.60824616
7.50784E-31

1.144036196
0.120214825

0.689
1.866
0.000
640.000
640
X
X
1.176320223
0.095887016

0.008
1.357
0.247
640.000
640

0.467
1.411
0.001
640.000
640
X
1.40815134
0.001347295

0.346
2.177
0.000
640.000
640
X
2.193975922
1.35907E-09

0.647
1.602
0.000
640.000
640
X
X
1.220522796
0.054149969

X
1.597696908
0.000274851

124

Table 5.9d: Relating binary DES adoption measures to binary (big) full extent of DES disadoption (linear probability model)
Physician early DES initial adopter
(before sample mean)
Physician big DES initial adopter
(more than sample mean)
Physician fast DES full adopter (less
time than sample mean)
Physician big DES full adopter (more
than sample mean)
Physician age (at time of DES safety
concern publicization)
Physician years of experience (at time
of DES safety concern pub)
Physician has cardiology fellowship
training
Physician has interventional
cardiology fellowship training
Physician total num. DES placed
before safety concerns
Physician total num. DES placed from
safety concern pub. thru 2007
r2
F
p
N
Unique docs
Practice FEs
Hospital FEs
Incremental F stat
Prob > incrm F

Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 4
(β/[95%CI])

Model 5
(β/[95%CI])

Model 6
(β/[95%CI])

Model 7
(β/[95%CI])

Model 8
(β/[95%CI])

Model 9
(β/[95%CI])

-0.160**
[-0.28,-0.04]

-0.182*
[-0.33,-0.04]

-0.090
[-0.22,0.04]

-0.090
[-0.26,0.08]

-0.119
[-0.25,0.01]

-0.079
[-0.21,0.05]

-0.088
[-0.25,0.08]

-0.042
[-0.19,0.10]

0.009
[-0.19,0.21]

-0.020
[-0.11,0.07]

0.004
[-0.11,0.12]

0.046
[-0.05,0.14]

0.112
[-0.02,0.24]

-0.022
[-0.11,0.07]

-0.010
[-0.09,0.07]

0.019
[-0.09,0.13]

0.032
[-0.06,0.13]

0.121
[-0.01,0.25]

-0.023
[-0.11,0.06]

-0.083
[-0.20,0.03]

0.007
[-0.09,0.10]

-0.052
[-0.18,0.08]

-0.023
[-0.11,0.06]

-0.087*
[-0.17,-0.01]

-0.122*
[-0.23,-0.01]

-0.032
[-0.13,0.06]

-0.084
[-0.22,0.05]

0.008
[-0.10,0.11]

0.005
[-0.13,0.13]

0.012
[-0.10,0.13]

-0.017
[-0.16,0.13]

0.009
[-0.10,0.11]

-0.048
[-0.15,0.05]

-0.037
[-0.17,0.09]

-0.007
[-0.12,0.11]

-0.041
[-0.19,0.10]

-0.001
[-0.02,0.01]

-0.003
[-0.02,0.01]

0.004
[-0.01,0.02]

-0.005
[-0.02,0.01]

0.008
[-0.01,0.03]

-0.001
[-0.01,0.01]

0.000
[-0.01,0.01]

-0.005
[-0.02,0.01]

0.003
[-0.01,0.02]

-0.009
[-0.03,0.01]

0.067
[-0.09,0.22]

0.037
[-0.11,0.18]

0.022
[-0.15,0.19]

0.076
[-0.08,0.23]

0.075
[-0.12,0.27]

0.090
[-0.06,0.24]

0.103
[-0.04,0.24]

0.152
[-0.02,0.32]

0.177*
[0.02,0.33]

0.180
[-0.03,0.39]

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

-0.002***
[-0.00,-0.00]

-0.001**
[-0.00,-0.00]

-0.001***
[-0.00,-0.00]

-0.001
[-0.00,0.00]

0.018
1.456
0.170
640.000
640

0.151
11.168
0.000
640.000
640

0.501
1.552
0.000
640.000
640
X

0.354
2.121
0.000
640.000
640

1.022024597
0.395106713

49.12642054
1.49817E-20

1.129706909
0.143585277

0.644
1.522
0.000
640.000
640
X
X
1.115563613
0.189412357

0.012
1.891
0.110
640.000
640

0.461
1.373
0.003
640.000
640
X
1.359913924
0.003536302

0.308
1.831
0.000
640.000
640
X
1.819443019
4.00888E-06

0.623
1.445
0.001
640.000
640
X
X
1.185013959
0.085146686

X
1.316634717
0.022540796

125

Table 5.10a: Relating area below DES adoption curve to area above DES disadoption curve (basic OLS regression results)
Physician area below DES adoption
curve
Physician age (at time of DES safety
concern publicization)
Physician years of experience (at time
of DES safety concern pub)
Physician has cardiology fellowship
training
Physician has interventional
cardiology fellowship training
Physician total num. DES placed
before safety concerns
Physician total num. DES placed from
safety concern pub. thru 2007
Physician age (at time of DES safety
concern publicization)
r2
F
p
N
Unique docs
Practice FEs
Hospital FEs
Incremental F stat
Prob > incrm F

Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 4
(β/[95%CI])

Model 5
(β/[95%CI])

Model 6
(β/[95%CI])

Model 7
(β/[95%CI])

Model 8
(β/[95%CI])

Model 9
(β/[95%CI])

-0.024
[-0.05,0.01]

-0.012
[-0.05,0.03]

-0.034*
[-0.07,-0.00]

-0.011
[-0.05,0.03]

-0.022
[-0.05,0.01]

-0.002
[-0.03,0.03]

-0.010
[-0.05,0.03]

-0.021
[-0.05,0.01]

-0.010
[-0.05,0.03]

-0.001
[-0.06,0.05]

-0.002
[-0.06,0.05]

0.003
[-0.06,0.07]

-0.023
[-0.08,0.03]

0.008
[-0.06,0.08]

0.013
[-0.04,0.07]

0.010
[-0.04,0.06]

0.006
[-0.06,0.07]

0.033
[-0.02,0.09]

-0.008
[-0.07,0.06]

0.476
[-0.13,1.08]

0.431
[-0.15,1.02]

0.596
[-0.10,1.29]

0.362
[-0.25,0.98]

0.717*
[0.02,1.41]

0.449
[-0.12,1.02]

0.492
[-0.06,1.05]

0.375
[-0.30,1.05]

0.521
[-0.06,1.11]

0.279
[-0.42,0.98]

0.001
[-0.00,0.00]

0.001
[-0.00,0.00]

0.001
[-0.00,0.00]

0.001
[-0.00,0.00]

-0.005***
[-0.01,-0.00]

-0.004**
[-0.01,-0.00]

-0.004**
[-0.01,-0.00]

-0.003
[-0.01,0.00]

3.753***
[2.11,5.39]

4.039***
[1.98,6.09]

4.976***
[3.11,6.84]

6.027***
[3.84,8.22]

0.011
1.346
0.243
640.000
640

0.081
6.944
0.000
640.000
640

0.459
1.327
0.006
640.000
640
X

0.342
2.051
0.000
640.000
640

1.068241057
0.371285697

16.11283337
4.20075E-10

1.12939667
0.14385962

0.692
1.915
0.000
640.000
640
X
X
1.51504688
0.000411753

0.004
2.455
0.118
640.000
640

0.422
1.196
0.058
640.000
640
X
1.190276009
0.063459848

0.282
1.662
0.000
640.000
640
X
1.653347903
9.74193E-05

0.653
1.674
0.000
640.000
640
X
X
1.446711723
0.001390972

X
1.668351474
7.57559E-05
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Table 5.10d: Relating area below DES adoption curve to area above DES disadoption curve, binary measures (linear prob model)
Physician big area below DES
adoption curve (> sample mean)
Physician age (at time of DES
safety concern publicization)
Physician years of experience (at
time of DES safety concern pub)
Physician has cardiology
fellowship training
Physician has interventional
cardiology fellowship training
Physician total num. DES placed
before safety concerns
Physician total num. DES placed
from safety concern pub. thru 2007
Physician age (at time of DES
safety concern publicization)
r2
F
p
N
Unique docs
Practice FEs
Hospital FEs
Incremental F stat
Prob > incrm F

Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 4
(β/[95%CI])

Model 5
(β/[95%CI])

Model 6
(β/[95%CI])

Model 7
(β/[95%CI])

Model 8
(β/[95%CI])

Model 9
(β/[95%CI])

-0.045
[-0.14,0.05]

-0.054
[-0.16,0.05]

-0.054
[-0.15,0.05]

-0.012
[-0.13,0.11]

-0.050
[-0.14,0.04]

-0.006
[-0.10,0.09]

-0.054
[-0.17,0.06]

-0.014
[-0.12,0.09]

-0.005
[-0.14,0.13]

-0.003
[-0.02,0.01]

-0.003
[-0.02,0.01]

-0.006
[-0.02,0.01]

-0.006
[-0.02,0.01]

-0.005
[-0.02,0.01]

0.008
[-0.00,0.02]

0.008
[-0.01,0.02]

0.009
[-0.01,0.02]

0.011
[-0.00,0.02]

0.009
[-0.01,0.03]

0.107
[-0.04,0.26]

0.095
[-0.05,0.24]

0.134
[-0.03,0.30]

0.094
[-0.06,0.25]

0.155
[-0.03,0.34]

0.107
[-0.03,0.25]

0.111
[-0.03,0.25]

0.061
[-0.10,0.22]

0.123
[-0.03,0.27]

0.029
[-0.16,0.22]

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

-0.001***
[-0.00,-0.00]

-0.001*
[-0.00,-0.00]

-0.001*
[-0.00,-0.00]

-0.001
[-0.00,0.00]

0.846***
[0.44,1.25]

0.854***
[0.36,1.35]

1.286***
[0.81,1.77]

1.422***
[0.83,2.01]

0.009
1.168
0.323
640.000
640

0.069
5.870
0.000
640.000
640

0.487
1.487
0.000
640.000
640
X

0.280
1.537
0.001
640.000
640

1.224244386
0.29921226

13.59196166
1.3313E-08

1.317472931
0.007998101

0.628
1.441
0.001
640.000
640
X
X
1.268174827
0.027915548

0.001
0.941
0.332
640.000
640

0.459
1.394
0.002
640.000
640
X
1.395132576
0.001730064

0.216
1.171
0.124
640.000
640
X
1.172522462
0.122801889

0.591
1.289
0.012
640.000
640
X
X
1.263658209
0.029075629

X
1.233635279
0.06330788
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CHAPTER 6: Relating medical technology disadoption to physician
group size
In the previous chapter, I examined the relationship between physicians’ disadoption of
technology and their preceding adoption of the same technology, focusing on the
empirical setting of drug-eluting stents. While this analysis provides insight into the two
related processes of adoption and disadoption, I am interested in developing a deeper
understanding of technology disadoption by examining how it is related to other factors.
In Chapter 4, I developed a theoretical model that related physician group size to
technology disadoption, and in this chapter I will empirically study that relationship.

As already mentioned above (e.g. in Chapters 1 and 2), an examination of the relationship
between physician group size and medical technology disadoption is one of the core aims
of this dissertation. As discussed in Chapter 2, the topic of group size has already been
the subject of frequent examination in both the broader technology adoption literature and
the health services research literature. The relationship and similarities between
technology adoption and disadoption (discussed at length above, in Chapter 3), suggest
that if research has shown group size to be a relevant determinant of technology adoption,
it likely also warrants investigation for its relationship to disadoption. Aside from the
fact that group size may correlate closely with technology-adoption-relevant factors (e.g.
firm profits or access to investment capital), there are also theoretical reasons to believe
that group size could influence the technology disadoption (or adoption) decision, as was
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discussed and modeled in Chapter 4. If information is or can be shared among members
of a group, then there is reason to believe that the size of an individual’s group will help
determine that individual’s access to information, and thus influence that individual’s
technology disadoption behavior.

Not only is there reason to believe that group size is potentially of importance to
technology disadoption in general, it is also a factor of specific interest within the field of
health care. The trend of increasing physician group size in the US (as described in
Chapter 2) suggests that this is an important organization characteristic to consider when
studying physician behavior, with significant relationships previously identified for some
physician behaviors. Not only are physician group sizes changing (namely, increasing)
and group size can influence physician practice in general, there is also reason to think
that group size is of particular relevance for physicians’ choice of technology. As
Schiller says (1995 AEA P&P), groups play an important role in shaping decisions and
behavior “not [on] matters of plain fact (which way is north), but subtle matters, for
which many pieces of information are relevant, and for which limitations of time and
natural intelligence prevent each individual from individually discovering all relevant
information.” This description is a near perfect match for the physicians’ clinical practice
environment. As described by Phelps (2000 Handbook Health Econ), the practice of
clinical medicine requires knowledge so vast that uncertainty is inevitable. “The set of
diseases that healers must recognize is immense [and] the relevant code book for
treatments also has thousands of treatments, many of which can potentially affect
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numerous diseases. For doctors to understand well the complete set of relationships
between these treatments and the myriad of diseases that their patients may bring to the
patient encounter is literally impossible.” Add to this the continuous flow of new
technology into the realm of medical diagnosis and treatment, and it becomes clear that
physicians are constantly facing difficult decisions with nuanced choices. Thus, when
practicing in groups, it is only natural for physicians to turn to their peers for information.

Given these factors, it is also natural for researchers to study how group size may be an
important factor in shaping physicians’ technology disadoption behavior. I began is
inquiry in Chapter 4 with the development of a basic theoretical model that related
physician group size to disadoption behavior. As shown there, the model predicted an
ambiguous relationship between group size and the timing of technology disadoption.
Thus, I continue the investigation by examining the empirical relationship between group
size and disadoption, again focusing on the setting of physician DES use.

6.1 – Research questions
1) What is the observed empirical relationship between a physicians’s time to initial
disadoption of DES and that physician’s group size?
2) What are the observed empirical relationships between the other measures of
physician’s disadoption of DES (namely, time to minimum use, initial extent of
disadoption, full extent of disadoption, and area below the DES adoption curve) and
that physician’s group size?
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3) How do various covariates and controls, including physician characteristics (e.g. age
and training) and experience (e.g. DES volume), shape the observed empirical
relationships between DES disadoption measures and that physician’s group size?
4) Can empirical analysis identify a causal relationship between a physician’s group size
and that physician’s DES disadoption behavior by using an instrumental variable for
physician group size?
5) Given that a physician can belong to multiple different groups (e.g. office, practice,
and hospital) with different types of members (e.g. general cardiologists vs.
cardiologists who implant stents), how do the sizes of those different groups relate
differentially to that physician’s DES disadoption behavior, as measured with the
various different measures?

6.2 – Data and methods
Data processing
That data used in this chapter is the same as that used in Chapter 5; see above for a
detailed description of the original data and how the data has been processed. In addition
to the processing discussed there, additional work is needed here to create a measure of
physician group size, which will be the primary explanatory variable of interest in this
chapter’s analyses.

As described above, the SK&A physician database provides information on which
practices a physician belongs to, along with the location of those practices. This dataset
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thus provides the information on the size of the first two types of physician groups:
practices and office (or practice locations). Whereas practices are identified simply by
their given practice or company name, an office (or practice location) is represented by
the combination of a practice/company name and a physical location, which is
determined by state, city, and street address. Thus, offices are nested within practices; a
practice may (or may not) consist of multiple different offices and a physician who
belongs to an office necessarily belongs to the corresponding “parent” practice. How
exactly physicians are organized and managed within offices and practices is unclear.
Though we can reasonably expect a physician to have more direct interaction with other
physicians in the same office than with other physicians who belong to different offices
in the same practice, the level of communication between or integration of different
offices in a practice is unclear and likely varies across practices. Thus, the question of
how a physician’s group size relates to behavior, namely DES disadoption behavior, is
one that must be addressed empirically, as will be done below. The third type of group
that physicians can be assigned to within the data used here is a hospital, which requires
less description than practice or office. Physicians who implant stents (of any kind) in
the same hospital in a given year are considered to “belong” to that hospital (in the same
way that they belong to practices or offices) in that year26. Figure 6.1 plots the
distributions of group size observed in the dataset, using each of the three different group
types.

26

In fact, because the hospital discharge data has time granularity at the quarter level (whereas the SK&A
dataset is only defined at the year level), physicians’ hospital groups can be defined at either the quarter or
year level. However, because the practice and office measures are defined at the year level (on account of
the SK&A dataset), my analyses here will focus on hospital groups defined at the year level.
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Figure 6.1: Observed distribution of physician group size, by each of three different
group types
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In addition to measuring physician group size with a simple count measure, this variable
was also used to generate a categorical variable which grouped physicians into
approximately equally sized quantiles based on group size. In the case of practices and
offices, this corresponded to group size categories of 1 physician (because there is an
inherent interest in solo-physician practices, relative to any multi-physician group), 2-5
physicians, 6-12 physicians, and 13+ physicians. The observed hospital group sizes are,
unsurprisingly, much larger than practice or office groups and have there are virtually no
physicians in single-physician hospital groups. Thus, the hospital group size quantiles
used were 1-29 physicians, 30-44 physicians, 45-59 physicians, 60-99 physicians, and
100+ physicians. The sizes of these quantiles for each group type are also shown in
Figure 6.1. Dividing physician group size into quantiles provides the benefit of allowing
categorical analysis, rather than assuming a specific functional form (e.g. linear) for the
relationship between group size and the various outcome variables (i.e. DES disadoption
measures) of interest.

In addition to having choice of which type of organization (office, practice, or hospital) is
relevant when measuring physician group size, there is also the issue of which type of
physician is relevant. As already noted, I focus specifically on cardiologists here,
considering only physicians who have self-identified as specializing in cardiology in the
SK&A database. Indeed, we expect each one of these groups (especially hospitals) to
contain other physicians, not to mention other medical professionals, who I do not count
in these group size measures. As described in the theoretical model, the mechanism
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through which I suggest that group size influences technology disadoption behavior is the
sharing of information. If we are studying the disadoption of DES, the individuals in a
group that we would expect to have and share information about coronary stents are the
cardiologists. Because it seems unlikely that other physicians (e.g. generalists or
specialists in other fields) would gather or share knowledge on coronary stents, I can
safely restrict my group size measure to include only cardiologists (and use the label
“cardiology-relevant group size” if necessary). But beyond identified specialty (or
training), we might be more specifically interested in how these physicians practice. For
example, which group of cardiologists is more relevant for this issue of informationsharing: all cardiologists or just cardiologists who implant coronary stents (and should
thus logically have more knowledge of the technology)? To address this, I can separately
identify and count within groups the cardiologists who implant stents from the general
pool of cardiologists. Ultimately, as with the type of organization, I view this question of
which type of cardiologist is most relevant to DES disadoption behavior as an empirical
question, to which I turn to the data for insight, if not answers.

After identifying which offices, practices, and hospitals each physician is associated with
and what type of physicians are of interest, I can simply count the number of physicians
who belong to each group, thus giving each group a size. However, this is a group-level
measure, but with outcomes that are defined at the physician level, we want a physicianlevel group size measure. Because, as mentioned above, a single physician can belong to
multiple groups (whether offices, practices, or hospitals), we can determine an
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individual’s “composite group size” by simply adding up the size of each of the different
same-level groups she belongs to. So, if a physician belongs to three different practices
which have 3, 4, and 8 other physicians in them, that physician’s “composite” practice
size would be 15. With this calculation, I produce the primary explanatory variable of
interest in this chapter’s analyses.

Methods
The analysis methods used here are generally very similar to those used in Chapter 5 (see
above for a detailed description and discussion). As the outcome variables of interest
(i.e. the different measures of DES disadoption) are continuous, ordinary least squares
linear regression is the primary method of analysis. The right-hand-side variables used in
these analyses are generally the same as those used in Chapter 5, with a few changes.
First, the primary explanatory variable of interest is group size, though physician
measures of DES adoption are included as covariates in some models. While the primary
interest is in identifying how group size relates to DES disadoption, the adoption
measures are included in the interest of controlling for unobserved factors that relate to
DES disadoption behavior and may be correlated with DES adoption measures27.

Second, because the primary explanatory variable is group size and there is relatively
little variation in group size within groups (despite the use of “composite group size,”

27

Of course, Chapter 5 analyzed the relationship between DES disadoption and adoption. Though, as
discussed in that chapter, many of the individual DES adoption measures did not have statistically
significant relationship with the DES disadoption measures, the interest here is in how the full set of DES
adoption measures collectively may relate to any given DES disadoption outcome measure.
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described above, because the majority of physicians do not practice in multiple groups),
group-level fixed effects cannot be included due to collinearity issues. Because grouplevel fixed effects cannot be used, but there is concern that other group members may
influence an individual’s technology use and disadoption behavior (independent of the
impact of group size itself), I use the physician-level covariates used before to calculate
and include group-level versions of these variables. Specifically, I include measures of
the “physician characteristic” and “physician DES use” variables for non-self physicians
in a group (i.e. for a given physician, all other physicians who share a group with that
physician). These include, for example, the fraction of non-self physicians in a group
with cardiology fellowship training and the average number of DES implanted by nonself physicians in a group per quarter after the publicization of DES safety concerns. The
self-physician is excluded from these measures because we are interested in how a
physician’s peers’ characteristics and behavior may influence that physician, and because
the inclusion of a physician’s own characteristics could create collinearity between the
different covariates. However, because these group-level measures are defined for nonself physicians, they are missing for single-physician groups. As a result, for the analyses
where these group-level covariates are included, I have to exclude single-physician
groups, which significantly reduces sample size (at least for group measures focusing on
practices and offices).

As in Chapter 5, the primary outcome of interest in these analyses is time to initial DES
disadoption, and the three other measures of disadoption behavior—i.e. initial extent of
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DES disadoption, time to minimum DES use, and full extent of DES disadoption—along
with the measurement of area above DES disadoption curve are secondary outcomes.
Though I perform simple OLS regressions for each of these outcome variables, I also
convert each of these variables into binary form (as I did in Chapter 5) and perform logit
analyses, to examine the potential for a more general (i.e. non-linear) relationship
between group size and DES disadoption behavior. Furthermore, the fact that the
primary outcome variable captures “time to an event” suggests that survival/hazard
analysis would be appropriate (if not optimal) in this setting. Thus, I also perform
discrete-time hazard analysis, utilizing the cloglog link function, to examine the
relationship between group size and the primary outcome of interest, time to initial DES
disadoption.28

Instrumental variable analysis
One goal in this chapter is to identify a causal relationship between group size and
physician DES disadoption behavior. Despite the inclusion of physician- and group-level
covariates in the analyses, there are still concerns about the endogeneity of group size.
For example, one may be concerned that physicians are selecting into groups of different
sizes in accordance with some unobservable characteristics (e.g. affinity for reading
scientific literature) that are also correlated with the likelihood of DES disadoption. One
potential approach to address this endogeneity concern is to use an instrumental variable
28

Indeed, because time to initial DES disadoption as also the primary outcome variable in Chapter 5,
discrete-time hazard analysis should also have been considered there, and it was. However, because such
analysis uses the cloglog function and the Chapter 5 analyses included many practice- and hospital-level
fixed effects, this analysis was very resource intensive and, as such, I was unable to produce estimates for
such analyses.
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(IV) for group size. After performing simple, non-instrumented regression analyses, I
instrument for physician group size by using the ZIP-Code-level mean size of
ophthalmology and orthopedic surgery groups (which are also determined in the original
SK&A database)29. Though this instrument can be used for the size of practices and
offices, as those are identified in the SK&A database, which provides addresses for
practices and offices, it unfortunately cannot be used for hospital group size because
hospitals in the discharge dataset do not have addresses and are labeled with blinded
identifiers that cannot be mapped outside of the dataset, making the identity and location
of the hospitals unknown. Another limitation to this instrument is the fact that it is not
defined for all physicians in the sample, which thus causes a decrease in the analysis
sample size.

As with any instrumental variable selection, this choice must satisfy the conditions of
exogeneity and relevance. Because we have no reason to think that the size of
ophthalmology or orthopedic surgery groups would have any relationship with
cardiologists’ DES disadoption behavior (except through the size of cardiology groups),
we can be comfortable that the instrument is exogenous and the exclusion restriction
holds. As for relevance, it is plausible that there are reasons for geographic correlation of

29

As discussed above, considerable time and effort was spent processing and cleaning the portion of the
SK&A dataset that was specific to cardiologists in Florida and New York. Due to the labor-intensity of this
process, it was not repeated for ophthalmology or orthopedic surgery practices, which means that the sizes
of those practices are unlikely to be determined with the same reliability as the cardiology practices.
However, as long as there is no systematic bias in this expected measurement error of ophthalmology and
orthopedic surgery practice sizes, there is no reason to be concerned about introducing bias into the
instrumental variable analysis. Though the measurement error might weaken the strength of the
instruments, the degree of correlation between them and physician group size is a matter of empirical
observation, and as long as there is sufficient correlation, the instruments can still be used.
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physician group size across different specialties. For example, if patient characteristics
are important in determining the optimal physician group size, independent of specialty,
and patient characteristics vary by geography, we may observe correlation between group
sizes of different specialties. Alternatively, there may be external factors related to
business or reimbursement environment that geographically influence physician group
size. Ultimately, the question of instrument relevance can be answered empirically, and
will be show below, with the results.

6.3 – Results
Primary outcome
Table 6.1 provides results from the standard OLS regression of the primary outcome,
time to initial DES disadoption, against physician group size, with different models
providing various sets of covariates. Table 6.2 performs generally the same analyses, but
includes practice-level covariates (including non-self physician characteristics and DES
use measures), which requires removal of solo-physician practices from the sample.
Across these two different groups of analyses, we observe comparable results. Most
importantly, in the fully-specified models, there is a positive relationship between group
size and time to initial DES disadoption—indicating that physicians in larger groups
begin the disadoption process later—but this coefficient is not statistically significant.
Turning to the coefficient estimates on the covariates, we observe that the physician-level
variables exhibit relationships with the time to initial DES disadoption measure that are
very similar to the ones observed in the Chapter 5 analysis, e.g. earlier initial DES
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disadoption is observed among interventional-cardiology-fellowship-trained physicians
and those who implant more DES per quarter after the publicization of safety concerns.
Also relating these results to those from Chapter 5, we note that set of DES adoption
measures collectively do not provide a statistically significant increase on the predictive
power of the model (as determined by the incremental F-statistic and its p-value), but
there is a significant negative relationship between time to maximum DES use and time to
initial DES disadoption, indicating that physicians who were faster to adopt DES (i.e.
took less time to reach their maximum DES use rate) generally start disadopting later.
The signs of the coefficients on the other individual DES adoption measures are the same
here as they were in the Chapter 5 analysis, and the lack of statistical significance is also
the same. That is, we observe that physicians who were faster to adopt DES (i.e. took
less time to reach their maximum DES use rate) generally start disadopting later, and that
physicians who start adopting DES later also start disadopting DES later, though the
magnitude of these findings is not statistical significantly different from zero.

In addition to physician-level factors, we can now also observe relationships between the
outcome variable and practice-level characteristics. When viewed collectively, the
“physician characteristics” of the non-self physicians (e.g. age, experience, and training)
in a practice provide significant statistical predictive power in these models of time to
initial DES adoption, while the “physician DES use measures” (e.g. number of DES
implanted before and after safety concern publicization) do not significantly increase the
models’ predictive power. Interestingly, we see that an increase in the fraction of
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interventional-cardiology-fellowship-trained physicians in a practice is associated with
later initial DES disadoption, whereas an increase in the fraction of (non-interventional)
cardiology-fellowship-trained physicians in a practice may be related to earlier initial
DES disadoption.

Though these analyses provide insight into the relationship between a physician’s DES
disadoption behavior and that physician’s group size, there are still concerns about
endogeneity in these analyses, as discussed above. Despite the inclusion of various
physician- and practice-level characteristics in the above analyses, one may still be
worried that unobserved factors might influence physician selection into practices, thuse
confounding the relationship between group size and disadoption behavior. For this
reason, I perform an instrumental variable analysis (as detailed above), the results of
which are provided in Tables 6.3 and 6.4, repeating the analyses just described. In
examining these results, we first consider the performance of the instrument itself. As
these tables show, the first stage F-statistic for the instrumental variable is less than 10 in
each of the model specifications, indicating that it is a relatively weak instrument (i.e.
there is weak ZIP-code level correlation between cardiologist group size and the group
sizes of the other selected specialties). Instrument weakness aside, the over-identification
test gives a p-value much greater than 0.05, suggesting that the instruments collectively
are valid and not over-identified, i.e. that none of the individual instruments is observably
endogenous (assuming that at least one of the instruments is exogenous). However, we
also observe a p-value on the Durbin-Wu-Hausman test that is greater than 0.05 in all
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model specifications (and much greater than 0.05 in some specifications), which indicates
that observationally there is not a high degree of endogeneity between group size and
time to initial DES disadoption, indicating that bias generated by unobserved variables
may not be too large and the need for an IV analysis is not as great as may have been
feared.

Having considered the relevance, strength, and validity of the instruments, we now turn
to the estimation results. The primary analysis results, i.e. the effect of group size on time
to initial DES disadoption, are generally unchanged from the previous simple OLS
analysis. In other words, when instrumenting for group size, I again observe a positive
relationship between group size and time to initial DES disadoption, but the coefficient
estimates remain statistically insignificant (compared to zero). Furthermore, the observed
relationships with the other covariates are virtually unchanged after instrumenting for
group size. Because the instrumental variable analysis decreased the sample size (due to
some physicians missing values for the instrumental variables), I also repeated the earlier
OLS regression analyses on these reduced samples. These results, which are shown in
Tables 6.5 and 6.6 (rather than the results from Tables 6.1 and 6.2), are the ones that
should be compared to the instrumental variable analysis results. However, these results
(in Tables 6.5 and 6.6) are generally qualitatively unchanged from the results described
earlier for the larger samples (in Tables 6.1 and 6.2).
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The results in Tables 6.1 – 6.6 are all generated using a continuous measure for group
size. However, as described above, I also created a categorical measure of group size to
allow a more generalized (i.e. non-linear) examination of the potential relationship
between group size and DES disadoption behavior. Repeating each of the above analyses
with this categorical group size measure, I provide the results from the fully-specified
model from each these analyses in Table 6.7. The single-physician group is the
omitted/reference category, except for the analyses which include group-level covariates,
where single-physician groups were dropped from the sample, so the next smallest group
(2-5 physicians) becomes the omitted/reference category. Across each of these model
specifications, we observe no statistically significant relationships between any of the
group size categories and time to initial DES disadoption, noting also that the coefficient
point estimates for some of the groups change sign across model specifications.
Otherwise, the relationships between the covariates and the DES disadoption measure are
qualitatively similar in these analyses to those observed in the previous analyses.

The analyses presented in Tables 6.1 – 6.7 all use the same outcome variable, a
continuous measure of time to initial DES disadoption, with linear regression. However,
as discussed above, this variable can be made binary and we can replace OLS regression
with logit analysis. Tables 6.8 and 6.9 provide results from these binary-outcome
analyses, with the tables representing different sets of covariates and treatment of singlegroup physicians, analogous to the analyses that produced Tables 6.1 and 6.2. In these
analyses, the outcome variable is a binary variable indicating early initial DES
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disadoption, so a negative coefficient estimate on group size would indicate that an
increase in group size is associated with a decreased likelihood of early initial
disadoption, i.e. larger groups tend to begin the disadoption process later. Indeed, this is
the general trend that we observe when examining Tables 6.8 and 6.9 (i.e. larger groups
are associated with later initial DES disadoption), though similar to the earlier analyses,
the estimated coefficients are not statistically different from zero.

In addition to these binary-outcome analyses, we can also use discrete-time hazard
analyses to investigate the relationship between group size and the timing of initial DES
disadoption. Tables 6.10 and 6.11 provide the results from discrete-time hazard analyses,
where “risk of initial DES disadoption” is the dependent variable, and the result are
organized analogously to Tables 6.1 and 6.2 (or Tables 6.8 and 6.9). In these analyses,
coefficients represent estimated hazard rates, so a negative coefficient estimate on the
group size variable would indicate that an increase in group size is associated with
decreased “disadoption hazard” and thus later initial disadoption. Though the earlier
results might lead us to expect negative coefficients here, interestingly the coefficients on
group size in Tables 6.10 and 6.11 are positive, suggesting that larger groups tend to start
the disadoption process earlier, though once again these results are not generally
statistically significant.

Each of these four new tables uses a continuous measure of physician group size (as was
the case in Tables 6.1 – 6.6). Table 6.12 repeats the analyses shown in Tables 6.8 – 6.11,
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but uses a categorical measure of group size (similar to the approach in Table 6.7). The
most notable observation from Table 6.12 is that, once again, there is no statistically
significant relationship between group size and the timing of initial DES disadoption,
thus making it difficult to draw definitive conclusions about the differential DES
disadoption behavior in any of the group size categories.

Different measures of group size
Each of the analyses shown in Tables 6.1 – 6.12 defines group size as the number of
cardiologists in a physician’s practice. However, as discussed above, a physician’s group
can be identified and measured by using different types of organizations and/or
physicians. Tables 6.13 and 6.14 show results from regression analyses that use different
measurements of group size, which are determined by a combination of organization type
(practice, office, or hospital) and physician type (all cardiologists or only cardiologists
who implant stents). In these tables, each cell provides the coefficient estimate (and 95%
confidence interval for the coefficient) on physician group size from a fully-specified
model that includes group-level covariates and excludes single-physician groups (i.e.
Model 6, from Tables 6.2, 6.4, and 6.6) for the analysis of one of the given group size
measurements. (For example, in Table 6.13 the cell in the top left-hand corner,
corresponding to the “all-cardiologist, practice-level” measure of group size, is taken
from Table 6.2—specifically, the group size coefficient for Model 6 in the top right-hand
corner of Table 6.2.) Thus, each cell in these tables represents a single cell pulled from a
full table of regression analysis results. Table 6.13 presents results from analyses where

147
group size is measured continuously, whereas Table 6.14 contains results from analyses
using the categorical measure of group size. Both tables also provide results from both
the standard, non-instrumented OLS regressions and the instrumental variable analyses.
As noted above, because I cannot identify hospitals’ locations and the instruments used
here are ZIP-Code-based, I am unable to instrument for hospital group size, so those table
entries are left blank.

Starting with Table 6.13, we first notice that none of the coefficient estimates is
statistically significantly different from zero. With that said, we observe that most of the
point estimates for the relationship between group size and time to initial DES
disadoption are positive, as we observed in earlier analyses. The one exception to this
when groups are measured at physician office level and group size is instrumented for
(with ZIP-code-level other specialty practice size). We also observe that, with the
exception of the hospital-based group size measures, when group size is determined by
counting only cardiologists who implant stents, the coefficient estimates (for the effect of
group size on time to initial DES disadoption) are of larger magnitude than when group
size is determined by counting all cardiologists. In terms of coefficient magnitude, we
also notice that the estimates for practice-based group size are comparable to the
estimates for office-based group size, whereas the point estimates for hospital-based
group size are much smaller, indicating that the marginal increase in hospital size has a
smaller impact on time to initial DES disadoption than does the marginal increase in
practice or group size. Finally, we observe that for each type of group size measurement,
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the magnitude of coefficient estimates is larger for instrumental variable analysis than for
basic OLS analysis (though as already mentioned, in the case of office-based group size,
the coefficients change in sign in addition to getting larger).

Table 6.14 is analogous to Table 6.13, but uses categorical group sizes measures instead
of continuous measures. Again, the measures of practice- and office-based group sizes
show virtually no statistically significant relationship with time to initial DES
disadoption, but we do observe several significant coefficients for hospital-based group
size. Specifically, we see that each group category has a negative coefficient, indicating
that each of the group size categories is associated with a shorter time to initial DES
disadoption than the smallest, omitted hospital-based group category. Otherwise, we
observe no obvious relationships across the different group size category measures.

Secondary outcomes
We next turn to the secondary outcomes of interest, which are the other three singledimension measures of DES disadoption—initial extent of DES disadoption, time to
minimum DES use, and full extent of DES disadoption—and the one multi-dimensional
measure of DES disadoption—area above the DES disadoption curve. The results for
these outcomes are provided in Tables 6.15 – 6.22, which replicate the format of Tables
6.13 and 6.14, showing the relationship between the given outcome variable and group
size as measured by various different variables, both with basic linear regression and
instrumental variable analysis. With few exceptions, there are generally no statistically
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significant relationships between group size and the other measures of DES disadoption
behavior, and there are few consistently signed (i.e. positive or negative) relationships.
However, it does appear that there may be a weak negative relationship between
physician office size (and possibly practice size) and initial extent of DES disadoption,
suggesting that physicians in larger officers (or practices) may exhibit smaller drops in
DES use rates upon initial disadoption.

Sensitivity analyses
As was also noted in Chapter 5, the results shown here are all specific to a single DES
disadoption definition. To test the sensitivity of these results to the specifications of this
definition, the analyses are repeated using multiple different DES disadoption definitions.
Figure 6.2 plots coefficient estimates (and their 95% confidence intervals) from analyses
of group size and the primary outcome variable, time to initial DES disadoption, with a
different plot for each combination of the three types of organization (practice, office,
and hospital) and two types of physician (all cardiologists and stent-placing
cardiologists), analogous to the results shown in Table 6.13, with each point in the plots
corresponding to an analysis with an outcome variable based on a different DES
disadoption definition. As the plots and calculated coefficient means show, the
coefficient estimates are generally positive but lacking statistical significance. These
plots were repeated for the secondary outcome variables—i.e. the three other
unidimensional measures of DES disadoption and the one multidimensional measure of
DES disadoption—and none of the results were statistically significant.
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Figure 6.2: Coefficient estimates from models relating time to initial DES disadoption to
group size, with a different plot presented for six different measurements of group size.
Each point represents the use of a different DES disadoption definition. Within-plot
coefficient means (with 90% confidence intervals) are calculated and shown in text.
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6.4 – Discussion
The analyses performed here attempt to provide fundamental insight into the
determinants of physicians’ technology disadoption behavior, choosing to focus
specifically on the role of physician group size and the empirical setting of DES use.
One of the key results from the above analyses is the observation that physician group
size may have a positive relationship with time to initial DES disadoption, i.e. physicians
in larger groups tend to start the DES disadoption process later. However, while this
relationship is observed across multiple different analyses, the coefficient estimates,
while generally positive, are generally not significantly different from zero, statistically
speaking. Yet, the replication of the result across different analyses and specifications
gives some weight to its validity (as compared to a spurious result), despite the lack of
conventional statistical significance.

Recalling the theoretical model that I developed in Chapter 4, that theory predicted an
ambiguous relationship between group size and time to disadoption, on account of larger
groups providing a “benefit” of greater access to information (via more peers), but also
introducing the “disadvantage” of an opportunity to free-ride off others’ knowledge
acquisition, and thus incentivizing the shirking of effort expenditure on own knowledge
acquisition. The empirical observation that larger group size may be related to later
initial DES disadoption (which I postulate is mediated through decreased effort
expenditure toward acquisition of critical information) is suggestive that, in the
framework of the theoretical model, the negative effect of free-riding incentive (i.e.
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individuals’ decrease in effort expenditure on knowledge acquisition) may outweigh the
positive effect of increased access to more potential knowledge (via larger group size).
Of course, it must be acknowledged again that these results are generally not statistically
significant in the conventional sense.

As described above, to address potential concerns over the potentially endogenous
relationship between physician group size and DES disadoption behavior, I conducted an
instrumental variable analysis aimed at identifying the causal effect of group size on DES
disadoption. Though the instrumental variable analyses generally do not produce
statistically significant results (like the basic OLS analyses), it is worth commenting on
the fact that instrumenting for group size tends to cause an increase in the estimated
effect size of group size on time to initial DES disadoption. We recall that I was
motivated to instrument for group size to address concerns that physicians are selecting
into practices of different sizes based on unobserved characteristics that are also related
to DES disadoption behavior. Thus, if using an instrumental variable removes this
endogeneity of group size and, in so doing, increases the size of the effect, it suggests that
there may be an underlying negative relationship between group size and time to
disadoption (again with the caveat of no statistical significance). That is, these findings
suggest that cardiologists who prefer to select into larger practices may also be more
prone to starting the DES disadoption process earlier. Indeed, one potential explanation
for this finding is the observation that academic medical groups tend to be very large (e.g.
associated with large teaching hospitals), but also attract physicians who are on the
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forefront of knowledge acquisition, and thus may possibly be the first to learn about
safety concerns surrounding DES and begin the disadoption process earlier. However, it
is particularly interesting to note that, while instrumentation for group size produces
larger, positive coefficient estimates on the practice-based group size measure, the same
instrumentation produces negative coefficient estimates on the office-based group size
measure. Following the same reasoning discussed above, this relationship suggests that,
while cardiologists who select into larger practices are more likely to begin DES
disadoption earlier, cardiologists who selection into larger offices are more likely to begin
DES disadoption later. One possible explanation for this could be if physicians who do
not want to expend great personal effort on keeping up-to-date with new clinical
technologies and guidelines prefer to join larger offices, where they expect to have close
contact with a large number of other clinicians, from whom they can hopefully learn new
information and with whom they can pool resources to reduce their learning costs. Of
course, again, all of these results and potential explanations are considered with the
understanding that these results are not statistically significant.

Aside from the estimated coefficients on office-based group size, most of the analyses
performed here indicate a positive relationship between group size and time to initial
DES disadoption, but there is another notable case that appears to disagree with the
general trend. Namely, the discrete-time hazard analysis of initial DES disadoption
“risk” indicates that larger group size is associated with earlier initial DES disadoption.
However, this result may be a mechanical artifact of the data. For example, if a large
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portion of the sample exhibits early initial DES disadoption and if there is the same
distribution of time to initial DES disadoption among both large and small groups (i.e.
indicating that there is no true difference in initial DES disadoption “risk” by group size),
but there are more individuals in large groups than small groups, the result of a discretetime hazard analysis will indicate a greater initial disadoption hazard for large groups
than small groups due to the increased sample prevalence of DES disadoption in large
groups. Indeed, we do observe a large portion of the sample having early DES
disadoption (see Figure 5.1) and a larger number of big than small groups (see Figure
6.1), so the nature of the sample composition may explain the observed hazard analysis
results, rather than a true relationship between increased group size and earlier DES
disadoption. Of course, it is worth recalling (yet again) that the other analyses performed
in this chapter do not definitively indicate that an increase in group size has a true
relationship (either causal or not) with slower initial DES disadoption.

Indeed, there are multiple reasons that the analyses performed here might not provide any
significant findings, even if a true relationship does exist between physician group size
and technology disadoption behavior. While there are many reasons that DES serves as a
strong empirical setting to study technology disadoption (as detailed in Chapter 2), there
are also drawbacks specific to this choice. First, there was a relatively large amount of
uncertainty surrounding the technology. Though the original publications and research
on DES were extremely positive, it did not take long for serious safety concerns to
surface and gain attention. Of course, uncertainty is a fundamental component to any
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example of technology adoption or disadoption, but the hype and publicity surrounding
DES, along with the high-stakes (i.e. life-or-death) nature of its application, magnified
the potential impact of any given piece of new information regarding the technology, thus
making individuals more prone to large and frequent fluctuations in technology use. As I
described above, my empirical characterize DES disadoption behavior is based on
changes in technology usage rates, so fluctuations in DES rates can create significant
noise in the various disadoption measures. Such noise, which is compounded by the
relatively small sample size that I study—which I discussed in Chapter 5, and may
significantly under-power these analyses, especially given the reduced sample sizes
resulting from the use of IV analysis in this chapter—would obviously compromise the
ability to identify true functional relationships in the data.

Second, our ability to identify true empirical relationships between physician
organization and DES disadoption behavior is inhibited by the relatively brief timeline of
global DES adoption and disadoption. Though the short period of combined DES
adoption and disadoption is beneficial in that it allows us to observe both types of
behavior in a relatively small and accessible amount of data, it is simultaneously
detrimental to our research objectives. As described in Chapter 2, DES witnessed very
rapid adoption, followed by generalized disadoption, and subsequently re-adoption, all in
less than 5 years. While this timeline may not seem short compared to some other
technology trajectories (e.g. smart phones or clothing), the fact that data observations are
at the quarter level means that the potential window for observable DES adoption and
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disadoption behaviors is rather small and, as a result, the potential variation in measures
of these behaviors is quite limited. Given that the existence of variation is a fundamental
requirement for meaningful econometric analysis, it should not be surprising that the
coefficient estimates calculated here are not statistically significant.

Despite these empirical limitations, this data analysis still does reveal some potentially
interesting relationships, including the examination of different measures of group size.
Though the original analysis of group size and time to initial DES disadoption focused
specifically on physicians’ practice size, where “size” is a count of the number of selfidentified cardiologists in the practice, there are potentially other group sizes to consider,
as discussed and analyzed above. In my investigation of different group size
measurements, the primary results for which are shown in Tables 6.13 and 6.14 (along
with Tables 6.15 – 6.22, for the secondary outcome variables), I am able to compare the
relationships between time to initial DES disadoption and practice size, office size, and
hospital size. Aside from the interesting difference in sign on the coefficient estimates
for practice size and office size that arises with instrumental variable analysis (which I
discussed above), we also notice that the magnitude of the coefficients on practice and
group size are relatively comparable, while the coefficient estimate for hospital size is
considerably smaller. One potential explanation for this observed difference is the fact
that hospitals tend to be much larger than practices or offices. In the dataset used here,
average hospital size is approximately 6-7 times larger than average practice or office
size (54 versus 9 and 7). Given the bigger size, it is expected that the marginal effect of
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increasing hospital size by 1 physician would have a smaller effect on a physician’s DES
disadoption behavior than the marginal effect of increasing either practice or office size
by 1 physician. Another explanation that would be consistent with these results of
different magnitudes of coefficient estimates would be stronger relationships and
communications between physicians in practices or offices as opposed to hospitals. This
explanation would agree with other research which has found (specifically in the setting
of DES use by cardiologists) that peer effects on medical technology selection are greater
among physicians within practices than between physicians who work in the same
hospital (Huesch 2011 Soc Sci Med). Indeed, such a result would make sense via the
influence of knowledge-sharing if practices and offices represent the central organization
where cardiologists practice and see patients, and hospitals serve as a simple “workshop”
where they operate and place stents. Of course, this is just one theoretical explanation,
and we must remember the limited statistical significance of these results, and the fact
that other factors may produce such results.

Table 6.13 also compares group size measures that differ in terms of which physicians
are counted to determine the given group size. Across all types of organizations
(practice, office, and hospital), we observe that effect of an increase in the number of
stent-implanting cardiologists has a larger impact on time to initial DES disadoption than
an increase in the number of general cardiologists. This observation agrees with intuition
and an understanding of both the data used here and the institutional details of the clinical
situation. The measure of general cardiologists is based on physicians’ self-identified

158
specialty and includes physicians’ secondary and tertiary specialties. This likely means
that some general practitioners are included in the sample because dealing very
frequently with cardiac issues (given that heart disease is the leading cause of death in the
United States, and conditions such as hypertension, hyperlipidemia, and heart failure are
encountered with exceptional regularity in primary care practices) will prompt some
general practitioners to consider cardiology to be one of their specialties. However, the
measure of cardiologists who implant stents is identified in the discharge data, so it does
not have the potential to be inflated to include non-cardiologists. Given that learning is
the postulated mechanism through which group size influences DES disadoption, it is
logical that physicians who actually implant stents would more reason to quickly acquire
critical information regarding DES, and thus we’d expect the second group size measure
to have a bigger impact on time to initial DES disadoption.

Aside from this observed relationship between group size and time to initial DES
disadoption, I also analyze the relationship between group size and the other measures of
DES disadoption (initial extent of DES disadoption, time to minimum DES use, full extent
of DES disadoption, and area above the DES disadoption curve). However, I find
virtually no significant association between group size and any of these other DES
disadoption measures. Having not developed a theoretical framework that relates group
size to these disadoption measures, it cannot be said that this finding is either surprising
or expected. Of course, the observed empirical result may also be a result of issues with
the data (e.g. noise in the measures, lack of statistical power) instead of fundamental (or
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theoretical) ambiguity, so further investigation is required to develop deeper
understanding of these measures of disadoption. Indeed, one extension of analysis is to
consider not just how group size relates to the technology disadoption process—while
controlling for the measures of the similar adoption process—but to consider how group
size relates differentially to the disadoption and adoption processes. It is this topic that I
turn to next.
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Table 6.1: Effect of physician practice size (all cardiologists) on initial time to DES
disadoption, single-group physicians included, continuous group size measure; basic
OLS regression results
Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 7
(β/[95%CI])

-0.006
[-0.04,0.02]

-0.005
[-0.03,0.02]

0.002
[-0.03,0.03]

0.003
[-0.03,0.03]

Physician age (at time of DES safety
concern publicization)

0.074
[-0.01,0.16]

0.065
[-0.02,0.15]

0.063
[-0.02,0.15]

Physician years of experience (at
time of DES safety concern pub)

-0.053
[-0.14,0.03]

-0.042
[-0.13,0.04]

-0.044
[-0.13,0.04]

Physician has cardiology fellowship
training

-0.446
[-1.47,0.58]

-0.528
[-1.54,0.48]

-0.557
[-1.57,0.46]

Physician has interventional
cardiology fellowship training

-0.758
[-1.67,0.16]

-1.058*
[-1.97,-0.15]

-1.101*
[-2.07,-0.13]

-0.004***
[-0.01,-0.00]

-0.003***
[-0.01,-0.00]

0.005**
[0.00,0.01]

0.005*
[0.00,0.01]

Physician group size (number of
cardiologists)

Physician total num. DES placed
before safety concerns
Physician total num. DES placed
from safety concern pub. thru 2007
Physician time (quarters) to initial
DES adoption

-0.011
[-0.16,0.14]

Physician time (quarters) from
adoption to max DES use

-0.041*
[-0.08,-0.00]

Physician initial level DES use
(increase) upon adoption

-0.144
[-1.32,1.04]

Physician full level DES use
(increase) after adoption

2.223
[-4.56,9.00]

r2
F
p
N
Unique docs
Incremental F stat
Prob > incrm F

0.000
0.168
0.682
532.000
532

0.018
1.941
0.086
532.000
532
2.383553605
0.050434834

0.056
4.472
0.000
532.000
532
10.62192561
3.00617E-05

0.066
3.322
0.000
532.000
532
1.293234336
0.271539095

161
Table 6.2: Effect of physician practice size (all cardiologists) on initial time to DES
disadoption, single-group physicians excluded, continuous group size measure; basic
OLS regression results
Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 4
(β/[95%CI])

Model 5
(β/[95%CI])

Model 6
(β/[95%CI])

0.001
[-0.03,0.03]

0.000
[-0.03,0.03]

0.005
[-0.03,0.04]

0.013
[-0.02,0.05]

0.004
[-0.03,0.04]

0.005
[-0.03,0.04]

Physician age (at time of DES
safety concern publicization)

0.082
[-0.01,0.18]

0.074
[-0.02,0.17]

0.065
[-0.03,0.16]

0.060
[-0.03,0.15]

0.059
[-0.04,0.15]

Physician years of experience (at
time of DES safety concern pub)

-0.065
[-0.16,0.03]

-0.055
[-0.15,0.04]

-0.034
[-0.12,0.06]

-0.033
[-0.12,0.06]

-0.035
[-0.13,0.06]

Physician has cardiology
fellowship training

-0.529
[-1.59,0.53]

-0.602
[-1.65,0.44]

-0.663
[-1.70,0.37]

-0.627
[-1.67,0.41]

-0.660
[-1.70,0.38]

Physician has interventional
cardiology fellowship training

-0.769
[-1.72,0.18]

-1.088*
[-2.03,-0.14]

-1.104*
[-2.04,-0.17]

-1.134*
[-2.07,-0.20]

-1.210*
[-2.19,-0.23]

Physician total num. DES placed
before safety concerns

-0.004***
[-0.01,-0.00]

-0.003***
[-0.01,-0.00]

-0.003***
[-0.01,-0.00]

-0.003**
[-0.01,-0.00]

Physician total num. DES placed,
from safety concern pub. to 2007

0.005*
[0.00,0.01]

0.005*
[0.00,0.01]

0.005*
[0.00,0.01]

0.005*
[0.00,0.01]

Practice average doc age at time
of DES safety concern pub.

0.030
[-0.01,0.07]

0.019
[-0.02,0.06]

0.017
[-0.03,0.06]

Practice average doc yrs exper. at
time of DES safety concern pub

-0.043
[-0.09,0.00]

-0.030
[-0.08,0.02]

-0.028
[-0.08,0.02]

Practice fraction of docs with
cardiology fellowship training

-1.409*
[-2.78,-0.04]

-1.315
[-2.70,0.07]

-1.300
[-2.70,0.09]

Practice fraction of docs with
intvntl card fellowship training

1.261*
[0.08,2.45]

1.333*
[0.14,2.52]

1.383*
[0.19,2.58]

Practice total # DES placed
before DES safety concerns

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

Practice total num. DES placed
from safety concern pub. to 2007

0.000
[0.00,0.00]

0.000
[0.00,0.00]

Physician group size (number of
cardiologists)

Physician time (quarters) to
initial DES adoption

0.016
[-0.14,0.17]

Physician time (quarters) from
adoption to max DES use

-0.043*
[-0.08,-0.00]

Physician initial level DES use
(increase) upon adoption

-0.337
[-1.58,0.90]

Physician full level DES use
(increase) after adoption

5.568
[-1.78,12.9]

r2

0.000

0.018

0.057

0.091

0.093

0.107

F

0.005

1.732

3.964

4.158

3.911

3.389

p

0.943

0.126

0.000

0.000

0.000

0.000

N

471.000

471.000

471.000

471.000

471.000

471.000

471

471

471

471

471

471

Incremental F stat

2.16376855

9.38817507

4.30018276

1.17254722

1.74722150

Prob > incrm F

0.07209137

0.00010075

0.00200076

0.27944822

0.13850694

Unique docs

162
Table 6.3: Effect of physician practice size (all cardiologists) on initial time to DES
disadoption, single-group physicians included, continuous group size measure;
instrumental variable regression results
Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 7
(β/[95%CI])

0.065
[-0.07,0.20]

0.067
[-0.07,0.20]

0.081
[-0.06,0.22]

0.093
[-0.04,0.23]

Physician age (at time of DES
safety concern publicization)

0.065
[-0.04,0.17]

0.053
[-0.05,0.15]

0.050
[-0.05,0.15]

Physician years of experience (at
time of DES safety concern pub)

-0.051
[-0.15,0.05]

-0.038
[-0.13,0.06]

-0.040
[-0.14,0.06]

Physician has cardiology
fellowship training

-0.628
[-1.80,0.54]

-0.783
[-1.93,0.37]

-0.775
[-1.94,0.39]

Physician has interventional
cardiology fellowship training

-0.799
[-1.85,0.25]

-1.076*
[-2.12,-0.03]

-1.054
[-2.17,0.06]

-0.004***
[-0.01,-0.00]

-0.004***
[-0.01,-0.00]

0.005*
[0.00,0.01]

0.005*
[0.00,0.01]

Physician group size (number of
cardiologists)

Physician total num. DES placed
before safety concerns
Physician total num. DES placed
from safety concern pub. thru 2007
Physician time (quarters) to initial
DES adoption

-0.055
[-0.22,0.11]

Physician time (quarters) from
adoption to max DES use

-0.038
[-0.08,0.01]

Physician initial level DES use
(increase) upon adoption

0.161
[-1.18,1.50]

Physician full level DES use
(increase) after adoption

1.063
[-8.45,10.57]

r2
F
p
N
Unique docs
Chi-squared
Incremental chi2
Prob > incrm chi2
IV Hausman p-value
First stage F
IV overid. p-value

.

.

0.009

0.002

0.339
452.000
452
0.915050481
7.026266436

0.172
452.000
452
7.73210558
6.532713885
0.162740779
0.282509649
6.674699106
0.210301053

0.000
452.000
452
26.31467178
18.59761003
9.15335E-05
0.253089586
6.710031475
0.272853427

0.002
452.000
452
29.75563169
3.748149045
0.441161699
0.193877601
6.592914493
0.208809368
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Table 6.4: Effect of physician practice size (all cardiologists) on initial time to DES
disadoption, single-group physicians excluded, continuous group size measure;
instrumental variable regression results
Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 4
(β/[95%CI])

Model 5
(β/[95%CI])

Model 6
(β/[95%CI])

0.058
[-0.08,0.19]

0.062
[-0.08,0.20]

0.075
[-0.06,0.21]

0.091
[-0.06,0.24]

0.107
[-0.04,0.26]

0.138
[-0.02,0.29]

Physician age (at time of DES
safety concern publicization)

0.069
[-0.04,0.18]

0.057
[-0.05,0.17]

0.043
[-0.06,0.15]

0.048
[-0.06,0.16]

0.044
[-0.07,0.16]

Physician years of experience (at
time of DES safety concern pub)

-0.060
[-0.17,0.05]

-0.048
[-0.15,0.06]

-0.033
[-0.14,0.07]

-0.036
[-0.14,0.07]

-0.038
[-0.15,0.07]

Physician has cardiology
fellowship training

-0.789
[-1.99,0.42]

-0.936
[-2.13,0.26]

-1.055
[-2.27,0.16]

-1.103
[-2.34,0.13]

-1.169
[-2.44,0.11]

Physician has interventional
cardiology fellowship training

-0.750
[-1.85,0.35]

-1.014
[-2.11,0.08]

-0.985
[-2.09,0.12]

-0.953
[-2.06,0.16]

-0.961
[-2.14,0.22]

Physician total num. DES placed
before safety concerns

-0.004***
[-0.01,-0.00]

-0.003***
[-0.01,-0.00]

-0.003**
[-0.01,-0.00]

-0.003**
[-0.01,-0.00]

Physician total num. DES placed
from safety concern pub. to 2007

0.004
[-0.00,0.01]

0.004
[-0.00,0.01]

0.004
[-0.00,0.01]

0.004
[-0.00,0.01]

Practice average doc age at time
of DES safety concern pub.

0.029
[-0.02,0.08]

0.039
[-0.01,0.09]

0.038
[-0.01,0.09]

Practice average doc yrs exper. at
time of DES safety concern pub

-0.009
[-0.09,0.07]

-0.017
[-0.08,0.04]

-0.011
[-0.07,0.05]

Practice fraction of docs with
cardiology fellowship training

-2.465**
[-4.20,-0.73]

-2.589**
[-4.41,-0.76]

-2.732**
[-4.61,-0.85]

Practice fraction of docs with
intvntl card fellowship training

1.712*
[0.20,3.23]

1.686*
[0.30,3.08]

1.816*
[0.38,3.25]

Practice total number DES placed
before DES safety concerns

-0.000
[-0.00,0.00]

-0.000
[-0.00,0.00]

Practice total num. DES placed
from safety concern pub. to 2007

0.000
[0.00,0.00]

0.000
[0.00,0.00]

Physician group size (number of
cardiologists)

Physician time (quarters) to
initial DES adoption

0.013
[-0.16,0.19]

Physician time (quarters) from
adoption to max DES use

-0.034
[-0.08,0.01]

Physician initial level DES use
(increase) upon adoption

-0.233
[-1.66,1.20]

Physician full level DES use
(increase) after adoption

6.888
[-4.84,18.6]

r2

.

.

0.021

0.051

0.037

0.007

p

0.410

0.205

0.002

0.000

0.000

0.000

N

400.000

F
400.000

400.000

400.000

400.000

400.000

Unique docs

400

400

400

400

400

400

Chi-squared

0.67795974

7.21026818

22.9934406

38.4399506

39.8172531

42.8781696

Incremental chi2

6.86775016

5.69330862

16.2208832

15.7908687

0.29251957

3.83751880

Prob > incrm chi2

0.22325279

0.00030038

0.00331301

0.58861043

0.42844164

IV Hausman p-value

0.38103512

0.33249003

0.29749213

0.16268946

0.07777907

First stage F

6.58383514

6.68082938

6.41994871

8.01560460

7.56653347

IV overid. p-value

0.20193021

0.32268951

0.29981937

0.33314883

0.37037035
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Table 6.5: Effect of physician practice size (all cardiologists) on initial time to DES
disadoption, single-group physicians included, continuous group size measure; basic
OLS regression results, with sample matching instrumental variable analysis (i.e. Table
6.3 results)
Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 7
(β/[95%CI])

-0.003
[-0.04,0.03]

-0.004
[-0.04,0.03]

0.005
[-0.03,0.04]

0.006
[-0.03,0.04]

Physician age (at time of DES safety
concern publicization)

0.052
[-0.04,0.15]

0.041
[-0.05,0.14]

0.036
[-0.06,0.13]

Physician years of experience (at
time of DES safety concern pub)

-0.039
[-0.13,0.05]

-0.026
[-0.12,0.07]

-0.024
[-0.12,0.07]

Physician has cardiology fellowship
training

-0.648
[-1.80,0.51]

-0.766
[-1.90,0.37]

-0.732
[-1.88,0.42]

Physician has interventional
cardiology fellowship training

-0.851
[-1.89,0.19]

-1.127*
[-2.16,-0.10]

-1.153*
[-2.24,-0.06]

-0.004***
[-0.01,-0.00]

-0.004***
[-0.01,-0.00]

0.006*
[0.00,0.01]

0.006*
[0.00,0.01]

Physician group size (number of
cardiologists)

Physician total num. DES placed
before safety concerns
Physician total num. DES placed
from safety concern pub. thru 2007
Physician time (quarters) to initial
DES adoption

-0.031
[-0.19,0.13]

Physician time (quarters) from
adoption to max DES use

-0.037
[-0.08,0.01]

Physician initial level DES use
(increase) upon adoption

0.102
[-1.22,1.42]

Physician full level DES use
(increase) after adoption

-0.415
[-9.52,8.69]

r2
F
p
N
Unique docs
Incremental F stat
Prob > incrm F

0.000
0.042
0.837
452.000
452

0.016
1.410
0.219
452.000
452
1.751551877
0.137626603

0.055
3.685
0.001
452.000
452
9.24148388
0.000116887

0.062
2.647
0.003
452.000
452
0.841025058
0.499653213
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Table 6.6: Effect of physician practice size (all cardiologists) on initial time to DES
disadoption, single-group physicians excluded, continuous group size measure; basic
OLS regression results, with sample matching instrumental variable analysis (i.e. Table
6.4 results)
Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 4
(β/[95%CI])

Model 5
(β/[95%CI])

Model 6
(β/[95%CI])

0.004
[-0.03,0.04]

0.002
[-0.03,0.04]

0.009
[-0.03,0.04]

0.018
[-0.02,0.06]

0.011
[-0.03,0.05]

0.012
[-0.03,0.05]

Physician age (at time of DES
safety concern publicization)

0.061
[-0.05,0.17]

0.048
[-0.06,0.16]

0.043
[-0.06,0.15]

0.038
[-0.07,0.14]

0.032
[-0.08,0.14]

Physician years of experience (at
time of DES safety concern pub)

-0.052
[-0.16,0.05]

-0.038
[-0.14,0.06]

-0.019
[-0.12,0.08]

-0.019
[-0.12,0.08]

-0.015
[-0.12,0.09]

Physician has cardiology
fellowship training

-0.747
[-1.94,0.45]

-0.862
[-2.04,0.32]

-0.914
[-2.09,0.26]

-0.886
[-2.06,0.29]

-0.862
[-2.05,0.33]

Physician has interventional
cardiology fellowship training

-0.858
[-1.93,0.21]

-1.132*
[-2.20,-0.07]

-1.142*
[-2.19,-0.09]

-1.156*
[-2.21,-0.10]

-1.232*
[-2.34,-0.12]

Physician total num. DES placed
before safety concerns

-0.004***
[-0.01,-0.00]

-0.003***
[-0.01,-0.00]

-0.003***
[-0.01,-0.00]

-0.003**
[-0.01,-0.00]

Physician total num. DES placed
from safety concern pub. to 2007

0.005*
[0.00,0.01]

0.005*
[0.00,0.01]

0.005*
[0.00,0.01]

0.005
[-0.00,0.01]

Practice average doc age at time
of DES safety concern pub.

0.046*
[0.01,0.09]

0.036
[-0.01,0.08]

0.036
[-0.01,0.08]

Practice average doc yrs exper. at
time of DES safety concern pub

-0.041
[-0.09,0.01]

-0.030
[-0.09,0.03]

-0.029
[-0.09,0.03]

Practice fraction of docs with
cardiology fellowship training

-2.252**
[-3.86,-0.64]

-2.165**
[-3.79,-0.54]

-2.165*
[-3.82,-0.51]

Practice fraction of docs with
intvntl card fellowship training

1.297*
[0.01,2.59]

1.353*
[0.06,2.65]

1.363*
[0.05,2.67]

Practice total number DES placed
before DES safety concerns

0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

Practice total num. DES placed
from safety concern pub. to 2007

0.000
[0.00,0.00]

0.000
[0.00,0.00]

Physician group size (number of
cardiologists)

Physician time (quarters) to
initial DES adoption

0.017
[-0.15,0.19]

Physician time (quarters) from
adoption to max DES use

-0.037
[-0.08,0.01]

Physician initial level DES use
(increase) upon adoption

-0.253
[-1.65,1.14]

Physician full level DES use
(increase) after adoption

3.111
[-7.52,13.7]

r2

0.000

0.016

0.054

0.093

0.095

0.103

F

0.054

1.310

3.205

3.631

3.380

2.736

p

0.816

0.259

0.003

0.000

0.000

0.000

N

400.000

400.000

400.000

400.000

400.000

400.000

400

400

400

400

400

400

Incremental F stat

1.62366742

7.83067601

4.19257278

0.65259984

0.82339142

Prob > incrm F

0.16745421

0.00046276

0.00246003

0.41968096

0.51083096

Unique docs
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Table 6.7: Effect of physician practice size (all cardiologists) on initial time to DES
disadoption; replication of fully specified models from Tables 6.1 – 6.6, for categorical
group size variable (instead of continuous group size measure)
Model 7
(β/[95%CI])

Model 6
(β/[95%CI])

Model 7
(β/[95%CI])

Model 6
(β/[95%CI])

Model 7
(β/[95%CI])

Model 6
(β/[95%CI])

Physician group size category: 25 docs/practice

-0.341
[-1.14,0.46]

Ref

-6.649
[-43.48,30.2]

Ref

-0.408
[-1.30,0.48]

Ref

Physician group size category: 612 docs/practice

0.064
[-0.71,0.84]

0.462
[-0.16,1.09]

-6.216
[-35.3,22.87]

3.085
[-20.7,26.87]

0.010
[-0.86,0.88]

0.428
[-0.26,1.11]

Physician group size category:
13+ docs/practice

-0.124
[-0.97,0.73]

0.249
[-0.57,1.06]

-4.067
[-32.15,24.0]

3.747
[-9.60,17.09]

0.072
[-0.90,1.04]

0.609
[-0.31,1.53]

Physician age (at time of DES
safety concern publicization)

0.063
[-0.02,0.15]

0.058
[-0.04,0.15]

0.007
[-0.19,0.21]

0.054
[-0.12,0.23]

0.038
[-0.06,0.13]

0.035
[-0.07,0.14]

Physician years of experience (at
time of DES safety concern pub)

-0.043
[-0.13,0.04]

-0.036
[-0.13,0.06]

-0.014
[-0.17,0.14]

-0.060
[-0.30,0.18]

-0.026
[-0.12,0.07]

-0.021
[-0.12,0.08]

Physician has cardiology
fellowship training

-0.515
[-1.53,0.50]

-0.596
[-1.64,0.45]

-1.374
[-4.15,1.40]

-0.846
[-4.04,2.35]

-0.709
[-1.86,0.45]

-0.852
[-2.04,0.34]

Physician has interventional
cardiology fellowship training

-1.102*
[-2.08,-0.13]

-1.244*
[-2.23,-0.26]

-0.374
[-3.90,3.15]

-1.094
[-2.35,0.16]

-1.129*
[-2.22,-0.03]

-1.227*
[-2.33,-0.12]

Physician total num. DES placed
before safety concerns

-0.004***
[-0.01,-0.00]

-0.003**
[-0.01,-0.00]

-0.002
[-0.01,0.01]

-0.005
[-0.02,0.01]

-0.004***
[-0.01,-0.00]

-0.003**
[-0.01,-0.00]

Physician total num. DES placed
from safety concern pub. to 2007

0.005*
[0.00,0.01]

0.005*
[0.00,0.01]

0.004
[-0.01,0.02]

0.007
[-0.01,0.02]

0.006*
[0.00,0.01]

0.005*
[0.00,0.01]

Practice average doc age at time
of DES safety concern pub.

0.009
[-0.03,0.05]

-0.006
[-0.44,0.43]

0.031
[-0.02,0.08]

Practice average doc yrs exper. at
time of DES safety concern pub

-0.021
[-0.07,0.03]

0.025
[-0.38,0.43]

-0.023
[-0.08,0.04]

Practice fraction of docs with
cardiology fellowship training

-1.189
[-2.58,0.20]

-1.942
[-8.29,4.41]

-2.128*
[-3.80,-0.46]

Practice fraction of docs with
intvntl card fellowship training

1.384*
[0.20,2.57]

1.637*
[0.19,3.08]

1.375*
[0.07,2.68]

Practice total # DES placed
before DES safety concerns

0.000
[-0.00,0.00]

-0.000
[-0.00,0.00]

0.000
[-0.00,0.00]

Practice total num. DES placed
from safety concern pub. to 2007

0.000
[0.00,0.00]

0.000
[0.00,0.00]

0.000
[0.00,0.00]

Physician time (quarters) to
initial DES adoption

-0.016
[-0.16,0.13]

0.012
[-0.14,0.16]

-0.007
[-0.32,0.30]

-0.025
[-0.42,0.37]

-0.038
[-0.20,0.12]

0.012
[-0.16,0.18]

Physician time (quarters) from
adoption to max DES use

-0.039*
[-0.08,-0.00]

-0.041*
[-0.08,-0.00]

-0.022
[-0.15,0.11]

-0.025
[-0.15,0.10]

-0.036
[-0.08,0.01]

-0.036
[-0.08,0.01]

Physician initial level DES use
(increase) upon adoption

-0.069
[-1.25,1.12]

-0.250
[-1.49,0.99]

0.741
[-4.61,6.10]

0.236
[-4.98,5.45]

0.193
[-1.13,1.52]

-0.195
[-1.60,1.21]

Physician full level DES use
(increase) after adoption

2.206
[-4.58,8.99]

5.598
[-1.75,12.94]

4.772
[-19.7,29.24]

8.094
[-11.8,27.97]

0.013
[-9.11,9.14]

3.588
[-7.04,14.22]

r2
F
p
N
Unique docs
Chi-squared
Incremental chi2
Prob > incrm chi2
IV Hausman p-value
First stage F
IV overid. p-value

0.069
2.971
0.000
532.000
532
1.208503586
0.306175936

0.111
3.324
0.000
471.000
471
1.645510969
0.161724345

.

.

0.081
452.000
452
20.60859566
2.403863705
0.661929143
0.872827023

0.002
400.000
400
39.26394931
3.333784352
0.503597289
0.60268869

0.067
2.409
0.004
452.000
452
0.819781812
0.513005083

0.107
2.685
0.000
400.000
400
0.80297695
0.523827499

0.068646826

0.16134496
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Table 6.8: Effect of physician practice size (all cardiologists) on binary (early) initial
time to DES disadoption, single-group physicians included, continuous group size
measure; logit regression results
Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 7
(β/[95%CI])

0.004
[-0.02,0.03]

0.004
[-0.02,0.03]

-0.000
[-0.02,0.02]

-0.000
[-0.02,0.02]

Physician age (at time of DES safety
concern publicization)

-0.028
[-0.10,0.04]

-0.024
[-0.10,0.05]

-0.022
[-0.09,0.05]

Physician years of experience (at
time of DES safety concern pub)

0.009
[-0.06,0.08]

0.002
[-0.07,0.07]

0.001
[-0.07,0.07]

Physician has cardiology fellowship
training

0.447
[-0.33,1.23]

0.508
[-0.29,1.30]

0.515
[-0.29,1.32]

Physician has interventional
cardiology fellowship training

0.733
[-0.17,1.64]

0.984*
[0.05,1.92]

1.075*
[0.07,2.08]

0.003***
[0.00,0.00]

0.003**
[0.00,0.00]

-0.005**
[-0.01,-0.00]

-0.005*
[-0.01,-0.00]

Physician group size (number of
cardiologists)

Physician total num. DES placed
before safety concerns
Physician total num. DES placed
from safety concern pub. thru 2007
Physician time (quarters) to initial
DES adoption

0.001
[-0.13,0.13]

Physician time (quarters) from
adoption to max DES use

0.028
[-0.01,0.06]

Physician initial level DES use
(increase) upon adoption

-0.032
[-1.04,0.97]

Physician full level DES use
(increase) after adoption

-2.358
[-8.74,4.03]

chi2
p
N
Unique docs
Incremental LR chi2
Prob > incrm chi2

0.094
0.759
532.000
532

10.537
0.061
532.000
532
10.44319408
0.033588538

24.338
0.001
532.000
532
13.80083301
0.001007366

27.903
0.003
532.000
532
3.565239077
0.468028179
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Table 6.9: Effect of physician practice size (all cardiologists) on binary (early) initial
time to DES disadoption, single-group physicians excluded, continuous group size
measure; logit regression results
Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 4
(β/[95%CI])

Model 5
(β/[95%CI])

Model 6
(β/[95%CI])

-0.009
[-0.03,0.02]

-0.008
[-0.03,0.02]

-0.010
[-0.04,0.02]

-0.025
[-0.06,0.00]

-0.018
[-0.05,0.02]

-0.019
[-0.05,0.01]

Physician age (at time of DES
safety concern publicization)

-0.032
[-0.11,0.05]

-0.029
[-0.11,0.05]

-0.022
[-0.10,0.06]

-0.016
[-0.10,0.07]

-0.011
[-0.10,0.07]

Physician years of experience (at
time of DES safety concern pub)

0.013
[-0.06,0.09]

0.006
[-0.07,0.08]

-0.006
[-0.09,0.07]

-0.007
[-0.09,0.07]

-0.011
[-0.09,0.07]

Physician has cardiology
fellowship training

0.468
[-0.34,1.28]

0.515
[-0.31,1.34]

0.604
[-0.25,1.46]

0.570
[-0.28,1.42]

0.551
[-0.31,1.42]

Physician has interventional
cardiology fellowship training

0.640
[-0.29,1.57]

0.935
[-0.03,1.90]

0.963
[-0.02,1.94]

1.005*
[0.02,1.99]

1.218*
[0.15,2.29]

Physician total num. DES placed
before safety concerns

0.003***
[0.00,0.00]

0.003***
[0.00,0.00]

0.003***
[0.00,0.00]

0.003**
[0.00,0.00]

Physician total num. DES placed
from safety concern pub. to 2007

-0.006**
[-0.01,-0.00]

-0.006**
[-0.01,-0.00]

-0.005**
[-0.01,-0.00]

-0.005*
[-0.01,-0.00]

Practice average doc age at time
of DES safety concern pub.

-0.011
[-0.04,0.02]

-0.001
[-0.04,0.04]

0.002
[-0.04,0.04]

Practice average doc yrs exper. at
time of DES safety concern pub

0.015
[-0.03,0.06]

0.003
[-0.04,0.05]

0.000
[-0.05,0.05]

Practice fraction of docs with
cardiology fellowship training

1.156
[-0.08,2.39]

1.094
[-0.16,2.34]

1.068
[-0.20,2.33]

Practice fraction of docs with
intvntl card fellowship training

-1.162*
[-2.18,-0.15]

-1.240*
[-2.27,-0.21]

-1.300*
[-2.33,-0.27]

Practice total # DES placed
before DES safety concerns

-0.000
[-0.00,0.00]

-0.000
[-0.00,0.00]

Practice total num. DES placed
from safety concern pub. to 2007

0.000
[0.00,0.00]

0.000
[0.00,0.00]

Physician group size (number of
cardiologists)

Physician time (quarters) to
initial DES adoption

-0.038
[-0.18,0.10]

Physician time (quarters) from
adoption to max DES use

0.021
[-0.02,0.06]

Physician initial level DES use
(increase) upon adoption

-0.025
[-1.14,1.09]

Physician full level DES use
(increase) after adoption

-5.204
[-13.3,2.90]

chi2

0.475

9.212

22.931

38.127

39.283

p

0.491

0.101

0.002

0.000

0.000

0.000

N

471.000

471.000

471.000

471.000

471.000

471.000

Unique docs

471

43.420

471

471

471

471

471

Incremental LR chi2

8.73742231

13.7183799

15.1967016

1.15625831

4.13624416

Prob > incrm chi2

0.06800845

0.00104976

0.00431015

0.28224288

0.38788110
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Table 6.10: Effect of physician practice size (all cardiologists) on risk of initial DES
disadoption, single-group physicians included, continuous group size measure;
discrete-time hazard analysis
Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 7
(β/[95%CI])

0.015*
[0.00,0.03]

0.013
[-0.00,0.03]

0.010
[-0.00,0.02]

0.008
[-0.00,0.02]

-0.074***
[-0.12,-0.03]

-0.060**
[-0.10,-0.02]

-0.062**
[-0.10,-0.02]

Physician years of experience

0.053**
[0.01,0.09]

0.037
[-0.00,0.07]

0.041*
[0.00,0.08]

Physician has cardiology
fellowship training

0.175
[-0.28,0.63]

0.148
[-0.27,0.56]

0.228
[-0.20,0.65]

Physician has interventional
cardiology fellowship training

0.181
[-0.26,0.62]

0.334
[-0.09,0.76]

0.225
[-0.21,0.66]

0.001***
[0.00,0.00]

0.002***
[0.00,0.00]

-0.001*
[-0.00,-0.00]

-0.001**
[-0.00,-0.00]

Physician group size (number of
cardiologists)
Physician age (years)

Physician total num. DES placed
before safety concerns
Physician cumulative total number
of DES implanted
Physician time (quarters) to initial
DES adoption

0.050
[-0.00,0.10]

Physician time (quarters) from
adoption to max DES use

0.005
[-0.01,0.02]

Physician initial level DES use
(increase) upon adoption

-0.005
[-0.54,0.53]

Physician full level DES use
(increase) after adoption

-0.670
[-3.70,2.36]

chi2
p
N
Unique docs

4.980
0.026
2440.000
630

23.414
0.000
2440.000
630

56.829
0.000
2440.000
630

59.470
0.000
2440.000
630
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Table 6.11: Effect of physician practice size (all cardiologists) on risk of initial DES
disadoption, single-group physicians excluded, continuous group size measure;
discrete-time hazard analysis
Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Model 4
(β/[95%CI])

Model 5
(β/[95%CI])

Model 6
(β/[95%CI])

0.011
[-0.00,0.03]

0.010
[-0.00,0.02]

0.009
[-0.00,0.02]

0.005
[-0.01,0.02]

0.002
[-0.01,0.02]

0.002
[-0.01,0.02]

-0.064*
[-0.11,-0.01]

-0.050*
[-0.10,-0.01]

-0.050*
[-0.10,-0.01]

-0.049*
[-0.09,-0.00]

-0.052*
[-0.10,-0.01]

Physician years of experience

0.048*
[0.00,0.09]

0.033
[-0.01,0.07]

0.033
[-0.01,0.07]

0.032
[-0.01,0.07]

0.037
[-0.00,0.08]

Physician has cardiology
fellowship training

0.104
[-0.43,0.64]

0.116
[-0.35,0.58]

0.159
[-0.30,0.62]

0.120
[-0.32,0.56]

0.176
[-0.27,0.62]

Physician has interventional
cardiology fellowship training

0.331
[-0.13,0.80]

0.526*
[0.10,0.95]

0.485*
[0.06,0.91]

0.438*
[0.02,0.86]

0.315
[-0.12,0.75]

0.002***
[0.00,0.00]

0.001***
[0.00,0.00]

0.001*
[0.00,0.00]

0.001*
[0.00,0.00]

-0.002**
[-0.00,-0.00]

-0.001**
[-0.00,-0.00]

-0.001
[-0.00,0.00]

-0.001
[-0.00,0.00]

Practice average doc age (among
non-self physicians)

0.005
[-0.01,0.03]

0.005
[-0.01,0.02]

0.005
[-0.01,0.02]

Practice average doc yrs exper.
(among non-self physicians)

-0.020
[-0.06,0.02]

-0.020
[-0.06,0.02]

-0.020
[-0.06,0.02]

Practice fraction of docs with
cardiology fellowship training

0.339
[-0.29,0.96]

0.311
[-0.30,0.93]

0.303
[-0.31,0.92]

Practice fraction of docs with
intvntl card fellowship training

-0.230
[-0.77,0.31]

-0.143
[-0.67,0.39]

-0.163
[-0.70,0.38]

Practice total # DES placed preDES safety pub (non-self docs)

0.000*
[0.00,0.00]

0.000*
[0.00,0.00]

Practice total cumulative # DES
placed (by non-self physicians)

-0.000*
[-0.00,-0.00]

-0.000*
[-0.00,-0.00]

Physician group size (number of
cardiologists)
Physician age (years)

Physician total num. DES placed
before safety concerns
Physician cumulative total
number of DES implanted

Physician time (quarters) to
initial DES adoption

0.045
[-0.01,0.10]

Physician time (quarters) from
adoption to max DES use

-0.003
[-0.02,0.02]

Physician initial level DES use
(increase) upon adoption

-0.026
[-0.60,0.54]

Physician full level DES use
(increase) after adoption

-0.919
[-4.39,2.55]

chi2

1.917

14.001

43.256

49.869

61.802

P

0.166

0.016

0.000

0.000

0.000

0.000

N

1912.000

1912.000

1912.000

1912.000

1912.000

1912.000

523

523

523

523

523

523

Unique docs

61.417
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Table 6.12: Effect of physician practice size (all cardiologists) on early initial DES
disadoption (logit analysis) and risk of initial DES disadoption (hazard analysis), with
categorical group size measure
BINARY OUTCOME, LOGIT ANALYSIS

DISCRETE-TIME HAZARD ANALYSIS

Model 7
(β/[95%CI])

Model 6
(β/[95%CI])

Model 7
(β/[95%CI])

Model 6
(β/[95%CI])

Physician group size category:
2-5 docs/practice

0.602
[-0.04,1.24]

Ref

0.195
[-0.11,0.50]

Ref

Physician group size category:
2-5 docs/practice

Physician group size category:
6-12 docs/practice

0.507
[-0.12,1.13]

-0.284
[-0.86,0.29]

0.166
[-0.14,0.47]

-0.065
[-0.34,0.21]

Physician group size category:
6-12 docs/practice

Physician group size category:
13+ docs/practice

0.404
[-0.28,1.09]

-0.370
[-1.10,0.36]

0.306
[-0.03,0.64]

0.068
[-0.29,0.42]

Physician group size category:
13+ docs/practice

Physician age (at time of DES
safety concern publicization)

-0.019
[-0.09,0.05]

-0.011
[-0.10,0.07]

-0.060**
[-0.1,-0.02]

-0.051*
[-0.1,-0.01]

Physician age (years)

Physician years of experience (at
time of DES safety concern pub)

-0.001
[-0.07,0.07]

-0.010
[-0.09,0.07]

0.039*
[0.00,0.08]

0.036
[-0.00,0.08]

Physician years of experience

Physician has cardiology
fellowship training

0.564
[-0.25,1.38]

0.522
[-0.35,1.39]

0.214
[-0.21,0.64]

0.160
[-0.29,0.61]

Physician has cardiology
fellowship training

Physician has interventional
cardiology fellowship training

1.004
[-0.00,2.01]

1.245*
[0.17,2.32]

0.210
[-0.22,0.64]

0.328
[-0.10,0.75]

Physician has interventional
cardiology fellowship training

Physician total num. DES placed
before safety concerns

0.002**
[0.00,0.00]

0.003**
[0.00,0.00]

0.001***
[0.00,0.00]

0.001*
[0.00,0.00]

Physician total num. DES placed
before safety concerns

Physician total #. DES placed
from safety concern pub to 2007

-0.004*
[-0.01,-0.0]

-0.005*
[-0.01,-0.0]

-0.001*
[-0.00,-0.0]

-0.001
[-0.00,0.00]

Physician cumulative total
number of DES implanted

Practice average doc age at time
of DES safety concern pub.

0.006
[-0.03,0.05]

0.006
[-0.01,0.03]

Practice average doc age (among
non-self physicians)

Practice average doc yrs exper at
time of DES safety concern pub

-0.003
[-0.05,0.05]

-0.021
[-0.06,0.02]

Practice average doc yrs exper.
(among non-self physicians)

Practice fraction of docs with
cardiology fellowship training

0.973
[-0.30,2.24]

0.277
[-0.34,0.90]

Practice fraction of docs with
cardiology fellowship training

Practice fraction of docs with
intvntl card fellowship training

-1.270*
[-2.3,-0.24]

-0.154
[-0.68,0.37]

Practice fraction of docs with
intvntl card fellowship training

Practice total # DES placed
before DES safety concerns

-0.000
[-0.00,0.00]

0.000*
[0.00,0.00]

Practice total #. DES placed preDES safety pub (non-self docs)

Practice total # DES placed from
safety concern pub. to 2007

0.000
[0.00,0.00]

-0.000*
[-0.00,-0.0]

Practice total cumulative #. DES
placed (by non-self physicians)

Physician time (quarters) to
initial DES adoption

-0.005
[-0.13,0.12]

-0.035
[-0.17,0.10]

0.050
[-0.00,0.10]

0.046
[-0.01,0.10]

Physician time (quarters) to
initial DES adoption

Physician time (quarters) from
adoption to max DES use

0.027
[-0.01,0.06]

0.020
[-0.02,0.06]

0.005
[-0.01,0.02]

-0.003
[-0.02,0.02]

Physician time (quarters) from
adoption to max DES use

Physician initial level DES use
(increase) upon adoption

-0.061
[-1.08,0.95]

-0.065
[-1.18,1.05]

-0.028
[-0.56,0.51]

-0.049
[-0.62,0.52]

Physician initial level DES use
(increase) upon adoption

Physician full level DES use
(increase) after adoption

-2.474
[-8.94,3.99]

-5.209
[-13.3,2.89]

-0.791
[-3.68,2.09]

-0.805
[-4.34,2.73]

Physician full level DES use
(increase) after adoption

chi2

31.463

43.443

59.755

60.358

chi2

p

0.003

0.000

0.000

0.000

p

N

532.000

471.000

2440.000

1912.000

N

532

471

630

523

Incremental LR chi2

3.56704358

4.08428673

Prob > incrm chi2

0.46775770

0.39471904

Unique docs

Unique docs
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Table 6.13: Effect of physician group size, continuous measures, on time to initial DES
disadoption, using different group measures (organization and physician type) and
analysis methods (OLS and IV)

Physician type

Time to initial DES disadoption
All
docs
Stent
docs
All
docs
Stent
docs

Physician group size
(continuous count)
Physician group size
(continuous count)
Physician group size
(continuous count)
Physician group size
(continuous count)

Practice
β/[95%CI]
0.005
[-0.03,0.04]
0.014
[-0.05,0.08]
0.138
[-0.02,0.29]
0.246
[-0.04,0.53]

Organization type
Office
Hospital
β/[95%CI]
β/[95%CI]
0.047
0.001
[-0.01,0.11]
[-0.00,0.00]
0.083
0.001
[-0.01,0.17]
[-0.00,0.00]
-0.100
X
[-0.31,0.11]
-0.206
X
[-0.49,0.07]

OLS
analysis
(non-IV)
IV
analysis
(2SLS)

Table 6.14: Effect of physician group size, categorical measures, on time to initial DES
disadoption, using different group measures (organization and physician type) and
analysis methods (OLS and IV)
Time to initial DES disadoption

Physician type

All
docs

Stent
docs

All
docs

Stent
docs

Physician group
category #2
Physician group
category #3
Physician group
category #4
Physician group
category #5
Physician group
category #2
Physician group
category #3
Physician group
category #4
Physician group
category #5
Physician group
category #2
Physician group
category #3
Physician group
category #4
Physician group
category #2
Physician group
category #3
Physician group
category #4

Practice
β/[95%CI]

Organization type
Office
β/[95%CI]

Hospital
β/[95%CI]

Ref

Ref

Ref

0.462
[-0.16,1.09]
0.249
[-0.57,1.06]

-0.056
[-1.15,1.04]
0.887
[-0.46,2.23]

X

X

-0.319
[-1.10,0.46]
-0.953**
[-1.67,-0.24]
-0.358
[-1.12,0.40]

Ref

Ref

Ref

-0.109
[-0.79,0.57]
0.524
[-0.72,1.77]

-0.708
[-1.78,0.36]
1.682
[-0.17,3.53]

X

X

-1.209**
[-1.97,-0.45]
-1.413***
[-2.08,-0.74]
-0.779*
[-1.51,-0.04]

Ref

Ref

3.085
[-20.70,26.87]
3.747
[-9.60,17.09]

0.569
[-8.19,9.33]
-1.981
[-6.48,2.52]

Ref

Ref

-1.897
[-13.00,9.20]
5.693
[-1.29,12.68]

-3.192
[-8.26,1.87]
-2.983
[-8.07,2.10]

OLS
analysis
(non-IV)

X
X
X
X

IV
analysis
(2SLS)

X
X

For practice and office groups: category#1 = 1 doc; category#2 = 2-5 docs; category#3 = 6-12 docs;
category #4 = 13+ docs; For hospital groups: category#1 = 1-29 docs; category #2=30-44 docs;
category#3 = 45-59 docs; category#4 = 60-99; category#5 = 100+ docs
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Table 6.15: Effect of physician group size, continuous measures, on initial extent of DES
disadoption, using different group measures (organization and physician type) and
analysis methods (OLS and IV)

Physician type

Initial extent of DES disadoption
All
docs
Stent
docs
All
docs
Stent
docs

Physician group size
(continuous count)
Physician group size
(continuous count)
Physician group size
(continuous count)
Physician group size
(continuous count)

Practice
β/[95%CI]
0.000
[-0.00,0.00]
-0.000
[-0.00,0.00]
0.001
[-0.00,0.01]
-0.000
[-0.01,0.01]

Organization type
Office
Hospital
β/[95%CI]
β/[95%CI]
-0.000
-0.000
[-0.00,0.00]
[-0.00,0.00]
-0.000
-0.000
[-0.00,0.00]
[-0.00,0.00]
-0.013*
X
[-0.03,-0.00]
-0.010
X
[-0.02,0.00]

OLS
analysis
(non-IV)
IV
analysis
(2SLS)

Table 6.16: Effect of physician group size, categorical measures, on initial extent of DES
disadoption, using different group measures (organization and physician type) and
analysis methods (OLS and IV)
Initial extent of DES disadoption

Physician type

All
docs

Stent
docs

All
docs

Stent
docs

Physician group
category #2
Physician group
category #3
Physician group
category #4
Physician group
category #5
Physician group
category #2
Physician group
category #3
Physician group
category #4
Physician group
category #5
Physician group
category #2
Physician group
category #3
Physician group
category #4
Physician group
category #2
Physician group
category #3
Physician group
category #4

Practice
β/[95%CI]

Organization type
Office
Hospital
β/[95%CI]
β/[95%CI]

Ref

Ref

Ref

-0.027*
[-0.05,-0.00]
-0.026
[-0.06,0.01]

0.001
[-0.04,0.05]
-0.008
[-0.06,0.05]

X

X

-0.000
[-0.03,0.03]
0.010
[-0.02,0.04]
-0.002
[-0.03,0.03]

Ref

Ref

Ref

-0.031*
[-0.06,-0.00]
0.014
[-0.03,0.06]

-0.026
[-0.07,0.02]
0.004
[-0.07,0.08]

X

X

0.004
[-0.03,0.03]
0.009
[-0.02,0.04]
-0.005
[-0.03,0.02]

Ref

Ref

0.170
[-0.88,1.22]
0.129
[-0.46,0.72]

-0.317
[-0.83,0.19]
-0.189
[-0.45,0.07]

Ref

Ref

0.118
[-0.31,0.55]
-0.038
[-0.31,0.23]

-0.153
[-0.41,0.10]
-0.221
[-0.48,0.04]

OLS
analysis
(non-IV)

X
X
X
X

IV
analysis
(2SLS)

X
X

For practice and office groups: category#1 = 1 doc; category#2 = 2-5 docs; category#3 = 6-12 docs;
category #4 = 13+ docs; For hospital groups: category#1 = 1-29 docs; category #2=30-44 docs;
category#3 = 45-59 docs; category#4 = 60-99; category#5 = 100+ docs
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Table 6.17: Effect of physician group size, continuous measures, on time to minimum
DES use, using different group measures (organization and physician type) and analysis
methods (OLS and IV)

Physician type

Time to minimum DES use
All
docs
Stent
docs
All
docs
Stent
docs

Physician group size
(continuous count)
Physician group size
(continuous count)
Physician group size
(continuous count)
Physician group size
(continuous count)

Practice
β/[95%CI]
-0.052
[-0.13,0.03]
-0.073
[-0.21,0.07]
-0.043
[-0.34,0.26]
-0.114
[-0.66,0.43]

Organization type
Office
Hospital
β/[95%CI]
β/[95%CI]
-0.077
0.003
[-0.20,0.05]
[-0.01,0.01]
-0.007
0.003
[-0.20,0.18]
[-0.01,0.01]
0.191
X
[-0.32,0.70]
0.110
X
[-0.51,0.73]

OLS
analysis
(non-IV)
IV
analysis
(2SLS)

Table 6.18: Effect of physician group size, categorical measures, on time to minimum
DES use, using different group measures (organization and physician type) and analysis
methods (OLS and IV)
Time to minimum DES use

Physician type

All
docs

Stent
docs

All
docs

Stent
docs

Physician group
category #2
Physician group
category #3
Physician group
category #4
Physician group
category #5
Physician group
category #2
Physician group
category #3
Physician group
category #4
Physician group
category #5
Physician group
category #2
Physician group
category #3
Physician group
category #4
Physician group
category #2
Physician group
category #3
Physician group
category #4

Practice
β/[95%CI]

Organization type
Office
β/[95%CI]

Hospital
β/[95%CI]

Ref

Ref

Ref

-0.995
[-2.30,0.31]
-0.879
[-2.59,0.83]

-1.477
[-3.84,0.88]
-1.963
[-4.86,0.94]

X

X

0.813
[-0.82,2.44]
1.281
[-0.21,2.77]
1.227
[-0.36,2.82]

Ref

Ref

Ref

-0.187
[-1.63,1.26]
-0.622
[-3.27,2.03]

1.533
[-0.80,3.86]
-0.468
[-4.50,3.56]

X

X

1.215
[-0.38,2.81]
1.726*
[0.32,3.13]
1.584*
[0.04,3.12]

Ref

Ref

1.453
[-43.43,46.33]
0.671
[-24.50,25.85]

16.678
[-16.77,50.13]
-2.387
[-19.57,14.80]

Ref

Ref

5.872
[-15.71,27.45]
-2.649
[-16.24,10.94]

5.272
[-6.73,17.27]
-2.570
[-14.62,9.48]

OLS
analysis
(non-IV)

X
X
X
X

IV
analysis
(2SLS)

X
X

For practice and office groups: category#1 = 1 doc; category#2 = 2-5 docs; category#3 = 6-12 docs;
category #4 = 13+ docs; For hospital groups: category#1 = 1-29 docs; category #2=30-44 docs;
category#3 = 45-59 docs; category#4 = 60-99; category#5 = 100+ docs
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Table 6.19: Effect of physician group size, continuous measures, on full extent of DES
disadoption, using different group measures (organization and physician type) and
analysis methods (OLS and IV)

Physician type

Full extent of DES disadoption
All
docs
Stent
docs
All
docs
Stent
docs

Physician group size
(continuous count)
Physician group size
(continuous count)
Physician group size
(continuous count)
Physician group size
(continuous count)

Practice
β/[95%CI]
0.002
[-0.00,0.00]
0.000
[-0.00,0.00]
-0.006
[-0.02,0.00]
-0.015
[-0.04,0.00]

Organization type
Office
Hospital
β/[95%CI]
β/[95%CI]
-0.004
-0.000
[-0.01,0.00]
[-0.00,0.00]
-0.003
-0.000
[-0.01,0.00]
[-0.00,0.00]
-0.014
X
[-0.03,0.00]
-0.016
X
[-0.04,0.00]

OLS
analysis
(non-IV)
IV
analysis
(2SLS)

Table 6.20: Effect of physician group size, categorical measures, on full extent of DES
disadoption, using different group measures (organization and physician type) and
analysis methods (OLS and IV)
Full extent of DES disadoption

Physician type

All
docs

Stent
docs

All
docs

Stent
docs

Physician group
category #2
Physician group
category #3
Physician group
category #4
Physician group
category #5
Physician group
category #2
Physician group
category #3
Physician group
category #4
Physician group
category #5
Physician group
category #2
Physician group
category #3
Physician group
category #4
Physician group
category #2
Physician group
category #3
Physician group
category #4

Practice
β/[95%CI]

Organization type
Office
Hospital
β/[95%CI]
β/[95%CI]

Ref

Ref

Ref

-0.032
[-0.08,0.01]
0.008
[-0.05,0.07]

0.049
[-0.03,0.13]
-0.025
[-0.12,0.07]

X

X

0.008
[-0.05,0.07]
0.023
[-0.03,0.08]
-0.012
[-0.07,0.04]

Ref

Ref

Ref

-0.010
[-0.06,0.04]
0.015
[-0.07,0.10]

0.034
[-0.04,0.11]
-0.075
[-0.21,0.06]

X

X

0.034
[-0.02,0.09]
0.045
[-0.00,0.09]
0.019
[-0.03,0.07]

Ref

Ref

1.136
[-2.97,5.24]
0.585
[-1.72,2.89]

-0.036
[-0.66,0.59]
-0.279
[-0.60,0.04]

Ref

Ref

0.502
[-0.69,1.69]
-0.500
[-1.25,0.25]

-0.304
[-0.77,0.16]
-0.276
[-0.75,0.19]

OLS
analysis
(non-IV)

X
X
X
X

IV
analysis
(2SLS)

X
X

For practice and office groups: category#1 = 1 doc; category#2 = 2-5 docs; category#3 = 6-12 docs;
category #4 = 13+ docs; For hospital groups: category#1 = 1-29 docs; category #2=30-44 docs;
category#3 = 45-59 docs; category#4 = 60-99; category#5 = 100+ docs
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Table 6.21: Effect of physician group size, continuous measures, on area above DES
disadoption curve, using different group measures (organization and physician type)
and analysis methods (OLS and IV)

Physician type

Full extent of DES disadoption
All
docs
Stent
docs
All
docs
Stent
docs

Physician group size
(continuous count)
Physician group size
(continuous count)
Physician group size
(continuous count)
Physician group size
(continuous count)

Practice
β/[95%CI]
0.002
[-0.02,0.03]
-0.006
[-0.05,0.04]
-0.005
[-0.10,0.11]
-0.039
[-0.25,0.17]

Organization type
Office
Hospital
β/[95%CI]
β/[95%CI]
-0.021
-0.001
[-0.07,0.02]
[-0.00,0.00]
-0.006
-0.001
[-0.08,0.06]
[-0.00,0.00]
-0.037
X
[-0.16,0.09]
-0.088
X
[-0.26,0.08]

OLS
analysis
(non-IV)
IV
analysis
(2SLS)

Table 6.22: Effect of physician group size, categorical measures, on area above of DES
disadoption curve, using different group measures (organization and physician type)
and analysis methods (OLS and IV)
Full extent of DES disadoption

Physician type

All
docs

Stent
docs

All
docs

Stent
docs

Physician group
category #2
Physician group
category #3
Physician group
category #4
Physician group
category #5
Physician group
category #2
Physician group
category #3
Physician group
category #4
Physician group
category #5
Physician group
category #2
Physician group
category #3
Physician group
category #4
Physician group
category #2
Physician group
category #3
Physician group
category #4

Practice
β/[95%CI]

Organization type
Office
Hospital
β/[95%CI]
β/[95%CI]

Ref

Ref

Ref

-0.479*
[-0.92,-0.04]
-0.059
[-0.64,0.52]

-0.290
[-1.09,0.51]
-0.216
[-1.20,0.77]

X

X

-0.163
[-0.73,0.40]
0.011
[-0.50,0.53]
-0.227
[-0.77,0.32]

Ref

Ref

Ref

-0.075
[-0.56,0.41]
0.225
[-0.66,1.11]

0.177
[-0.69,1.05]
0.144
[-1.25,1.54]

X

X

0.133
[-0.41,0.67]
0.239
[-0.24,0.72]
0.019
[-0.50,0.54]

Ref

Ref

17.578
[-44.55,79.7]
10.362
[-25.14,45.9]

-0.082
[-3.87,3.71]
-0.076
[-4.29,4.14]

Ref

Ref

5.217
[-3.37,13.80]
-2.367
[-8.82,4.09]

-2.424
[-7.22,2.38]
-1.378
[-6.41,3.65]

OLS
analysis
(non-IV)

X
X
X
X

IV
analysis
(2SLS)

X
X

For practice and office groups: category#1 = 1 doc; category#2 = 2-5 docs; category#3 = 6-12 docs;
category #4 = 13+ docs; For hospital groups: category#1 = 1-29 docs; category #2=30-44 docs;
category#3 = 45-59 docs; category#4 = 60-99; category#5 = 100+ docs
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CHAPTER 7: Differential relationships of disadoption and adoption to
physician group size
In the previous chapters, I investigated the relationship between physician group size and
technology disadoption behavior, from both theoretical and empirical perspectives. In
this chapter, I extend that investigation by performing another type of analysis. As
discussed multiple times above (e.g. in Chapters 2 and 3), many parallels can and should
be drawn between technology adoption and disadoption due to the many similarities
between the two processes. In Chapter 5, I used the empirical setting of cardiologists’
DES use to explore the relationships between these two related phenomena, and in
Chapter 6 I studied the relationship between cardiologist group size and DES
disadoption, while controlling for adoption behavior as a potential explanatory factor of
disadoption. However, following these analyses, we now come to another natural
question by extension: how is the relationship between physician group size and
disadoption different from the relationship between physician group size and adoption?
That is, if we believe the two processes are similar and we observe that group size
influences physician behavior for one of the processes (disadoption), how does group size
differentially influence the other process? In this chapter, I will explore this question.
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7.1 – Research questions
1) What is the observed empirical differential relationship between a physician’s group
size and that physician’s time to initial disadoption and time to initial adoption, as
studied in the setting of cardiologist use of drug-eluting stents?
2) What are the observed empirical differential relationships between a physician’s
group size and the other measures of physician’s adoption and disadoption of DES
(namely, time to maximum/minimum use, initial extent of adoption/disadoption, and
full extent of adoption/disadoption)?
3) Can empirical analysis identify a causal differential relationship between a physician’s
group size and that physician’s DES adoption and disadoption behaviors, by using an
instrumental variable for physician group size?
5) Given that a physician can belong to multiple different groups (e.g. office, practice,
and hospital), how do the sizes of those different groups relate differentially to that
physician’s DES adoption and disadoption behavior, as measured with the various
different measures?

7.2 – Data and methods
Data processing
The data used for empirical analyses in this chapter are the same as those used in
Chapters 5 and 6, so those chapters can be referenced for details of the original data and
basic data processing steps. However, for the analyses planned here, additional data
processing is necessary.
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In order to perform the desired analyses for this chapter, a significant restructuring of the
data is required. For many of the analyses above, the dataset was ultimately reduced to
either the physician-quarter level (with one observation per physician-quarter) or the
physician level (one observation per physician). However, for this chapter, I restructure
the data so that it is instead at the physician-phase-quarter level or physician-phase level,
where “phase” represents a larger time period, which is either the “DES adoption phase”
or the “DES disadoption phase.” The beginning and end dates of each phase are a
function of the conditions used for the DES disadoption definition that is used for the
given analysis (because these conditions determine, among other things, how early DES
disadoption is possible, as discussed in Chapter 5), but for the most commonly used DES
disadoption definition (for which physicians become “at risk” for disadoption after the
publicization of DES safety concerns in September 2006), the “DES adoption phase”
runs from 2003Q2 to 2005Q2, and the “DES disadoption phase” runs from 2006Q3 to
2008Q130. In transforming the data to be organized at the phase-level, I combine the
DES adoption measures with their analogous DES disadoption measures to make single
“DES change” measures. For example, time to initial DES adoption is combined with
time to initial DES disadoption to create a single time to initial DES change variable,
with the two different outcomes distinguished by a separate “phase” variable, which takes

30

One can observe here that the adoption and disadoption phases are not perfectly adjacent, which is
intentional. The gap between these phases represents the time when global DES use was generally high
and not changing, i.e. after most physicians had fully adopted DES, but had not yet started the disadoption
process.
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on a different (binary) value for adoption and disadoption outcomes31. The relevance and
value of this data transformation will be discussed in more detail below, when the
methods used for analyses in this chapter will be described.

Another important data processing step required here involves physician group size. As
described in Chapter 6, physician group size can be measured at (at least) 3 levels: office,
practice, and hospital. Whereas hospital group size information comes from the same
source as the coronary stent placement information (i.e. the discharge datasets), the office
and practice group size information comes from a separate source: the SK&A database.
As a result, when studying how a physician’s office or practice size relates to that
physician’s DES adoption behavior, we face an issue: the SK&A dataset only dates back
to 2005 (as mentioned in Chapter 5), whereas DES were approved by the FDA in 2003
and many physicians started using the technology in 2003 and 2004. Thus, if I want to
relate office or practice size to a physician’s DES adoption behavior, I need to make
some assumptions and impute, or “back-fill,” physicians’ office and practice size in 2003
and 2004. To do this, I simply take a physician’s group size in 2005 (or her earliest year
of observation) and carry that group size measurement back into the preceding years for
which it is missing. Of course, doing this assumes that physicians’ office and practice
sizes did not change from 2003 to 2005 (or later, if a physician first appears in the data
later), which we don’t believe to be strictly true. However, even if this assumption is not
globally true, as long as it is equally valid for all individuals and there are not systematic
31

In the terminology or syntax of Stata (the statistical software package used for the majority of data
processing and analysis performed in this dissertation), this basically amounts to using the “reshape”
function to reshape the data from wide form to long form.
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differences between individuals for whom the assumption is more or less valid, then this
assumption will not introduce systematic bias into the subsequent analyses.

To further address potential concerns about this imputation assumption, it is also worth
noting here that for many analyses, the dataset will be organized at the physician-phase
level, so each physician will have one observation each for the DES adoption and
disadoption phases. When organized as such, the variables defined at the quarter- or
year-level, which include group size, are averaged to take a single, phase-specific value.
In this case, for the most common DES disadoption definitions, the adoption phase
includes not only 2003 and 2004, but also 2005, for which office and practice size
measures were originally found in the data and not back-filled. Of course, concerns
about data extrapolation and imputation of values still exist, but they are mitigated by the
fact that the final average values of interest include as inputs the “true,” non-extrapolated
values (as opposed to having average values that are based only on extrapolated or
imputed values).

Methods
Though the appearance of the data is much different after the above processing, with
observations now at the phase-level (whether physician-phase or physician-phasequarter) and variables now combining previously separate measures (i.e. DES adoption
and disadoption measures), the outcome variables are still continuous and of the same
general appearance and magnitude as before, so the same types of analyses as were used
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in Chapter 6 can be used here. Of course, there are some basic changes, though.
Whereas the primary outcome variable of interest in the preceding two chapters was time
to initial DES disadoption, after data transformation described above, that outcome
variable becomes time to initial DES change, with similar changes for each of the
secondary outcome variables32. The data transformation also changes the potential
explanatory variables. Though I was able to control for all four DES adoption measures
in analyses in the past two chapters, those adoption measures have now been combined
with the disadoption measures. As a result, the only adoption/disadoption relevant
covariates that can be included in analyses here are, for a given “DES change” measure,
the three other combined “DES change” measures. For example, when the outcome
variable is time to initial DES change, I can control for time to max/min DES use, initial
extent of DES change, and full extent of DES change.

Regardless of the outcome variable, the primary explanatory variable of interest here is
physician group size. Of course, given that the outcome variable now represents a
combined DES adoption and disadoption measure, the interpretation of the regression
coefficient on this explanatory variable will now be different. However, as said above,
one of my core interests in this chapter is identifying the differential relationship between
group size and DES adoption and disadoption. This can be accomplished due to the data
transformation, which produced an “adoption phase” indicator variable, which has a
32

To specifically address the other adoption/disadoption measure along the time dimension: though this
measure was previously referred to as time to maximum DES use for the adoption phase and time to
minimum DES use for the disadoption phase, I will refer to the combined outcome as time to maximum DES
change, because in fact, the maximum and minimum DES use points were really chosen to measure the
biggest change in DES use after the adoption/disadoption processes began.

183
value of 1 for the disadoption phase and 0 for the adoption phase. The interaction of this
phase indicator variable with group size in the regression analysis produces a coefficient
that indicates the relationship (magnitude and sign) between an increase in group size and
the DES disadoption outcome measure, relative to the same increase in group size effect
and the analogous DES adoption outcome measure. Thus, the coefficient on this
interaction term quantifies empirically the differential relationship that I seek to
determine here, allowing a measurement of the difference between the two processes that
are related and seem generally very similar.

Another advantage allowed by the above data transformation also shows up in the righthand-side of the regression analyses to be performed here. Whereas in the previous
chapters, the outcome variables (i.e. DES disadoption measures) were determined at the
physician level, the outcome variables used in this chapter are determined at the
physician-phase level. As a result, there is within-physician variation of the outcome
variable, which allows the use of physician-level fixed effects in these analyses. In the
previous analyses, I could only control for sets of specified physician characteristics (e.g.
training and DES use) because physician-level fixed effects would have been perfectly
collinear with the outcomes. The use of physician-level fixed effects here, though, is
preferable because they can identify as much variation as the individual physician-level
characteristic variables, while also controlling for unobserved physician-level
characteristics that are time-invariant. Thus, the use of physician-level fixed effects helps
address endogeneity issues, including the concern that physicians may select into
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practices of different sizes according to unobserved characteristics that ultimately also
relate to technology disadoption (and/or adoption) behavior. Admittedly, one downside
to the inclusion of physician-level fixed effects is that we cannot simultaneously
determine the relationship between the various previously-studied physician-level factors
and the outcome variable of interest. However, as those other variables were generally
intended as covariates and were not the primary explanatory variable of interest, the
tradeoff is deemed to be worthwhile.

7.3 – Results
Table 7.1 provides the results from the standard OLS regression analysis of the new
primary outcome variable, time to initial DES change, against group size. First, we
observe a positive and statistically significant coefficient on the non-interacted group size
term, indicating that an increase in group size is associated with a physician starting the
DES change process (which views adoption and disadoption together) later. Next, we see
that there is a negative and statistically significant coefficient on the term that interacts
group size with an indicator for the disadoption phase. Furthermore, the coefficient on
the interaction terms is larger in magnitude than the coefficient on group size, indicating
that the impact of group size on disadoption is opposite and greater than its impact on
adoption. We also observe that the covariates—physician-level fixed effects and the
other three measures of DES behavior change—provide significant predictive power,
with each of the DES adoption/disadoption measures having a statistically significant
coefficient.
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Unlike in the previous chapters, where analyses of the three secondary disadoption
outcomes rarely (if ever) provided noteworthy results, the analyses of initial extent of
DES change, time to maximum DES change, and full extent of DES change provide
results (which are given in Tables 7.2 – 7.4) with statistically significant, non-zero
values. The analysis of each of these three outcomes, like the analysis of the primary
outcome, produces a positive coefficient estimate on the group size term and a negative
coefficient estimate on the interaction term. Furthermore, the individual coefficients on
each of the DES adoption/disadoption behavior covariates are also all statistically
significant.

Due to concerns about the endogeneity of physician group size (as discussed above and in
Chapter 6), I repeat the analysis for each of the DES behavior outcome variables,
instrumenting for physician group size. Unfortunately, the results for these IV analyses,
which are shown in Tables 7.5 – 7.8, find generally no statistically significant results
between either group size or the interaction term and any of the DES
adoption/disadoption outcomes (with the possible exception of full extent of DES
change), with most of the coefficients of interest being statistically indistinguishable from
zero.

Repeating the same general approach that was used in Chapter 6, I also investigate
different measurements of group size and how those different measurements relate to
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DES disadoption behavior. Table 7.9 shows the results from the set of analyses with time
to initial DES change as the dependent variable and group size (along with its interaction
with a disadoption phase indicator) is the independent variable, and with variation in the
method for measuring group size across analyses, i.e. with alteration of the type of
organization (practice, office, or hospital) and type of cardiologist (general or excluding
those who do not implant stents) that are considered when counting physicians. We first
notice that, regardless of which type of organization or physicians are considered when
measuring group size, the signs on the coefficient estimates are the same: the coefficient
estimate on group size is positive, whereas the coefficient on the interaction term (of
group size and disadoption phase) is negative. Next, as was the case in Chapter 6, we
observe that the coefficients are of similar magnitude for the practice-based group size
and office-based group size, while the coefficients for hospital-based group size
measurements are of considerably smaller. Also repeating a previously observed trend,
we can see that when group size measurements only count cardiologists who place stents,
as opposed to all cardiologists, the magnitude of the coefficient estimates is again larger.
Interestingly, whereas instrumenting for practice-based group size increases the
magnitude of the coefficient estimates but eliminates the statistical significance,
instrumenting for office-based group size does not eliminate the observed statistical
significance of coefficients, yet increases the magnitude of the estimates.

The results for the examination of how different group size measurements relate to the
secondary outcomes of interest (initial extent of DES change, time to maximum DES
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change, and full extent of DES change) are provided in Tables 7.10 – 7.12. Of note, we
see that in all cases the observed pattern in coefficient signs remains: there is positive
sign on the coefficient estimate for group size, but a negative sign on the coefficient
estimate for the interaction term. However, in most cases, the results are not statistically
significant. One set of exceptions, though, are the coefficients from the analysis of effect
of hospital-based group size on initial extent of DES change, seen in Table 7.10. Also,
the results in Table 7.12 show strong significant relationship between group size and full
extent of DES change, both for the group size and interaction coefficients, regardless of
which organization and physician type were used to measure group size. Generally
speaking, these coefficients relating group size to secondary DES behavior outcomes also
exhibit many of the trends observed in the analysis of time to initial DES change, e.g.
smaller magnitude for hospital-based group measurement, larger magnitude for stentimplanting cardiologist measurements, and (where there is sufficient statistical
significance to differentiate the point estimates from 0) larger magnitude for IV analyses.

7.4 – Discussion
As described above, the purpose of the analyses performed in this chapter is to identify
the difference in how group size influences DES disadoption behavior relative to how it
influences DES adoption behavior. Though the approach used here addresses this goal, it
comes with caveats. One major challenge is the interpretation of coefficients on variables
that now represent a combination of DES adoption and disadoption behavior. For
example, the coefficient on group size in these analyses indicates the relationship
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between group size and both adoption and disadoption together. If these processes are
separate and different, they are conflated into a single measure here, thus losing their
distinction. However, the interaction of group size with the disadoption phase indicator
variable separates out the effect of group size on disadoption. So, to determine the net
effect of group size on DES disadoption, these two coefficients need to be added
together. If group size has an identical impact on DES adoption and disadoption, the
coefficient estimate on the interaction term should be indistinguishable from zero.

Thus, it is interesting to observe that, in the analysis of time to initial DES change (in
Tables 7.1, 7.5, and 7.9), we observe a positive coefficient estimate on group size but a
larger negative coefficient on the interaction term, indicating that an increase in group
size is associated with an decrease in time to DES disadoption, but an increase in time to
DES adoption. Interestingly, this observation indicates that the two processes are not
symmetric, disagreeing with the theoretical model established in Chapter 4, but agreeing
with the empirical results noted in both Chapters 5 and 6. Despite belief that the
technology adoption and disadoption processes are theoretically similar in many ways,
the empirical results, now estimated three different ways, all indicate that along the
dimensions measured here, these two processes are notably different.

The observed difference in the effect of group size on adoption and disadoption is also
interesting in its own right, but it is also somewhat confusing that the estimated net effect
of group size on time to initial disadoption is of the opposite sign as was observed in
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Chapter 6 analyses. One major difference between these analyses and those performed in
Chapter 6 is the difference in covariates used in the analyses. Whereas Chapter 6 used a
long list of physician- and practice-level characteristics, along with DES adoption
measures, the analyses performed here replace physician- and practice-level
characteristics with physician-level fixed effects and DES adoption measures with the
combined adoption/disadoption measures. Though these combined adoption/disadoption
covariates have statistically significant coefficient estimates in many of the analyses here,
these coefficients are both complicated and confusing to interpret. For example, because
DES disadoption behaviors are included in both the covariate and outcome variable, the
observed relationship may be the result of correlation of different disadoption behaviors,
unlike the relationships between adoption and disadoption measures that were studied in
Chapters 5 and 6.

It should be noted in this discussion that (as described above), in order to study the
relationship between group size and technology adoption, I need to impute practice and
office size measures in 2003 and 2004. Though, as discussed above, we do not expect
there to be systematic within-sample bias in these imputed group size measures, there is
still a concern regarding global trends in group size over time. Namely, as discussed
earlier, physician practice have been systematically increasing in size (on average) over
recent years, which may mean that my backward imputation of group size overestimates
practice sizes in 2003 and 2004. If this is true, it may indicate that the coefficient
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estimates on the group size variable are underestimates, which could partially explain the
observed net negative effect of group size on time to initial DES disadoption.

Ultimately, the analyses performed here provide some insight into how group size
differentially relates to DES adoption behavior and DES disadoption behavior, but these
insights are somewhat limited and are counterbalanced by a series of new questions.
More investigation into this topic is required to develop a complete understanding of this
topic.
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Table 7.1: Effect of practice size (all cardiologists) on time to initial DES change, basic
OLS regression results
Physician time (quarters) to
initial DES change

Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Practice size (number of
cardiologists)

0.044**
[0.02,0.07]

0.059*
[0.00,0.12]

0.062*
[0.01,0.11]

-0.116***
[-0.14,-0.09]

-0.121***
[-0.15,-0.09]

-0.114***
[-0.15,-0.08]

Interaction: practice size X
disadoption indicator
Physician time (quarters) to
maximum DES change

-0.033*
[-0.07,-0.00]

Physician initial extent (size)
of DES change

6.050***
[5.13,6.97]

Physician full extent (size) of
DES change

-3.176***
[-4.00,-2.35]

r2
F
p
N
Unique docs
Physician FEs
Incremental F stata
Prob > incrm F

0.044
34.335
0.000
1500.000
639

0.502
1.350
0.000
1500.000
639
X
1.236083228
0.001972238

0.599
1.988
0.000
1500.000
639
X
69.2882838
4.04986E-40

Table 7.2: Effect of practice size (all cardiologists) on initial extent of DES change,
basic OLS regression results
Physician initial extent (size)
of DES change

Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Practice size (number of
cardiologists)

0.010***
[0.01,0.01]

0.009***
[0.00,0.01]

0.000
[-0.00,0.00]

-0.021***
[-0.02,-0.02]

-0.021***
[-0.02,-0.02]

-0.002
[-0.00,0.00]

Interaction: practice size X
disadoption indicator
Physician time (quarters) to
initial DES change

0.027***
[0.02,0.03]

Physician time (quarters) to
maximum DES change

-0.008***
[-0.01,-0.01]

Physician full extent (size) of
DES change
r2
F
p
N
Unique docs
Physician FEs
Incremental F stata
Prob > incrm F

0.475***
[0.43,0.52]
0.200
186.614
0.000
1500.000
639

0.548
1.627
0.000
1500.000
639
X
1.037940405
0.305820911

0.735
3.695
0.000
1500.000
639
X
201.6159992
6.6928E-99
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Table 7.3: Effect of practice size (all cardiologists) on time to maximum DES change,
basic OLS regression results
Physician time (quarters) to
maximum DES change

Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Practice size (number of
cardiologists)

0.138***
[0.08,0.19]

0.119*
[0.01,0.23]

0.096
[-0.01,0.20]

-0.135***
[-0.19,-0.08]

-0.134***
[-0.19,-0.08]

-0.094*
[-0.17,-0.02]

Interaction: practice size X
disadoption indicator
Physician time (quarters) to
initial DES change

-0.139*
[-0.28,-0.00]

Physician initial extent (size) of
DES change

-7.685***
[-9.68,-5.69]

Physician full extent (size) of
DES change
r2
F
p
N
Unique docs
Physician FEs
Incremental F stata
Prob > incrm F

5.988***
[4.29,7.69]
0.018
14.051
0.000
1500.000
639

0.518
1.440
0.000
1500.000
639
X
1.392915325
3.2058E-06

0.570
1.767
0.000
1500.000
639
X
35.04898756
2.27438E-21

Table 7.4: Effect of practice size (all cardiologists) on full extent of DES change, basic
OLS regression results
Physician full extent (size) of
DES change

Model 1
(β/[95%CI])

Model 2
(β/[95%CI])

Model 3
(β/[95%CI])

Practice size (number of
cardiologists)

0.018***
[0.02,0.02]

0.017***
[0.01,0.02]

0.011***
[0.01,0.02]

-0.036***
[-0.04,-0.03]

-0.036***
[-0.04,-0.03]

-0.024***
[-0.03,-0.02]

Interaction: practice size X
disadoption indicator
Physician time (quarters) to
initial DES change

-0.020***
[-0.02,-0.01]

Physician time (quarters) to
maximum DES change

0.009***
[0.01,0.01]

Physician initial extent (size)
of DES change

0.661***
[0.60,0.73]

r2
F
p
N
Unique docs
Physician FEs
Incremental F stata
Prob > incrm F

0.448
606.496
0.000
1500.000
639

0.591
1.938
0.000
1500.000
639
X
0.471012944
1

0.723
3.483
0.000
1500.000
639
X
136.9062509
1.89098E-72
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Table 7.5: Effect of practice size (all cardiologists) on time to initial DES change,
instrumental variable regression results
Physician time (quarters) to initial
DES change
Practice size (number of
cardiologists)
Interaction: practice size X
disadoption indicator
Physician time (quarters) to
maximum DES change
Physician initial extent (size) of
DES change
Physician full extent (size) of DES
change
r2
F
p
N
Unique docs
Physician FEs
Chi-squared
First stage F
Incremental chi2
Prob > incrm chi2

Model 1
(β/[95%CI])
-0.947
[-3.98,2.08]
1.945
[-4.42,8.31]

Model 2
(β/[95%CI])
0.034
[-0.42,0.48]
0.549
[-0.55,1.65]

.

.

Model 3
(β/[95%CI])
0.107
[-0.16,0.38]
-0.094
[-0.40,0.21]
-0.020
[-0.06,0.02]
6.494***
[5.59,7.40]
-2.873
[-6.97,1.22]
0.611

0.828
1096.000
484

1.000
1096.000
484
X
242.1580658
0.27789886
240.2876918
1

0.000
1096.000
484
X
1655.033333
1.851239779
302.7038498
2.58566E-65

0.377923035
0.109261804

Table 7.6: Effect of practice size (all cardiologists) on initial extent of DES change,
instrumental variable regression results
Physician initial extent (size) of
DES change
Practice size (number of
cardiologists)
Interaction: practice size X
disadoption indicator
Physician time (quarters) to initial
DES change
Physician time (quarters) to
maximum DES change
Physician full extent (size) of DES
change
r2
F
p
N
Unique docs
Physician FEs
Chi-squared
First stage F
Incremental chi2
Prob > incrm chi2

Model 1
(β/[95%CI])
-0.056
[-0.27,0.16]
0.124
[-0.33,0.57]

Model 2
(β/[95%CI])
0.017
[-0.00,0.03]
-0.027
[-0.07,0.02]

.

0.509

Model 3
(β/[95%CI])
-0.017
[-0.04,0.00]
0.021
[-0.00,0.04]
0.038***
[0.03,0.05]
-0.005**
[-0.01,-0.00]
0.774***
[0.47,1.08]
0.675

0.853
1096.000
484

0.000
1096.000
484
X
741.1423124
0.27789886
735.8059979
8.60796E-13

0.000
1096.000
484
X
2473.218788
2.032953926
205.9633879
2.17044E-44

0.318986698
0.109261804
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Table 7.7: Effect of practice size (all cardiologists) on time to maximum DES change,
instrumental variable regression results
Physician time (quarters) to
maximum DES change
Practice size (number of
cardiologists)
Interaction: practice size X
disadoption indicator
Physician time (quarters) to initial
DES change
Physician initial extent (size) of
DES change
Physician full extent (size) of DES
change
r2
F
p
N
Unique docs
Physician FEs
Chi-squared
First stage F
Incremental chi2
Prob > incrm chi2

Model 1
(β/[95%CI])
0.359
[-1.28,2.00]
-0.382
[-3.82,3.06]

Model 2
(β/[95%CI])
0.344
[-0.09,0.77]
-0.164
[-1.22,0.89]

0.002

0.527

Model 3
(β/[95%CI])
0.030
[-0.58,0.64]
0.202
[-0.50,0.90]
0.049
[-0.29,0.39]
-7.399***
[-9.77,-5.03]
10.441*
[0.17,20.71]
0.537

0.279
1096.000
484

0.000
1096.000
484
X
1181.907294
0.27789886
1165.080759
3.14089E-58

0.000
1096.000
484
X
1341.303877
1.824113705
88.26645945
5.16249E-19

2.550577445
0.109261804

Table 7.8: Effect of practice size (all cardiologists) on full extent of DES change,
instrumental variable regression results
Physician full extent (size) of DES
change
Practice size (number of
cardiologists)
Interaction: practice size X
disadoption indicator
Physician time (quarters) to initial
DES change
Physician time (quarters) to
maximum DES change
Physician initial extent (size) of
DES change
r2
F
p
N
Unique docs
Physician FEs
Chi-squared
First stage F
Incremental chi2
Prob > incrm chi2

Model 1
(β/[95%CI])
0.052
[-0.04,0.14]
-0.091
[-0.28,0.10]

Model 2
(β/[95%CI])
0.043***
[0.02,0.07]
-0.073*
[-0.14,-0.01]

.

0.286

Model 3
(β/[95%CI])
0.024*
[0.00,0.04]
-0.013
[-0.04,0.01]
-0.018***
[-0.03,-0.01]
0.011**
[0.00,0.02]
0.843***
[0.53,1.16]
0.682

0.248
1096.000
484

1.000
1096.000
484
X
223.004581
0.27789886
215.8092308
1

0.000
1096.000
484
X
2082.174851
1.301719839
175.3442844
8.92923E-38

2.791709401
0.109261804
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Table 7.9: Effect of physician group size on time to initial DES change, using different
group measures (organization and physician type) and analysis methods (standard and IV)
Time to initial DES change
Group size
All
docs

Interaction

Physician type

Group size
Stent
docs

Interaction
Group size

All
docs

Interaction
Group size

Stent
docs

Interaction

Practice
0.062*
[0.01,0.11]
-0.114***
[-0.15,-0.08]
0.086*
[0.00,0.17]
-0.198***
[-0.26,-0.14]
0.107
[-0.16,0.38]
-0.094
[-0.40,0.21]
0.306
[-0.81,1.42]
-0.422
[-2.05,1.20]

Organization type
Office
Hospital
0.078**
0.003
[0.02,0.13]
[-0.00,0.01]
-0.148***
-0.006**
[-0.19,-0.10] [-0.01,-0.00]
0.128**
0.003
[0.04,0.22]
[-0.00,0.01]
-0.211***
-0.006**
[-0.28,-0.14] [-0.01,-0.00]
0.335*
[0.00,0.67]
X
-0.397**
[-0.66,-0.14]
0.314
[-0.13,0.76]
X
-0.599**
[-1.05,-0.15]

Standard
(non-IV)
analysis

Instrumental
variable
analysis

See tables 7.1 and 7.5

Table 7.10: Effect of physician group size on initial extent of DES change, using different
group measures (organization and physician type) and analysis methods (standard and IV)
Initial extent of DES change
Group size

Physician type

All
docs

Stent
docs

All
docs

Stent
docs

Interaction

Practice
0.000
[-0.00,0.00]

Organization type
Office
Hospital
-0.000
0.001***
[-0.00,0.00]
[0.00,0.00]

-0.002
[-0.00,0.00]

-0.003*
[-0.01,-0.00]

-0.001***
[-0.00,-0.00]

Group size

-0.001
[-0.01,0.00]

-0.002
[-0.01,0.00]

0.001***
[0.00,0.00]

Interaction

-0.001
[-0.01,0.00]

-0.004
[-0.01,0.00]

-0.001***
[-0.00,-0.00]

Group size

-0.017
[-0.04,0.00]

-0.010
[-0.03,0.01]

Interaction

0.021
[-0.00,0.04]

-0.002
[-0.02,0.02]

Group size

-0.047
[-0.14,0.05]

0.003
[-0.03,0.03]

Interaction

0.075
[-0.06,0.21]

-0.023
[-0.06,0.01]

See tables 7.2 and 7.6

Standard
(non-IV)
analysis

X
Instrumental
variable
analysis
X
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Table 7.11: Effect of physician group size on time to maximum DES change, using different
group measures (organization and physician type) and analysis methods (standard and IV)
Time to max. DES change
Group size
All
docs

Interaction

Physician type

Group size
Stent
docs

Interaction
Group size

All
docs

Interaction
Group size

Stent
docs

Interaction

Practice
0.096
[-0.01,0.20]
-0.094*
[-0.17,-0.02]
0.107
[-0.06,0.27]
-0.127
[-0.26,0.00]
0.030
[-0.58,0.64]
0.202
[-0.50,0.90]
-0.266
[-2.71,2.18]
0.825
[-2.77,4.42]

Organization type
Office
0.067
[-0.04,0.17]
-0.082
[-0.17,0.00]
0.075
[-0.09,0.24]
-0.080
[-0.21,0.05]
0.556
[-0.11,1.22]
-0.556
[-1.12,0.01]
0.312
[-0.53,1.16]
-0.469
[-1.40,0.46]

Hospital
0.001
[-0.01,0.01]
-0.003
[-0.01,0.00]
0.002
[-0.01,0.01]
-0.003
[-0.01,0.01]

Standard
(non-IV)
analysis

X
Instrumental
variable
analysis
X

See tables 7.3 and 7.7

Table 7.12: Effect of physician group size on full extent of DES change, using different
group measures (organization and physician type) and analysis methods (standard and IV)
Full extent of DES change
Group size
All
docs

Interaction

zPhysician type

Group size
Stent
docs

Interaction
Group size

All
docs

Interaction
Group size

Stent
docs

Interaction

See tables 7.4 and 7.8

Practice
0.011***
[0.01,0.02]
-0.024***
[-0.03,-0.02]
0.020***
[0.01,0.03]
-0.042***
[-0.05,-0.04]
0.024*
[0.00,0.04]
-0.013
[-0.04,0.01]
0.060**
[0.02,0.10]
-0.079*
[-0.14,-0.02]

Organization type
Office
Hospital
0.014***
0.002***
[0.01,0.02]
[0.00,0.00]
-0.031***
-0.005***
[-0.03,-0.03] [-0.01,-0.00]
0.025***
0.003***
[0.02,0.03]
[0.00,0.00]
-0.050***
-0.005***
[-0.05,-0.05] [-0.01,-0.00]
0.022
[-0.01,0.05]
X
-0.006
[-0.03,0.02]
0.038*
[0.00,0.07]
X
-0.007
[-0.05,0.04]

Standard
(non-IV)
analysis

Instrumental
variable
analysis
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CHAPTER 8: Conclusions
The topic of medical technology disadoption is one that has been rarely studied in the
existing health economics and health services research literatures. However, given the
importance of medical technology in driving both the overall US health care system
expenditure and the annual growth rate of that expenditure, there is a large and growing
need for an in-depth understanding of the technology disadoption process. Indeed,
partially motivated by the understanding of the critical role of medical technology, there
is a well-established high level of academic interest in the technology adoption process,
resulting in a vast literature on medical technology diffusion. Nevertheless, as supported
by the growing popularity of the Choosing Wisely campaign, it has become increasingly
clear that the disadoption of medical technologies is an integral part of health system
operations designed to improve the efficacy and value of clinical medicine. Thus, there is
real value to improving our understanding and evaluation of the medical disadoption
process, including our knowledge of factors that influence that process.

The framework that I develop in this dissertation to characterize the disadoption process
provides a reproducible, quantitative means to evaluate changes in technology use. The
complexity of this framework highlights some of the intricacies of the disadoption
process and may provide some insight into why relatively little published research has
previously examined medical technology disadoption; though academically interesting
and practically important, technology disadoption is more nuanced and less intuitive than
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technology adoption, thus more challenging to study theoretically or empirically. Along
with the characterization framework, I also develop a decision-theoretic model, which
helps incorporate physician organizational features—specifically, group size—into our
understanding of the technology change behavior, generating insight and predictions to
be tested empirically. The technology of coronary drug-eluting stents (DES)—which
underwent rapid diffusion in the US in 2003-04, followed by widespread abandonment in
2006-07—provides a convenient setting for empirical investigation of technology
disadoption.

Among the interesting empirical results described in the preceding chapters is the finding
that there may be a negative relationship between physician group size and time to
initiation of the technology disadoption process, indicating that physicians in larger
groups begin to disadopt DES later. Though the results are not statistically significant,
point estimates of the coefficients are consistently negatively signed in various analyses
throughout Chapter 6. Interpreted in the context of the theoretical model I developed in
Chapter 4, these results suggest the possibility that, in the current setting of DES
disadoption, the balance between the opposing forces of collective benefit (through intragroup information sharing via shared efforts) and collective cost (through effort-shirking
incentivized by the possibility of free-loading on group members’ efforts) that comes
with increasing group size may weigh in favor of the communal cost and detriment. If
true, this result should give pause to researchers and policy-makers who promote the
virtues of increasing physician group sizes, offering the possibility that larger groups may
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contribute to delayed technology disadoption and its corresponding detriments. Even if
not true, the potential for these results should be sufficient to raise concerns about one
potential implication of the ongoing trend toward larger physician groups.

Of course, we must again note that these results are not statistically significant, so the
above interpretation is only suggestive. Furthermore, the findings from Chapter 7 point
toward an opposite relationship between group size and time to initial DES disadoption,
further highlighting the complexity of this issue and underlines the need for future
research. For such future work to build on the current research it would ideally include a
larger dataset, with more observation and variables, to provide additional statistical
power and process insight. However, even with such data improvements, it is likely that
concern for enodgeneity issues would remain, as it is hard to imagine an exogenous
variation in group size, i.e. a change in group size occurring without a simultaneous
change in physician practice environment in ways that would, independent of group size,
influence technology use decisions (or more specifically, in ways less concerning than
those already discussed in this dissertation). For these reasons, we must keep the current
results in perspective and, despite their weaknesses, appreciate the value that they add to
the current understanding and discussion of these issues.

Aside from these potential findings relating group size to timing of the disadoption
process, this dissertation also investigates the relationship between disadoption and the
preceding adoption of the same technology. One of the few empirical relationships
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observed between these two processes was a weak (likely statistically insignificant)
negative relationship between speed of technology adoption and timing of the initiation
of the disadoption process, i.e. physicians who took less time (were faster) to fully adopt
DES were more likely to take more time (be slower) to start disadopting DES (or
conversely, those who were slower to reach full adoption tended to be quicker to start the
disadoption process). As discussed above, this observation would be consistent with
physician behavior being shaped by, among other possible factors, product loyalty or risk
aversion. This theorized effect of these factors is also consistent with the observation that
higher levels of maximum technology use were associated with increased time to reach
minimum technology use post-disadoption, i.e. physicians with higher maximum levels
of DES use tended to take longer to reach their minimum DES use levels (or conversely,
physicians with lower maximum DES use levels tended to reach their post-disadoption
minimum DES use level more quickly). Of course, noting that these adoption and
disadoption behaviors are consistent with behavioral factors does not mean that those
factors cause the observed behaviors. Unfortunately, given the both the inherent
connection between adoption and disadoption, along with the complexity of these
behaviors, it is difficult to imagine a situation in which exogenous variation of
technology adoption behavior could be identified, allowing us to determine its
independent causal influence on the disadoption process.

Beyond this potentially weak relationship between timing of disadoption and rate of
adoption, I find empirically—across multiple different analytic approaches with multiple
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different specifications—that there is not strong evidence of symmetry between the
adoption and disadoption processes. This is one of the relatively few instances in
academic research where a null finding is just as interesting as, if not more than, a
statistically significant quantitative result, whether positive or negative. Indeed, one
major takeaway from this dissertation is that despite extensive investigation, there is little
empirical evidence of significant associations between a physician’s technology adoption
behavior and her disadoption behavior. This indicates that, despite the theoretic
similarities between these two processes, they appear to be empirically disparate and
unrelated. Of course, as discussed above, there are some setting-specific factors that may
contribute to or increase the possibility of these null results, including limited statistical
power and a relatively brief period of study. However, this null finding, if valid, should
enhance our motivation—already heightened by the inherent importance of the topic—for
further research into technology disadoption because it indicates that we may not be able
to draw much inference or insight into the disadoption process from the existing vast
literature on technology adoption. That is to say, these empirical results indicate that
researchers and policy-makers may possibly know even less than they think they do
about technology disadoption, with relatively little work currently available to guide their
evaluation and assessment of this high-value topic. Thus, the need for future research on
medical technology disadoption is even greater.
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APPENDIX 3: Illustrations of adoption/disadoption framework

Figure 3A.1: Three physicians’ technology
use during adoption

Figure 3A.2: Time to initial adoption

Figure 3A.4: Initial extent of adoption
Figure 3A.3: Time from initial to maximum
use (“speed” of adoption)

Table 3A.1: Summary of Figures 3A.1 – 3A.5

Figure 3A.5: Full extent of adoption
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Figure 3A.6: Three physicians’ technology use
during disadoption

Figure 3A.7 Time to initial disadoption

Figure 3A.9: Initial extent of disadoption
Figure 3A.8: Time from initial to maximum use
(“speed” of disadoption)

Table 3A.2: Summary of Figures 3A.6 – 3A.10

Figure 3A.10: Full extent of disadoption
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APPENDIX 4: Theoretical model calculations
Restating the first-order condition from equation (4) and applying equation (3) to solve
for 𝜕𝜅/𝜕𝑒:
𝑑𝑈 𝜕𝑈 𝜕𝜅 𝜕𝑈 𝜕𝑈 𝜕
𝜕𝑈
𝑛𝑡
=
+
=
{1 − [(1 − 𝜃)(1 − 𝑔(𝑒))] } +
𝑑𝑒 𝜕𝜅 𝜕𝑒 𝜕𝑒 𝜕𝜅 𝜕𝑒
𝜕𝑒
=

𝜕𝑈
𝜕𝑈
𝑛𝑡−1 𝜕𝑔
(1 − 𝜃)𝑛𝑡 𝑛𝑡(1 − 𝑔(𝑒))
+
=0
𝜕𝜅
𝜕𝑒 𝜕𝑒

Next, because one of our interests is examining the relationship between group size and
time (to disadoption), we can choose to express this equation as an explicit function of 𝑛
and 𝑡, and apply the implicit function theorem to determine 𝑑𝑡/𝑑𝑛. That is, we have:
𝐹(𝑛, 𝑡) =

𝜕𝑈
𝜕𝑈
𝑛𝑡−1 𝜕𝑔
(1 − 𝜃)𝑛𝑡 𝑛𝑡(1 − 𝑔(𝑒))
+
=0
𝜕𝜅
𝜕𝑒 𝜕𝑒

and we want to solve for:
𝑑𝑡
𝜕𝐹 ⁄𝜕𝑛
=−
𝑑𝑛
𝜕𝐹 ⁄𝜕𝑡
We start by solving for the numerator, using the convenient substitution 𝑦 = 𝑛𝑡 − 1:
𝜕𝐹 𝜕𝐹 𝜕𝑦
𝜕 𝜕𝑈
𝜕𝑈 𝜕𝑦
𝑦 𝜕𝑔
=
=
{ (1 − 𝜃)𝑦+1 (𝑦 + 1)(1 − 𝑔(𝑒))
+ }
𝜕𝑛 𝜕𝑦 𝜕𝑛 𝜕𝑦 𝜕𝜅
𝜕𝑒 𝜕𝑒 𝜕𝑛
=

𝜕𝑈
𝜕𝑔 𝜕𝑦 𝜕
𝑦
(1 − 𝜃)
{(𝑦 + 1)[(1 − 𝜃)(1 − 𝑔(𝑒))] }
𝜕𝜅
𝜕𝑒 𝜕𝑛 𝜕𝑦

=

𝜕𝑈
𝜕𝑔
(1 − 𝜃)
𝑡[(𝑦 + 1) ln(𝑓(𝑒)) (𝑓(𝑒))𝑦 + (𝑓(𝑒))𝑦 ]
𝜕𝜅
𝜕𝑒
=

𝜕𝑈
𝜕𝑔
(1 − 𝜃)
𝑡[𝑛𝑡 ln(𝑓(𝑒)) + 1](𝑓(𝑒))𝑛𝑡−1
𝜕𝜅
𝜕𝑒

where 𝑓(𝑒) = (1 − 𝜃)(1 − 𝑔(𝑒)). Solving for the denominator (𝜕𝐹/𝜕𝑡) is slightly more
complicated because time, 𝑡, is a function of effort, 𝑒. That is, for a given value of 𝜅, the
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likelihood of critical knowledge acquisition, the amount of time 𝑡 required to reach that
likelihood will depend on the knowledge acquisition effort expenditure 𝑒. So, what we
need to calculate here is:
𝜕𝐹 𝜕𝐹 𝜕𝑒
=
𝜕𝑡
𝜕𝑒 𝜕𝑡
The calculation of 𝜕𝑒/𝜕𝑡 will require us to revisit equation (3), which we rewrite here:
𝐺(𝑒, 𝑡) = 1 − 𝜅 − [(1 − 𝜃)(1 − 𝑔(𝑒))]

𝑛𝑡

=0

so that we can again apply the implicit function theorem:
𝜕𝑒
𝜕𝐺 ⁄𝜕𝑡
=−
𝜕𝑡
𝜕𝐺 ⁄𝜕𝑒
Again, we start by solving for the numerator of this new expression, and we use the
substitution 𝑥 = 𝑛𝑡:
𝜕𝐺 𝜕𝐺 𝜕𝑥
𝜕
𝑥 𝜕𝑥
=
=
{1 − 𝜅 − [(1 − 𝜃)(1 − 𝑔(𝑒))] }
𝜕𝑡
𝜕𝑥 𝜕𝑡 𝜕𝑥
𝜕𝑡
= − ln(𝑓(𝑒)) (𝑓(𝑒))

𝑥

𝜕𝑥
𝑛𝑡
= −𝑛𝑡 ln(𝑓(𝑒)) (𝑓(𝑒)) 𝑛
𝜕𝑡

Now for the denominator:
𝜕𝐺
𝑛𝑡−1 𝜕𝑔
= (1 − 𝜃)𝑛𝑡 𝑛𝑡[(1 − 𝑔(𝑒))]
𝜕𝑒
𝜕𝑒
= (1 − 𝜃)𝑛𝑡(𝑓(𝑒))

𝑛𝑡−1 𝜕𝑔

𝜕𝑒

Combining the two, we have:
𝑛𝑡

𝑛𝑡 ln(𝑓(𝑒)) (𝑓(𝑒)) 𝑛
ln(𝑓(𝑒)) 𝑓(𝑒)𝑛
𝜕𝑒
𝜕𝐺 ⁄𝜕𝑡
=−
=
=
𝑛𝑡−1 𝜕𝑔
𝜕𝑔
𝜕𝑡
𝜕𝐺 ⁄𝜕𝑒 (1
(1 − 𝜃)
− 𝜃)𝑛𝑡(𝑓(𝑒))
𝜕𝑒
𝜕𝑒
Returning our attention to the previous expression, we can next calculate 𝜕𝐹/𝜕𝑒:
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𝜕𝐹
𝜕 𝜕𝑈
𝜕𝑈
𝑛𝑡−1 𝜕𝑔
=
{ (1 − 𝜃)𝑛𝑡 𝑛𝑡(1 − 𝑔(𝑒))
+ }
𝜕𝑒 𝜕𝑒 𝜕𝜅
𝜕𝑒 𝜕𝑒
=

2
𝜕𝑈
𝜕 2𝑈
𝑛𝑡−1 𝜕 𝑔
𝑛𝑡−2 𝜕𝑔
(1 − 𝜃)𝑛𝑡 𝑛𝑡 [(1 − 𝑔(𝑒))
(𝑛𝑡
+
−
1)(1
−
𝑔(𝑒))
]
+
𝜕𝜅
𝜕𝑒 2
𝜕𝑒
𝜕𝑒 2

Finally, we can combine all of the pieces:
𝑑𝑡
𝜕𝐹 ⁄𝜕𝑛
𝜕𝐹 ⁄𝜕𝑛
=−
=−
𝜕𝐹 𝜕𝑒
𝑑𝑛
𝜕𝐹 ⁄𝜕𝑡
𝜕𝑒 𝜕𝑡
−

=
[

𝜕𝑔
𝜕𝑈
(1 − 𝜃) 𝑡[𝑛𝑡 ln(𝑓(𝑒)) + 1](𝑓(𝑒))𝑛𝑡−1
𝜕𝜅
𝜕𝑒

𝑛𝑡−1 𝜕 2 𝑔
𝑛𝑡−2 𝜕𝑔
𝜕𝑈
𝜕 2 𝑈 ln(𝑓(𝑒)) 𝑓(𝑒)𝑛
(1 − 𝜃)𝑛𝑡 𝑛𝑡 ((1 − 𝑔(𝑒))
+ (𝑛𝑡 − 1)(1 − 𝑔(𝑒))
) + 2][
]
2
𝜕𝜅
𝜕𝑒
𝜕𝑔
𝜕𝑒
𝜕𝑒
(1 − 𝜃)
𝜕𝑒

As described in the text of the chapter, one of my primary interests is identifying the sign
of the above expression. Working through the individual components, utilizing the
assumptions about the functions 𝑈(𝑒, 𝜅) and 𝑔(𝑒) that were listed above, and using green
to label positively signed terms and red to label negatively signed terms, we have the
following:

in which the signs reduce to:
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In total, we can see that the sign of 𝑑𝑡/𝑑𝑛 as ambiguous, i.e. time to acquisition of
critical information, which triggers disadoption, may either increase or decrease with
group size. Examination reveals that the sign of the above expression depends on the
relative magnitudes of the different factors that appear in the first large term of the
denominator, including physician utility from knowledge and disutility from effort; time
(i.e. number of periods) and group size; and both the effort-based and effort-independent
likelihoods of acquiring critical knowledge.
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